<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">46043</article-id><article-id pub-id-type="doi">10.7554/eLife.46043</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Advance</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>Unique-region phosphorylation targets LynA for rapid degradation, tuning its expression and signaling in myeloid cells</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-131724"><name><surname>Brian</surname><given-names>Ben F</given-names><suffix>IV</suffix></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-141975"><name><surname>Jolicoeur</surname><given-names>Adrienne S</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-143962"><name><surname>Guerrero</surname><given-names>Candace R</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-131725"><name><surname>Nunez</surname><given-names>Myra G</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-141977"><name><surname>Sychev</surname><given-names>Zoi E</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-145208"><name><surname>Hegre</surname><given-names>Siv A</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-145209"><name><surname>Sætrom</surname><given-names>Pål</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8142-7441</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund9"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-145210"><name><surname>Habib</surname><given-names>Nagy</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4920-4154</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-141976"><name><surname>Drake</surname><given-names>Justin M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund10"/><xref ref-type="other" rid="fund11"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-131726"><name><surname>Schwertfeger</surname><given-names>Kathryn L</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund12"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-35371"><name><surname>Freedman</surname><given-names>Tanya S</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5168-5829</contrib-id><email>tfreedma@umn.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund13"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution content-type="dept">Department of Pharmacology</institution><institution>University of Minnesota</institution><addr-line><named-content content-type="city">Minneapolis</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution content-type="dept">College of Biological Sciences Center for Mass Spectrometry and Proteomics</institution><institution>University of Minnesota</institution><addr-line><named-content content-type="city">Minneapolis</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution content-type="dept">Department of Clinical and Molecular Medicine</institution><institution>Norwegian University of Science and Technology</institution><addr-line><named-content content-type="city">Trondheim</named-content></addr-line><country>Norway</country></aff><aff id="aff4"><label>4</label><institution content-type="dept">Department of Computer Science</institution><institution>Norwegian University of Science and Technology</institution><addr-line><named-content content-type="city">Trondheim</named-content></addr-line><country>Norway</country></aff><aff id="aff5"><label>5</label><institution content-type="dept">Department of Surgery and Cancer</institution><institution>Hammersmith Hospital, Imperial College London</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff6"><label>6</label><institution content-type="dept">Masonic Cancer Center</institution><institution>University of Minnesota</institution><addr-line><named-content content-type="city">Minneapolis</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution content-type="dept">Department of Urology</institution><institution>University of Minnesota</institution><addr-line><named-content content-type="city">Minneapolis</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution content-type="dept">Center for Immunology</institution><institution>University of Minnesota</institution><addr-line><named-content content-type="city">Minneapolis</named-content></addr-line><country>United States</country></aff><aff id="aff9"><label>9</label><institution content-type="dept">Department of Laboratory Medicine and Pathology</institution><institution>University of Minnesota</institution><addr-line><named-content content-type="city">Minneapolis</named-content></addr-line><country>United States</country></aff><aff id="aff10"><label>10</label><institution content-type="dept">Center for Autoimmune Diseases Research</institution><institution>University of Minnesota</institution><addr-line><named-content content-type="city">Minneapolis</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Davis</surname><given-names>Roger J</given-names></name><role>Reviewing Editor</role><aff><institution>University of Massachusetts Medical School</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Taniguchi</surname><given-names>Tadatsugu</given-names></name><role>Senior Editor</role><aff><institution>Institute of Industrial Science, The University of Tokyo</institution><country>Japan</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>08</day><month>07</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>8</volume><elocation-id>e46043</elocation-id><history><date date-type="received" iso-8601-date="2019-02-14"><day>14</day><month>02</month><year>2019</year></date><date date-type="accepted" iso-8601-date="2019-07-06"><day>06</day><month>07</month><year>2019</year></date></history><permissions><copyright-statement>© 2019, Brian et al</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Brian et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-46043-v2.pdf"/><related-article ext-link-type="doi" id="ra1" related-article-type="article-reference" xlink:href="10.7554/eLife.09183"/><abstract><object-id pub-id-type="doi">10.7554/eLife.46043.001</object-id><p>The activity of Src-family kinases (SFKs), which phosphorylate immunoreceptor tyrosine-based activation motifs (ITAMs), is a critical factor regulating myeloid-cell activation. We reported previously that the SFK LynA is uniquely susceptible to rapid ubiquitin-mediated degradation in macrophages, functioning as a rheostat regulating signaling (Freedman et al., 2015). We now report the mechanism by which LynA is preferentially targeted for degradation and how cell specificity is built into the LynA rheostat. Using genetic, biochemical, and quantitative phosphopeptide analyses, we found that the E3 ubiquitin ligase c-Cbl preferentially targets LynA via a phosphorylated tyrosine (Y32) in its unique region. This distinct mode of c-Cbl recognition depresses steady-state expression of LynA in macrophages derived from mice. Mast cells, however, express little c-Cbl and have correspondingly high LynA. Upon activation, mast-cell LynA is not rapidly degraded, and SFK-mediated signaling is amplified relative to macrophages. Cell-specific c-Cbl expression thus builds cell specificity into the LynA checkpoint.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>SFKs/Src-family kinases</kwd><kwd>Cbl E3 ubiquitin ligase</kwd><kwd>myeloid cell signaling</kwd><kwd>macrophage</kwd><kwd>mast cell</kwd><kwd>LynA</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000052</institution-id><institution>NIH Office of the Director</institution></institution-wrap></funding-source><award-id>R01AR073966</award-id><principal-award-recipient><name><surname>Freedman</surname><given-names>Tanya S</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000052</institution-id><institution>NIH Office of the Director</institution></institution-wrap></funding-source><award-id>R03AI130978</award-id><principal-award-recipient><name><surname>Freedman</surname><given-names>Tanya S</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000048</institution-id><institution>American Cancer Society</institution></institution-wrap></funding-source><award-id>UMN IRG-58-001-55</award-id><principal-award-recipient><name><surname>Freedman</surname><given-names>Tanya S</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100007249</institution-id><institution>University of Minnesota</institution></institution-wrap></funding-source><award-id>Grant-in-Aid #92286</award-id><principal-award-recipient><name><surname>Freedman</surname><given-names>Tanya S</given-names></name></principal-award-recipient></award-group><award-group id="fund13"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100007249</institution-id><institution>University of Minnesota</institution></institution-wrap></funding-source><award-id>New Faculty Research Award NF-0315-02</award-id><principal-award-recipient><name><surname>Freedman</surname><given-names>Tanya S</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100007249</institution-id><institution>University of Minnesota</institution></institution-wrap></funding-source><award-id>Equipment Award E-0918-01</award-id><principal-award-recipient><name><surname>Freedman</surname><given-names>Tanya S</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100007249</institution-id><institution>University of Minnesota</institution></institution-wrap></funding-source><award-id>Center for Autoimmune Diseases Research Pilot Grant</award-id><principal-award-recipient><name><surname>Freedman</surname><given-names>Tanya S</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000052</institution-id><institution>NIH Office of the Director</institution></institution-wrap></funding-source><award-id>T32DA007097</award-id><principal-award-recipient><name><surname>Schwertfeger</surname><given-names>Kathryn L</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100005416</institution-id><institution>Norwegian Research Council</institution></institution-wrap></funding-source><award-id>230338</award-id><principal-award-recipient><name><surname>Brian</surname><given-names>Ben F</given-names><suffix>IV</suffix></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000892</institution-id><institution>Prostate Cancer Foundation</institution></institution-wrap></funding-source><award-id>Young Investigator Award</award-id><principal-award-recipient><name><surname>Sætrom</surname><given-names>Pål</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000005</institution-id><institution>U.S. Department of Defense</institution></institution-wrap></funding-source><award-id>Prostate Cancer Research Program W81XWH-18-1-0542</award-id><principal-award-recipient><name><surname>Drake</surname><given-names>Justin M</given-names></name></principal-award-recipient></award-group><award-group id="fund11"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000052</institution-id><institution>NIH Office of the Director</institution></institution-wrap></funding-source><award-id>R01CA215052</award-id><principal-award-recipient><name><surname>Drake</surname><given-names>Justin M</given-names></name></principal-award-recipient></award-group><award-group id="fund12"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000052</institution-id><institution>NIH Office of the Director</institution></institution-wrap></funding-source><award-id>R01HD095858</award-id><principal-award-recipient><name><surname>Schwertfeger</surname><given-names>Kathryn L</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The ubiquitin ligase c-Cbl preferentially targets unique-region phosphorylated LynA for rapid degradation, regulating its expression and differentially tuning signaling responsiveness in macrophages and mast cells.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Phosphorylation of immunoreceptor tyrosine-based activation motifs (ITAMs) by Src-family kinases (SFKs) is the first enzymatic step in the activation of an innate immune response during a pathogen encounter. Initiation of cell-activating signaling typically occurs within clusters of ITAM-coupled receptors such as FcγR (<xref ref-type="bibr" rid="bib29">Guilliams et al., 2014</xref>) or the hemi-ITAM Dectin-1 (<xref ref-type="bibr" rid="bib7">Brown, 2006</xref>; <xref ref-type="bibr" rid="bib17">Deng et al., 2015</xref>), nucleated by highly multivalent immunoglobulin-G-decorated pathogens or fungal cell-wall β-glucans, respectively. Together, SFKs and phosphorylated ITAMs trigger activation of the tyrosine kinase Syk (<xref ref-type="bibr" rid="bib45">Lowell, 2011</xref>). The SFKs and Syk then drive activation of membrane-proximal signaling through adaptor proteins; cytoskeleton-modulating proteins, such as the FAK/Pyk2 kinases and Paxillin; and Tec kinases, which activate second-messenger pathways via phosphoinositide 3-kinase (PI3K) and phospholipases Cγ (PLCγ1/2). These early events ultimately lead to downstream signaling through Erk1/2 and other pathways (<xref ref-type="bibr" rid="bib45">Lowell, 2011</xref>). As the byproducts of activated macrophages can be toxic (<italic>e.g.</italic> release of reactive oxygen species) and drive inflammation (<italic>e.g.</italic> release of tumor necrosis factor α), the responsiveness of innate immune cells is tightly regulated (<xref ref-type="bibr" rid="bib28">Goodridge et al., 2011</xref>; <xref ref-type="bibr" rid="bib73">Takai, 2002</xref>; <xref ref-type="bibr" rid="bib70">Sondermann, 2016</xref>; <xref ref-type="bibr" rid="bib15">Chiffoleau, 2018</xref>).</p><p>Multiple mechanisms work together to tune the responsiveness of macrophages and other myeloid cells, including negative regulation by the phosphatases CD45 and CD148 (<xref ref-type="bibr" rid="bib28">Goodridge et al., 2011</xref>; <xref ref-type="bibr" rid="bib24">Freeman et al., 2016</xref>; <xref ref-type="bibr" rid="bib4">Bakalar et al., 2018</xref>), cytoskeletal barriers to diffusion (<xref ref-type="bibr" rid="bib38">Jaumouillé et al., 2014</xref>), signaling via immunoreceptor tyrosine inhibitory motifs (ITIMs) (<xref ref-type="bibr" rid="bib1">Abram and Lowell, 2008</xref>) and inhibitory ITAMs (<xref ref-type="bibr" rid="bib32">Hamerman and Lanier, 2006</xref>; <xref ref-type="bibr" rid="bib31">Hamerman et al., 2009</xref>), and degradation and sequestration of signaling molecules targeted for polyubiquitination by ubiquitin ligases (<xref ref-type="bibr" rid="bib46">Lutz-Nicoladoni et al., 2015</xref>; <xref ref-type="bibr" rid="bib43">Liyasova et al., 2015</xref>). The SFKs, which in myeloid cells typically include Fgr, Fyn, two isoforms of Hck, and two splice forms of Lyn, may also have positive and negative functions (<xref ref-type="bibr" rid="bib1">Abram and Lowell, 2008</xref>; <xref ref-type="bibr" rid="bib48">Mkaddem et al., 2017</xref>; <xref ref-type="bibr" rid="bib2">Alvarez-Errico et al., 2010</xref>; <xref ref-type="bibr" rid="bib63">Scapini et al., 2009</xref>). Layered onto the traditional positive- and negative-regulatory roles of the SFKs, activated LynA (the longer of the two Lyn splice forms) is rapidly and specifically targeted for polyubiquitination and degradation, forming the basis of a signaling checkpoint that blocks spurious macrophage activation (<xref ref-type="bibr" rid="bib23">Freedman et al., 2015</xref>). This checkpoint can be bypassed when LynA is upregulated, with LynA acting as a rheostat to tune macrophage sensitivity. For instance, LynA is transcriptionally upregulated when macrophages are treated with interferon (IFN)-γ, and these primed cells have a lower threshold for SFK-mediated signaling (<xref ref-type="bibr" rid="bib23">Freedman et al., 2015</xref>). The molecular mechanism that selectively targets LynA for polyubiquitination has not been elucidated previously.</p><p>Unlike Dectin-1 and FcγR signaling pathways in macrophages, which are typically triggered in the context of pathogen-induced µm-scale clusters of receptors (<xref ref-type="bibr" rid="bib28">Goodridge et al., 2011</xref>; <xref ref-type="bibr" rid="bib24">Freeman et al., 2016</xref>; <xref ref-type="bibr" rid="bib23">Freedman et al., 2015</xref>), mast-cell FcεR signaling has a low threshold for activation; small or even monovalent antigen-IgE complexes can induce a signaling response in the context of a cell-particle interaction (<xref ref-type="bibr" rid="bib3">Andrews et al., 2009</xref>; <xref ref-type="bibr" rid="bib21">Felce et al., 2018</xref>; <xref ref-type="bibr" rid="bib13">Carroll-Portillo et al., 2010</xref>). Supporting this more permissive signaling function, the binding dynamics of Syk with FcεRI in mast cells is unaffected by the size of receptor aggregates (<xref ref-type="bibr" rid="bib66">Schwartz et al., 2017</xref>). Like macrophages, mast cells express LynA, and the disparity in the receptor sensitivity of these two cell types has not previously been explained.</p><p>This paper describes the mechanism by which activated LynA is selectively targeted for rapid degradation, thereby tuning both its steady-state expression and its activation kinetics in a cell-specific manner. To reveal the requirements for LynA degradation, we synchronized receptor-independent SFK activation using the designer inhibitor 3-IB-PP1 (<xref ref-type="bibr" rid="bib53">Okuzumi et al., 2010</xref>; <xref ref-type="bibr" rid="bib52">Okuzumi et al., 2009</xref>; <xref ref-type="bibr" rid="bib65">Schoenborn et al., 2011</xref>), which specifically inhibits a variant of the SFK-inhibitory kinase Csk (Csk<sup>AS</sup>) (<xref ref-type="bibr" rid="bib23">Freedman et al., 2015</xref>; <xref ref-type="bibr" rid="bib65">Schoenborn et al., 2011</xref>; <xref ref-type="bibr" rid="bib75">Tan et al., 2014</xref>). Csk is responsible for phosphorylating a key inhibitory tyrosine in the C-terminal tail of all the SFKs. Inhibiting Csk<sup>AS</sup> with 3-IB-PP1 disrupts the dynamic equilibrium between Csk and the phosphatases CD45 and CD148, which dephosphorylate the inhibitory tyrosine, leading to rapid and robust SFK activation (<xref ref-type="bibr" rid="bib16">Chow and Veillette, 1995</xref>; <xref ref-type="bibr" rid="bib92">Zhu et al., 2011</xref>). 3-IB-PP1-induced SFK activation leads to the phosphorylation and likely activation of the E3 ubiquitin ligase c-Cbl (<xref ref-type="bibr" rid="bib22">Feshchenko et al., 1998</xref>; <xref ref-type="bibr" rid="bib18">Dou et al., 2012</xref>; <xref ref-type="bibr" rid="bib23">Freedman et al., 2015</xref>) and the preferential polyubiquitination and degradation of LynA in macrophages (<xref ref-type="bibr" rid="bib23">Freedman et al., 2015</xref>), but it was not clear whether these two events were linked. Using knockout and overexpression models coupled with analyses of protein abundance and cell signaling, we now demonstrate that c-Cbl controls the steady-state expression of LynA and mediates its rapid degradation upon activation in macrophages. Quantitative targeted mass spectrometry shows that LynA is targeted by c-Cbl in response to phosphorylation of tyrosine 32 (Y32) within the LynA unique region, a process mediated by LynA, LynB or the shorter isoform of Hck. This recognition mode is distinct from the slower-phase action of c-Cbl and other E3 ligases on LynB and the other SFKs (<xref ref-type="bibr" rid="bib23">Freedman et al., 2015</xref>; <xref ref-type="bibr" rid="bib61">Sanjay et al., 2001</xref>; <xref ref-type="bibr" rid="bib62">Sanjay et al., 2006</xref>). Finally, we have discovered that the LynA checkpoint is cell-specific. In mast cells, which express very little c-Cbl but abundant Cbl-b, LynA is not rapidly degraded upon activation, a function that can be rescued by induced overexpression of c-Cbl. The differential regulation of c-Cbl and LynA may drive mast cells toward a lower activation threshold than macrophages.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>c-Cbl mediates steady-state and activation-induced degradation of LynA in macrophages</title><p>We reported previously that activated LynA is rapidly polyubiquitinated and degraded in Csk<sup>AS</sup> macrophages treated with the Csk<sup>AS</sup> inhibitor (SFK activator) 3-IB-PP1 (<xref ref-type="bibr" rid="bib23">Freedman et al., 2015</xref>). To identify the E3 ubiquitin ligase that mediates this degradation, we tested the functions of c-Cbl and Cbl-b, known modulators of ITAM signaling in both adaptive and innate immune cells (<xref ref-type="bibr" rid="bib1">Abram and Lowell, 2008</xref>; <xref ref-type="bibr" rid="bib46">Lutz-Nicoladoni et al., 2015</xref>; <xref ref-type="bibr" rid="bib76">Tang et al., 2019</xref>). We bred <italic>Csk<sup>AS</sup>Cbl<sup>-/-</sup></italic> and <italic>Csk<sup>AS</sup>Cblb<sup>-/-</sup></italic> mice from the existing strains <italic>Cbl<sup>-/-</sup></italic> (<xref ref-type="bibr" rid="bib59">Rafiq et al., 2014</xref>) and <italic>Cblb<sup>-/-</sup></italic> (<xref ref-type="bibr" rid="bib14">Chiang et al., 2000</xref>) and generated Csk<sup>AS</sup>-expressing, c-Cbl-deficient (Csk<sup>AS</sup>c-Cbl<sup>KO</sup>) and Csk<sup>AS</sup>-expressing, Cbl-b-deficient (Csk<sup>AS</sup>Cbl-b<sup>KO</sup>) bone-marrow-derived macrophages (BMDMs). (For clarity we refer to BMDM subtypes using protein nomenclature.) Immunoblots of whole-cell lysates show the loss of expression of c-Cbl and Cbl-b in Csk<sup>AS</sup>c-Cbl<sup>KO</sup> and Csk<sup>AS</sup>Cbl-b<sup>KO</sup> BMDMs, respectively, compared to Csk<sup>AS</sup> BMDMs (<xref ref-type="fig" rid="fig1">Figure 1A–B</xref>). Resting (unprimed) BMDMs were then treated with 3-IB-PP1 to induce activation of the SFKs (<xref ref-type="fig" rid="fig1">Figure 1A</xref>).</p><fig-group><fig id="fig1" position="float"><object-id pub-id-type="doi">10.7554/eLife.46043.002</object-id><label>Figure 1.</label><caption><title>Loss of c-Cbl expression in macrophages leads to steady-state upregulation and delayed degradation of LynA protein.</title><p>(<bold>A</bold>) Immunoblots showing LynA, c-Cbl, and Cbl-b protein in Csk<sup>AS</sup>, Csk<sup>AS</sup>c-Cbl<sup>KO</sup>, and Csk<sup>AS</sup>Cbl-b<sup>KO</sup> BMDMs treated with 3-IB-PP1 for the indicated times. Interdomain-B-phosphorylated Syk<sup>pY352</sup> (pSyk, <xref ref-type="bibr" rid="bib88">Yan et al., 2013</xref>; <xref ref-type="bibr" rid="bib84">Wang et al., 2010</xref>; <xref ref-type="bibr" rid="bib42">Law et al., 1996</xref>), an SFK target and prerequisite for Syk activation, is shown as a control for 3-IB-PP1-initiated signaling; total Erk1/2 is shown as a loading control. (<bold>B–D</bold>) Densitometry quantification of relative levels of Cbl and LynA protein, corrected for total protein content using REVERT Total Protein Stain (TPS). (<bold>B</bold>) Quantification of c-Cbl (red) and Cbl-b (blue) in Csk<sup>AS</sup>c-Cbl<sup>KO</sup> and Csk<sup>AS</sup>Cbl-b<sup>KO</sup> BMDMs relative (rel.) to their steady-state levels in Csk<sup>AS</sup> BMDMs (dotted line). Expression of the other Cbl family member is shown in gray. Error bars reflect the standard error of the mean (SEM), n = 4 from three <italic>Csk<sup>AS</sup>Cbl<sup>-/-</sup></italic> mice and n = 3 from two <italic>Csk<sup>AS</sup>Cblb<sup>-/-</sup></italic> mice. (<bold>C–D</bold>) Quantification of LynA relative to the steady-state level in each genotype (<bold>C</bold>) or relative to the steady-state level in Csk<sup>AS</sup> BMDMs (<bold>D</bold>). SEM, n = 8 for Csk<sup>AS</sup>, n = 5 from three <italic>Csk<sup>AS</sup>Cbl<sup>-/-</sup></italic> mice, n = 3 from two <italic>Csk<sup>AS</sup>Cblb<sup>-/-</sup></italic> mice. The significance (Sig.) from two-way ANOVA (ANOVA<sub>2</sub>) with Tukey’s multiple comparison test (-Tukey) are as follows: [Csk<sup>AS</sup>c-Cbl<sup>KO</sup> vs. Csk<sup>AS</sup> black asterisks], [Csk<sup>AS</sup>c-Cbl<sup>KO</sup> vs. Csk<sup>AS</sup>Cbl-b<sup>KO</sup>, blue asterisks]; ****p&lt;0.0001, ***p=0.0001–0.0005, * P=0.0171–0.0459. No significant difference was detected between other pairs (ns). Note: some of the error bars are smaller than the line width. Refer to <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>. Paradoxical changes in Erk1/2 phosphorylation in Cbl-deficient cells are shown in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>. Supporting siRNA studies are shown <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>.</p><p><supplementary-material id="fig1sdata1"><object-id pub-id-type="doi">10.7554/eLife.46043.006</object-id><label>Figure 1—source data 1.</label><caption><title>Quantification of Cbl and LynA proteins in BMDMs lacking c-Cbl or Cbl-b.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-46043-fig1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-46043-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.46043.003</object-id><label>Figure 1—figure supplement 1.</label><caption><title>Paradoxical changes in Erk1/2 phosphorylation in Cbl-deficient cells obscure the contribution of LynA to signaling.</title><p>Immunoblot showing impaired activating phosphorylation of Erk1/2<sup>pT202/pY204</sup> (pErk1/2) in Csk<sup>AS</sup>c-Cbl<sup>KO</sup> BMDMs and enhanced Erk phosphorylation in Csk<sup>AS</sup>Cbl-b<sup>KO</sup> BMDMs compared to Csk<sup>AS</sup> BMDMs treated with 3-IB-PP1.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-46043-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.46043.004</object-id><label>Figure 1—figure supplement 2.</label><caption><title>siRNA knockdown of c-Cbl expression in macrophages leads to steady-state upregulation and delayed degradation of LynA protein.</title><p>(<bold>A</bold>) Immunoblots showing LynA, c-Cbl, and Cbl-b protein in Csk<sup>AS</sup> BMDMs transfected with non-targeting RNA (ctrl) or with siRNA constructs targeting <italic>Cbl</italic> or <italic>Cblb</italic> mRNA. Rested cells were treated with 3-IB-PP1 for the indicated times; β-Actin is shown as a loading control. (<bold>B–D</bold>) Quantification of relative c-Cbl, Cbl-b, and LynA protein, corrected for total protein content (TPS). SEM, n = 3. (<bold>B</bold>) Quantification of c-Cbl protein (red) and Cbl-b protein (blue), reported relative to their expression in ctrl BMDMs (dotted line). Remaining expression of the other Cbl family member is shown in gray. (<bold>C–D</bold>) Quantification of LynA, reported relative to the steady-state level in each siRNA condition (<bold>C</bold>) or relative to the level in the ctrl sample at steady state (<bold>D</bold>) in ctrl (black dotted), c-Cbl<sup>down</sup> (red), and Cbl-b<sup>down</sup> (blue) samples. Sig. from ANOVA<sub>2</sub>-Tukey: [c-Cbl<sup>down</sup> vs. ctrl, black asterisks], [c-Cbl<sup>down</sup> vs. Cbl-b<sup>down</sup>, blue asterisks]; ****p&lt;0.0001, ***p=0.0001–0.0005, **p=0.0015–0.0058, * P=0.0105–0.0451. Other pairs ns. Refer to <xref ref-type="supplementary-material" rid="fig1s2sdata1">Figure 1—figure supplement 2—source data 1</xref>.</p><p><supplementary-material id="fig1s2sdata1"><object-id pub-id-type="doi">10.7554/eLife.46043.005</object-id><label>Figure 1—figure supplement 2—source data 1.</label><caption><title>Quantification of Cbl and LynA proteins in BMDMs deficient in c-Cbl or Cbl-b.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-46043-fig1-figsupp2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-46043-fig1-figsupp2-v2.tif"/></fig></fig-group><p>Knockout of c-Cbl profoundly impaired the degradation of activated LynA in the first few minutes of 3-IB-PP1 treatment, with LynA levels remaining at 100% after 1 min of exposure to 3-IB-PP1 in Csk<sup>AS</sup>c-Cbl<sup>KO</sup> BMDMs compared to 60% in Csk<sup>AS</sup> BMDMs (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Csk<sup>AS</sup>c-Cbl<sup>KO</sup> BMDMs also expressed 3-fold more LynA protein than Csk<sup>AS</sup> at steady state (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). The impaired degradation and increased steady-state LynA expression together resulted in 6- to 8-fold elevations in LynA protein in the first minutes of 3-IB-PP1 treatment.</p><p>Although it has been reported previously that c-Cbl and Cbl-b have some redundant functions (<xref ref-type="bibr" rid="bib51">Naramura et al., 2002</xref>; <xref ref-type="bibr" rid="bib57">Purev et al., 2009</xref>), we were unable to detect any role for Cbl-b in suppressing the steady-state level or promoting the activation-induced degradation of LynA. Upon treatment for 1 min with 3-IB-PP1, LynA was 81% reduced in Csk<sup>AS</sup>Cbl-b<sup>KO</sup> compared to 60% in Csk<sup>AS</sup> BMDMs (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Although not statistically significant, steady-state expression of LynA was slightly depressed in Csk<sup>AS</sup>Cbl-b<sup>KO</sup> BMDMs (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). This increase in LynA degradation may be explained by a compensatory upregulation of c-Cbl protein expression in Csk<sup>AS</sup>Cbl-b<sup>KO</sup> BMDMs (<xref ref-type="fig" rid="fig1">Figure 1B</xref>).</p><p>In the above experiments, activating Syk phosphorylation was used as a control for 3-IB-PP1-induced SFK signaling. Notably, Syk phosphorylation is enhanced in 3-IB-PP1-treated Csk<sup>AS</sup>c-Cbl<sup>KO</sup> BMDMs, consistent with the higher expression level and longer half-life of LynA protein (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Syk phosphorylation is also enhanced in 3-IB-PP1-treated Csk<sup>AS</sup>Cbl-b<sup>KO</sup> BMDMs, but this is likely due to the direct role of Cbl-b on Syk inhibition (<xref ref-type="bibr" rid="bib69">Sohn et al., 2003</xref>). Analysis of activating phosphorylation of Erk1/2, a downstream signaling protein, is also complicated by the functions of the E3 ligases themselves. Erk phosphorylation in 3-IB-PP1-treated Csk<sup>AS</sup>c-Cbl<sup>KO</sup> BMDMs is impaired (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>), likely due to the loss of the adaptor function of c-Cbl in PI3K signaling (<xref ref-type="bibr" rid="bib81">Ueno et al., 1998</xref>; <xref ref-type="bibr" rid="bib37">Hunter et al., 1999</xref>). In 3-IB-PP1-treated Csk<sup>AS</sup>Cbl-b<sup>KO</sup> BMDMs, Erk1/2 phosphorylation, like Syk phosphorylation, is enhanced, again likely due to the negative-regulatory role of Cbl-b for Syk and other upstream signaling intermediates.</p><p>To test whether the enhancement of LynA degradation in Csk<sup>AS</sup>Cbl-b<sup>KO</sup> BMDMs was in fact due to c-Cbl upregulation, we complemented our observations in the Cbl knockout mice with experiments using small interfering (si)RNAs to knock down the expression of c-Cbl and Cbl-b. Csk<sup>AS</sup> BMDMs were transfected with non-targeting control RNA (ctrl) or with siRNA constructs targeting <italic>Cbl</italic> or <italic>Cblb</italic> mRNA. Rested transfectants were then treated with 3-IB-PP1 to induce SFK activation. Immunoblots of siRNA-transfected BMDM lysates (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A</xref>) showed modest but specific knockdown of c-Cbl (70% reduced) and Cbl-b (60% reduced), importantly, without a corresponding increase in c-Cbl expression as a consequence of Cbl-b knockdown (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B</xref>).</p><p>As in the knockout models, loss of c-Cbl but not Cbl-b resulted in impaired degradation of LynA in the first few minutes of 3-IB-PP1 treatment and increased steady-state expression of LynA protein. Without c-Cbl upregulation in Cbl-b-knockdown BMDMs, there was no increase in the LynA degradation efficiency or decrease in the steady-state level of LynA protein (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2C–D</xref>), supporting our hypothesis that this observation in Csk<sup>AS</sup>Cbl-b<sup>KO</sup> BMDMs was c-Cbl-dependent. The effects of c-Cbl knockdown are blunted relative to Csk<sup>AS</sup>c-Cbl<sup>KO</sup> BMDMs, likely due to incomplete knockdown. As in the knockout experiments, LynA degradation in c-Cbl<sup>KO</sup> BMDMs was not fully eliminated but occurred on a much slower timescale, similar to the degradation of the other SFKs (<xref ref-type="bibr" rid="bib23">Freedman et al., 2015</xref>).</p><p>Overall, we conclude that c-Cbl is solely responsible for the rapid and specific degradation of LynA, whereas other E3 ubiquitin ligases can complement the canonical SFK-binding and -polyubiquitinating function of c-Cbl (<xref ref-type="bibr" rid="bib61">Sanjay et al., 2001</xref>; <xref ref-type="bibr" rid="bib62">Sanjay et al., 2006</xref>), which mediates slower degradation of LynA and the other SFKs (<xref ref-type="bibr" rid="bib23">Freedman et al., 2015</xref>).</p></sec><sec id="s2-2"><title>A tyrosine residue in the unique-region insert of LynA is required for its rapid degradation</title><p>Susceptibility to rapid, activation-induced degradation differentiates LynA from the splice variant LynB and the other abundant SFKs in macrophages, Hck (59 and 56 kDa transcripts) and Fgr (<xref ref-type="bibr" rid="bib63">Scapini et al., 2009</xref>), which are degraded &gt;10 fold more slowly than LynA during 3-IB-PP1 treatment (<xref ref-type="bibr" rid="bib23">Freedman et al., 2015</xref>). The SFK FynT (Fyn) has also been reported to play an important role in macrophage inflammatory signaling (<xref ref-type="bibr" rid="bib48">Mkaddem et al., 2017</xref>). We now confirm that, like Hck, Fgr, and LynB, macrophage Fyn is long-lived during 3-IB-PP1 treatment (<xref ref-type="fig" rid="fig2">Figure 2A</xref>), although we have been unable to detect Fyn activation in response to 3-IB-PP1 (<xref ref-type="bibr" rid="bib23">Freedman et al., 2015</xref>). We also tested degradation of transfected LynA in comparison with endogenous Fyn and Lck in Jurkat T cells cotransfected with c-Cbl and a membrane-localized variant of Csk<sup>AS</sup> (memCsk<sup>AS</sup>) (<xref ref-type="bibr" rid="bib65">Schoenborn et al., 2011</xref>), which sensitizes Jurkat cells to 3-IB-PP1, enabling synchronized SFK activation. As in macrophages, LynA is rapidly degraded in Jurkat cells treated with 3-IB-PP1, in contrast to longer-lived Lck (<xref ref-type="bibr" rid="bib65">Schoenborn et al., 2011</xref>) and Fyn (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). This highlights the unique susceptibility of LynA to rapid, c-Cbl-mediated degradation and suggests that cell types, such as T cells, that do not express Lyn may lack an analogous, rapid off-switch for SFK signaling.</p><fig id="fig2" position="float"><object-id pub-id-type="doi">10.7554/eLife.46043.007</object-id><label>Figure 2.</label><caption><title>LynA is degraded more rapidly than Fyn and Lck during 3-IB-PP1 treatment.</title><p>Immunoblots and quantification of SFK levels over the course of 3-IB-PP1 treatment. In both panels total Erk1/2 protein is shown as a loading control. Quantified values are corrected for total protein content (TPS) and reported relative to the steady-state level of each SFK. (<bold>A</bold>) Levels of Fyn (dark orange), Hck (light orange), LynA (black), and LynB (brown dashed) in 3-IB-PP1-treated Csk<sup>AS</sup> BMDMs. SEM, n = 3. Sig. from ANOVA<sub>2</sub>-Tukey: [Fyn vs. LynA, dark orange asterisks], [Hck vs. LynA, light orange asterisks], [LynB vs. LynA, brown asterisks]; ****p&lt;0.0001, ***p=0.0006–0.0009, **p=0.0034. (<bold>B</bold>) Levels of Fyn (dark orange) and Lck (blue dashed) and His<sub>6</sub>V5-tagged LynA (black) in 3-IB-PP1-treated Jurkat T cells cotransfected with His<sub>6</sub>V5-tagged LynA, memCsk<sup>AS</sup>, and c-Cbl. SEM, n = 4. Sig. from ANOVA<sub>2</sub>-Tukey: [Lck vs. LynA, blue asterisks], [Fyn vs. LynA, dark orange asterisks]; **p=0.0018–0.0048. Other pairs ns. Refer to <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>.</p><p><supplementary-material id="fig2sdata1"><object-id pub-id-type="doi">10.7554/eLife.46043.008</object-id><label>Figure 2—source data 1.</label><caption><title>Quantification of SFKs during 3-IB-PP1 treatment in mouse BMDMs and Jurkat cells.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-46043-fig2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-46043-fig2-v2.tif"/></fig><p>To determine which residues in the LynA protein mediate the unique interaction with c-Cbl, we undertook a mutational analysis. We were, however, unable to achieve expression of LynA variants in Csk<sup>AS</sup> or Csk<sup>AS</sup>Lyn<sup>KO</sup> BMDMs (<xref ref-type="bibr" rid="bib23">Freedman et al., 2015</xref>) by transfection, Amaxa nucleofection, or lentiviral transduction, likely due to toxicity of overexpressed Lyn. As an alternative approach, we expressed LynA ectopically in Jurkat T cells by transient cotransfection of His<sub>6</sub>V5-tagged variants of Lyn along with a Cbl-family ligase and memCsk<sup>AS</sup>. As a proof of principle for this model, we first transfected Jurkat cells with wild-type LynA, memCsk<sup>AS</sup>, and either empty vector (ctrl), c-Cbl, or Cbl-b plasmid DNA (<xref ref-type="fig" rid="fig3">Figure 3A</xref>), which increased c-Cbl expression 3-fold and Cbl-b expression 25-fold, respectively, over endogenous levels (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). Overexpressing one Cbl family member did not affect the abundance of the other. Phosphorylation of Erk1/2, via the combined effects of transfected LynA and endogenous Lck, demonstrates that 3-IB-PP1 was applied to all transfectants (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). As predicted, c-Cbl overexpression in Jurkat cells increased the rate of LynA degradation (30% depletion after 5 min treatment with 3-IB-PP1 in c-Cbl-overexpressing Jurkat cells versus no detectable depletion in either ctrl or Cbl-b-overexpressing cells) (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). This observation is consistent with the knockout and siRNA experiments in BMDMs, demonstrating that Jurkat cells, which do not normally express Lyn, are capable of supporting rapid, c-Cbl-mediated degradation of LynA.</p><fig-group><fig id="fig3" position="float"><object-id pub-id-type="doi">10.7554/eLife.46043.009</object-id><label>Figure 3.</label><caption><title>Unique-region tyrosine 32 is required for activation-induced degradation of LynA.</title><p>(<bold>A</bold>) Immunoblots of Jurkat cells cotransfected with His<sub>6</sub>V5-tagged LynA, Myc-tagged memCsk<sup>AS</sup>, and either empty vector (ctrl), c-Cbl, or Cbl-b and treated with 3-IB-PP1. Phosphorylated Erk1/2<sup>pT202/pY204</sup> (pErk1/2) is shown as a qualitative control for 3-IB-PP1-initiated signaling from the combined effects of transfected LynA and endogenous Lck; total Erk1/2 is shown as a loading control. (<bold>B–C</bold>) Quantification of relative c-Cbl, Cbl-b, and His<sub>6</sub>V5-tagged LynA protein, corrected for total protein content (TPS). SEM, n = 4. (<bold>B</bold>) Quantification of overexpressed c-Cbl (orange) and Cbl-b (dark blue) relative to endogenous (ctrl) levels (dotted line). Endogenous expression of the other Cbl family member in each condition is shown in gray. (<bold>C</bold>) Quantification of LynA protein during 3-IB-PP1 treatment relative to the steady-state level for transfections of empty-vector ctrl (black dotted), c-Cbl (orange), or Cbl-b (dark blue). Sig. from ANOVA<sub>2</sub>-Tukey: [c-Cbl vs. ctrl, black asterisks], [c-Cbl vs. Cbl-b, blue asterisk]; **p=0.0092, *p=0.0270–0.0102. Other pairs ns. (<bold>D</bold>) N-terminal amino-acid sequences of mouse LynA and LynB (<xref ref-type="bibr" rid="bib89">Yi et al., 1991</xref>; <xref ref-type="bibr" rid="bib71">Stanley et al., 1991</xref>), including the 21 residue insert in the unique region of LynA, highlighting residues Y32 (olive), T27 (light gray), and K40 (dark gray). (<bold>E</bold>) Immunoblots of 3-IB-PP1-treated Jurkat cells cotransfected with c-Cbl, Myc-tagged memCsk<sup>AS</sup>, and His<sub>6</sub>V5-tagged Lyn constructs, including wild-type LynA, LynA<sup>Y32A</sup>, LynB, LynA<sup>K40R</sup>, LynA<sup>T27A</sup>, and LynA<sup>Y32F</sup>. (<bold>F</bold>) Quantification of protein levels of V5-tagged LynA (black dotted), LynA<sup>Y32A</sup> (olive), LynB (teal dotted), LynA<sup>K40R</sup> (dark gray), LynA<sup>T27A</sup> (light gray), and LynA<sup>Y32F</sup> (orange) over the course of 3-IB-PP1 treatment, corrected for total protein content (TPS) and reported relative to the steady-state level for each Lyn variant. SEM, n = 7 for LynA, n = 4 for LynA<sup>Y32A</sup> and LynB; n = 3 for LynA<sup>K40R</sup>, LynA<sup>T27A</sup>, and LynA<sup>Y32F</sup>. Sig. from ANOVA<sub>2</sub>-Tukey: [LynA<sup>Y32A</sup> vs. LynA, olive asterisks], [LynB vs. LynA, teal asterisks], [LynA<sup>Y32F</sup> vs. LynA, orange asterisks], [LynA<sup>K40R</sup> vs. LynA<sup>Y32A</sup>, dark gray asterisks], [LynA<sup>T27A</sup> vs. LynA<sup>Y32A</sup>, light gray asterisks], [LynB vs. LynA<sup>K40R</sup>, p=0.013, p=0.01], [LynB vs. LynA<sup>T27A</sup>, p&lt;0001], [Lyn<sup>Y32F</sup> vs. LynA<sup>K40R</sup>, p=0.012, 0.0157], [Lyn<sup>T27A</sup> vs. LynA<sup>Y32F</sup>, p&lt;0.0001], [Lyn<sup>Y32A</sup> vs. LynA<sup>K10R</sup>, p&lt;0.0001]; ****p&lt;0.0001, ***p=0.0006, *p=0.0166. Other pairs ns. Note: the error bar for LynA<sup>Y32F</sup> is smaller than the line width. Refer to <xref ref-type="supplementary-material" rid="fig3sdata1">Figure 3—source data 1</xref>. Refer to <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref> for microscopy showing localization of unique-region-only constructs of Lyn. Refer to <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref> for quantification of relative expression levels of LynA variants and LynB.</p><p><supplementary-material id="fig3sdata1"><object-id pub-id-type="doi">10.7554/eLife.46043.013</object-id><label>Figure 3—source data 1.</label><caption><title>Quantification of c-Cbl and Lyn proteins coexpressed in Jurkat cells.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-46043-fig3-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-46043-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.46043.010</object-id><label>Figure 3—figure supplement 1.</label><caption><title>The unique regions of LynA, LynB, and LynA<sup>Y32A</sup> are membrane-localized in resting and 3-IB-PP1-treated cells.</title><p>Representative epifluorescence images of GFP-tagged unique-region (UR) constructs of LynA, LynB, and LynA<sup>Y32A</sup>, showing localization in Jurkat cells before and after treatment for 5 min with 3-IB-PP1.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-46043-fig3-figsupp1-v2.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.46043.011</object-id><label>Figure 3—figure supplement 2.</label><caption><title>LynA<sup>Y32A</sup> and LynB are more highly expressed than wild-type LynA when expressed ectopically in Jurkat cells.</title><p>Quantification of His<sub>6</sub>V5-tagged LynA protein in Jurkat cells, reported relative to the steady-state expression of transfected wild-type His<sub>6</sub>V5-tagged LynA protein. Sig. from ANOVA<sub>2</sub>-Tukey: [LynA<sup>Y32A</sup> vs. LynA, olive asterisks], [LynB vs. LynA, teal asterisks], [LynA<sup>K40R</sup> vs. LynA<sup>Y32A</sup>, dark gray asterisks], [LynA<sup>T27A</sup> vs. LynA<sup>Y32A</sup>, light gray asterisks]; ***p=0.0002–0.0004, **p=0.0018–0.0062, * P=0.0216–0.0361. Other pairs ns. Refer to <xref ref-type="supplementary-material" rid="fig3s2sdata1">Figure 3—figure supplement 2—source data 1</xref>.</p><p><supplementary-material id="fig3s2sdata1"><object-id pub-id-type="doi">10.7554/eLife.46043.012</object-id><label>Figure 3—figure supplement 2—source data 1.</label><caption><title>Quantification of transfected Lyn constructs relative to wild-type LynA.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-46043-fig3-figsupp2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-46043-fig3-figsupp2-v2.tif"/></fig></fig-group><p>LynB, which lacks a 21 amino-acid insert found in the unique region of LynA (<xref ref-type="fig" rid="fig3">Figure 3D</xref>), was less efficiently degraded (10% depleted after 5 min treatment with 3-IB-PP1) than LynA (40% depleted after 5 min) in c-Cbl- and memCsk<sup>AS</sup>-cotransfected Jurkat cells (<xref ref-type="fig" rid="fig3">Figure 3E–F</xref>). Again, these data mirror our findings in Csk<sup>AS</sup> BMDMs (<xref ref-type="bibr" rid="bib23">Freedman et al., 2015</xref>) and confirm that the unique susceptibility of LynA to rapid degradation is preserved in the Jurkat model. We hypothesized that the c-Cbl recognition site in LynA must lie within the unique-region insert (residues 23–43), absent in LynB (<xref ref-type="bibr" rid="bib89">Yi et al., 1991</xref>; <xref ref-type="bibr" rid="bib71">Stanley et al., 1991</xref>), which contains a tyrosine residue reported to be phosphorylated in cancer cells (Y32; <xref ref-type="bibr" rid="bib36">Huang et al., 2013</xref>; <xref ref-type="bibr" rid="bib80">Tornillo et al., 2018</xref>), a predicted threonine phosphorylation site (T27; NetPhos 3.1, <xref ref-type="bibr" rid="bib5">Blom et al., 2004</xref>) and a predicted lysine ubiquitination site (K40; UbPred, <xref ref-type="bibr" rid="bib58">Radivojac et al., 2010</xref>) (<xref ref-type="fig" rid="fig3">Figure 3D</xref>).</p><p>Substituting tyrosine 32 with either alanine or phenylalanine blocked the rapid degradation of LynA (<xref ref-type="fig" rid="fig3">Figure 3E</xref>), reducing the depletion after 5 min treatment with 3-IB-PP1 from 40% (LynA) to 10% (LynA<sup>Y32A</sup>) or 8% (LynA<sup>Y32F</sup>), levels indistinguishable from LynB (10%) (<xref ref-type="fig" rid="fig3">Figure 3E–F</xref>). Substitution of Y32 did not alter the membrane localization of a unique-region construct at steady state or after 3-IB-PP1 treatment (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). Neither the predicted ubiquitination-site mutation (LynA<sup>K40R</sup>) nor the predicted threonine phosphorylation site mutation (LynA<sup>T27A</sup>) significantly affected the rate of LynA degradation (<xref ref-type="fig" rid="fig3">Figure 3F</xref>).</p><p>As in BMDMs, the efficiency of Lyn degradation correlated with its steady-state expression in Jurkat cells. LynB is 2-fold and LynA<sup>Y32A</sup> 3-fold more highly expressed than wild-type LynA, LynA<sup>K40R</sup>, or LynA<sup>T27A</sup> at steady state, resulting in 3- to 4-fold more protein remaining after 20 min treatment with 3-IB-PP1 (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>).</p><p>Overall, we conclude that the unique tyrosine residue Y32 in the LynA insert flags LynA for rapid, c-Cbl-mediated degradation and that this mechanism both determines the half-life of activated LynA protein during signaling and tunes its steady-state expression.</p></sec><sec id="s2-3"><title>Phosphorylation on tyrosine 32 targets activated LynA for polyubiquitination</title><p>Although phosphorylated LynA<sup>Y32</sup> has been found in liver and mammary tumor cells (<xref ref-type="bibr" rid="bib36">Huang et al., 2013</xref>; <xref ref-type="bibr" rid="bib80">Tornillo et al., 2018</xref>), it has been unclear whether this posttranslational modification is functionally relevant in hematopoietic cells and whether Y32 is phosphorylated as a consequence of SFK activation. To probe for Y32 phosphorylation, we performed quantitative analysis of LynA protein using targeted liquid-chromatography-coupled tandem mass spectrometry (LC-MS/MS) after immunoprecipitation of LynA from resting and 3-IB-PP1-treated BMDMs. We expected phosphorylation at this site to be transient due to the rapid degradation of LynA, and so we used a two-pronged approach to enrich potential Y32-phosphorylation: (i) to slow the rate of LynA polyubiquitination, we used BMDMs derived from <italic>Csk<sup>AS</sup>Cbl<sup>+/-</sup></italic> mice, and (ii) we applied 3-IB-PP1 as a 15 s pulse treatment. At this early time point, all SFKs are expected to be activation-loop phosphorylated, with only 20% of LynA polyubiquitinated, as we have observed in wild-type BMDMs (<xref ref-type="bibr" rid="bib23">Freedman et al., 2015</xref>).</p><p>Lysates from resting and 3-IB-PP1-treated BMDMs, normalized for total protein content, were subjected to immunoprecipitation using a LynA-specific antibody (<xref ref-type="bibr" rid="bib23">Freedman et al., 2015</xref>) (<xref ref-type="fig" rid="fig4">Figure 4A</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). Although some polyubiquitinated LynA species were generated, LynA was largely nonubiquitinated, as expected with low c-Cbl expression and an early time point of 3-IB-PP1 treatment. Bands from a Coomassie-stained gel containing nonubiquitinated and polyubiquitinated LynA were excised (<xref ref-type="fig" rid="fig4">Figure 4B</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>), normalized for protein content, and spiked with reference amounts of isotope-labeled control peptide corresponding to the tryptic fragment of Lyn encompassing pY32. These samples were then subjected to in-gel trypsin digestion and analyzed by LC-MS/MS.</p><fig-group><fig id="fig4" position="float"><object-id pub-id-type="doi">10.7554/eLife.46043.014</object-id><label>Figure 4.</label><caption><title>Tyrosine 32 is a site of activation-induced phosphorylation in macrophages.</title><p>(<bold>A</bold>) Blots showing immunoprecipitation of LynA from BMDMs derived from <italic>Csk<sup>AS</sup>Cbl<sup>+/- </sup></italic>mice with (+) or without (-) a 15 s treatment with 3-IB-PP1. Nonubiquitinated (nonUb) and polyubiquitinated (polyUb) LynA species in whole-cell and immunodepleted lysate (Lys<sup>w</sup> and Lys<sup>dep</sup>, respectively) and immunoprecipitate (IP) samples are shown. Uncropped immunoblots are shown in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>. (<bold>B</bold>) Coomassie-stained gel showing regions excised for LC-MS/MS analysis of polyUb LynA (higher boxes) and nonUb LynA (lower boxes); box colors correspond to the bar graphs below. Total IP protein content was quantified by applying densitometry to the whole lane and deriving a mass value via a BSA standard curve, shown in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>. Equivalent amounts of IP material were spiked with 125 fmol isotope-labeled control peptide (pY32*<sub>pep</sub>, a tryptic peptide containing phosphoY32) and subjected to in-gel trypsin digestion and LC-MS/MS. (<bold>C</bold>) Tryptic peptides Y32<sub>pep</sub> (IP-derived unphosphorylated peptide), pY32<sub>pep</sub> (IP-derived phosphopeptide), and added pY32*<sub>pep</sub> were quantified by using parallel reaction monitoring (PRM) to collect MS/MS spectra for peptide parent ions 687.3267 and 690.3336 <italic>m/z</italic>, respectively. Extracted ion chromatograms (XICs) were derived from Skyline for MS/MS fragment ions corresponding to y and b fragments from Y32, pY32, and pY32* peptides and used to quantify the ratios of pY32<sub>pep</sub>:pY32*<sub>pep</sub> or pY32<sub>pep</sub>:Y32<sub>pep</sub>. Representative ion-annotated XICs are shown in <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>. Assignment of XIC peaks using synthetic peptides is shown in <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>. Detection of phosphopeptides in IP samples is shown in <xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4</xref>. Peptide calibration curves are shown in <xref ref-type="fig" rid="fig4s5">Figure 4—figure supplement 5</xref>. (<bold>D–E</bold>) Quantitative analysis of Y32 phosphorylation in resting and 3-IB-PP1-treated BMDMs, including nonUb species from resting BMDMs (blue dotted), nonUb species from 3-IB-PP1-treated BMDMs (orange), and polyUb species from 3-IB-PP1-treated BMDMs (red). Although we analyzed a gel fragment that could contain polyUb species in resting BMDMs (gray dotted), this species was so rare as to be unquantifiable. Error bars represent the standard deviation (stdev) of n = 3 technical replicates. Data from two biological replicates are shown side by side. (<bold>D</bold>) Quantification of pY32<sub>pep</sub> in nonUb species from resting vs. 3-IB-PP1-treated BMDMs normalized to the total protein content of each IP. This analysis was used only for nonUb samples, which were roughly equimolar in resting and 3-IB-PP1-treated BMDMs. Sig. from two-tailed t tests for each experiment: [nonUb resting vs. nonUb 3-IB-PP1-treated, asterisks]; ****p&lt;0.0001. (<bold>E</bold>) Quantification of pY32<sub>pep</sub> in nonUb vs. polyUb species in 3-IB-PP1-treated BMDMs normalized to the amount of unphosphorylated Y32 <sub>pep</sub>. Sig. from two-tailed t tests for each experiment: [nonUb resting vs. nonUb 3-IB-PP1-treated, asterisks]; ****p&lt;0.0001. Refer to <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref>. Raw mass spectrometry files are available at the Panorama repository <ext-link ext-link-type="uri" xlink:href="http://panoramaweb.org">http://panoramaweb.org</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://panoramaweb.org/Freedman_LynA.url">http://panoramaweb.org/Freedman_LynA.url</ext-link>, ProteomeXchange ID: <ext-link ext-link-type="uri" xlink:href="http://proteomecentral.proteomexchange.org/cgi/GetDataset?ID=PXD014621">PXD014621</ext-link>).</p><p><supplementary-material id="fig4sdata1"><object-id pub-id-type="doi">10.7554/eLife.46043.027</object-id><label>Figure 4—source data 1.</label><caption><title>Summary quantification of pY32 peptide from LC-MS/MS data.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-46043-fig4-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-46043-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.46043.015</object-id><label>Figure 4—figure supplement 1.</label><caption><title>Uncropped blots and BSA standard curve for mass spectrometry samples.</title><p>(<bold>A</bold>) Uncropped images of LynA immunoblots show positions of molecular weight markers and serially diluted LynA immunoprecipitates. (<bold>B</bold>) Uncropped Coomassie-stained gel shwoing the BSA standard curve (left lanes) and the total protein inputs from the IPs in (<bold>A</bold>). The lower panel shows densitometry quantification of protein-stain signal intensity from each BSA standard (std) and fitting of the standard curve. The mass of total protein in each immunoprecipitate was then quantified to normalize the sample input for LC-MS/MS. Refer to <xref ref-type="supplementary-material" rid="fig4s1sdata1">Figure 4—figure supplement 1—source data 1</xref> for BSA calibration of IPs.</p><p><supplementary-material id="fig4s1sdata1"><object-id pub-id-type="doi">10.7554/eLife.46043.016</object-id><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>BSA standard curve for quantification of immunoprecipitated protein.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-46043-fig4-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-46043-fig4-figsupp1-v2.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.46043.017</object-id><label>Figure 4—figure supplement 2.</label><caption><title>Annotated XICs.</title><p>XICs from <xref ref-type="fig" rid="fig4">Figure 4C</xref> showing charge states and <italic>m/z</italic> values for y and b fragments from Y32 <sub>pep</sub>, pY32 <sub>pep</sub>, and pY32*<sub>pep</sub>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-46043-fig4-figsupp2-v2.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.46043.018</object-id><label>Figure 4—figure supplement 3.</label><caption><title>PRM chromatograms and spectra for unphosphorylated and phosphorylated LynA Y32 tryptic peptides.</title><p>(<bold>A</bold>) PRM chromatograms illustrating resolution of synthetic phosphorylated and unphosphorylated peptides (top and middle panels), resolution of pY32 and synthetic threonine-phosphorylated (pT) species (middle panel), and coelution of unlabeled pY32<sub>pep</sub> with isotope-labeled pY32*<sub>pep</sub> (middle and bottom panels). Species detected in LynA IPs (Y32 <sub>pep</sub>, pY32 <sub>pep</sub>, and pY32*<sub>pep</sub>) are indicated in bold type, phosphorylation sites are shown in red, and the isotope-labeled proline residue is shown in blue. (<bold>B–F</bold>) MS/MS spectra for synthetic peptides corresponding to tryptic peptides containing LynA Y32. The expected fragmentation pattern for each is indicated with phosphoions labeled in red/bold and isotope-labeled ions labeled in blue/bold. (<bold>B</bold>) MS/MS for Y32<sub>pep</sub> run at 647.3435 <italic>m/z</italic>. (<bold>C</bold>) MS/MS for pY32<sub>pep</sub> run at 687.3267 <italic>m/z</italic>, with highlighted fragment ions from phosphoY32. (<bold>D</bold>) MS/MS for pT30<sub>pep</sub> run at 687.3267 <italic>m/z</italic>, with highlighted fragment ions from phosphoT30. (<bold>E</bold>) MS/MS for pT37<sub>pep</sub> run at 687.3267 <italic>m/z</italic>, with highlighted fragment ions from phosphoT37. (<bold>F</bold>) MS/MS for pY32*<sub>pep</sub> run at 687.3267 <italic>m/z</italic>, with highlighted fragment ions from phosphoY32 and the isotope-labeled proline residue.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-46043-fig4-figsupp3-v2.tif"/></fig><fig id="fig4s4" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.46043.019</object-id><label>Figure 4—figure supplement 4.</label><caption><title>Y32 is the only site of phosphorylation detected in LynA Y32-containing tryptic peptide.</title><p>XICs of 687.3267 <italic>m/z</italic> (top) and 690.3336 m/z (bottom) with a 10 ppm tolerance window for nonUb LynA in IPs from 3-IB-PP1-treated BMDMs. The top chromatogram demonstrates that pY32<sub>pep</sub> TI[pY]VRDPTSNK but not pT30<sub>pep</sub> [pT]IYVRDPTSNK or pT37<sub>pep</sub> TIYVRDP[pT]SNK is detected under experimental conditions. The bottom chromatogram shows the co-isolation of isotope-labeled pY32*<sub>pep</sub> TI[pY]VRDP[<sup>13</sup>C<sub>5</sub> <sup>15</sup>N<sub>1</sub>]TSNK from the same sample.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-46043-fig4-figsupp4-v2.tif"/></fig><fig id="fig4s5" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.46043.020</object-id><label>Figure 4—figure supplement 5.</label><caption><title>Peptide calibration curves.</title><p>(<bold>A</bold>) Calibration curve for pY32 based on LC-MS/MS analysis. The results reflect the means and standard deviations of data acquired from three independent LC-MS/MS measurements. (<bold>B</bold>) Calibration curve for Y32 peptide. Refer to <xref ref-type="supplementary-material" rid="fig4s5sdata1">Figure 4—figure supplement 5—source data 1</xref>, <xref ref-type="supplementary-material" rid="fig4s5sdata2">2</xref> for calibration curve data. Refer to <xref ref-type="supplementary-material" rid="fig4s5sdata3">Figure 4—figure supplement 5—source data 3</xref>–<xref ref-type="supplementary-material" rid="fig4s5sdata6">6</xref> for peptide quantification from Skyline analysis.</p><p><supplementary-material id="fig4s5sdata1"><object-id pub-id-type="doi">10.7554/eLife.46043.021</object-id><label>Figure 4—figure supplement 5—source data 1.</label><caption><title>Standard curve for quantification of pY32 peptide relative to pY32* peptide in LynA immunoprecipitates.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-46043-fig4-figsupp5-data1-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig4s5sdata2"><object-id pub-id-type="doi">10.7554/eLife.46043.022</object-id><label>Figure 4—figure supplement 5—source data 2.</label><caption><title>Standard curve for quantification of pY32 peptide relative to Y32 peptide in LynA immunopr.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-46043-fig4-figsupp5-data2-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig4s5sdata3"><object-id pub-id-type="doi">10.7554/eLife.46043.023</object-id><label>Figure 4—figure supplement 5—source data 3.</label><caption><title>Quantification of pY32 peptide in nonUb LynA in resting BMDMs.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-46043-fig4-figsupp5-data3-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig4s5sdata4"><object-id pub-id-type="doi">10.7554/eLife.46043.024</object-id><label>Figure 4—figure supplement 5—source data 4.</label><caption><title>Quantification of pY32 peptide in polyUb LynA in resting BMDMs.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-46043-fig4-figsupp5-data4-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig4s5sdata5"><object-id pub-id-type="doi">10.7554/eLife.46043.025</object-id><label>Figure 4—figure supplement 5—source data 5.</label><caption><title>Quantification of pY32 peptide in nonUb LynA in 3-IB-PP1-treated BMDMs.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-46043-fig4-figsupp5-data5-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig4s5sdata6"><object-id pub-id-type="doi">10.7554/eLife.46043.026</object-id><label>Figure 4—figure supplement 5—source data 6.</label><caption><title>Quantification of pY32 peptide in polyUb LynA in 3-IB-PP1-treated BMDMs.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-46043-fig4-figsupp5-data6-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-46043-fig4-figsupp5-v2.tif"/></fig></fig-group><p>Peptides corresponding to phosphorylated and unphosphorylated LynA Y32, including the isotope-labeled standard, were detected in nonubiquitinated and polyubiquitinated LynA species from 3-IB-PP1-treated cells (<xref ref-type="fig" rid="fig4">Figure 4C</xref>, <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>). We were able to resolve phosphorylated and unphosphorylated Y32 peptide and other potential phosphorylated species within the same tryptic peptide via their LC elution profiles: pY32 peptide coeluted with its isotopically labeled counterpart, and these were clearly separated from unphosphorylated and threonine-phosphorylated species (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3A</xref>). The identity of each peptide was assigned via the MS/MS fragmentation pattern at the expected <italic>m/z</italic> (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3B–F</xref>).</p><p>In the LynA immunoprecipitates the tryptic peptide spanning residue 32 was phosphorylated at Y32 but not at T30 or T37 (<xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4</xref>). Search results in the PEAKS software package did not yield any matches for single or double threonine phosphorylation in combination with pY32, enabling complete analysis of LynA Y32 phosphorylation using an isotope-labeled pY32 peptide as the sole reference. Molar quantities of phosphorylated and unphosphorylated LynA Y32 peptide were derived by integrating the appropriate extracted ion chromatogram (XIC) peaks and correcting these values using standard curves with known molar ratios of unlabeled and isotope-labeled pY32 peptides (<xref ref-type="fig" rid="fig4s5">Figure 4—figure supplement 5A</xref>). For some analyses, a second calibration curve was used to determine the relative quantities of unphosphorylated Y32 peptide (<xref ref-type="fig" rid="fig4s5">Figure 4—figure supplement 5B</xref>).</p><p>We detected LynA Y32 phosphorylation in 3-IB-PP1-treated BMDMs in two independent experiments. After immunoprecipitation and sample processing, pY32 was 6- to 12-fold enriched in nonubiquitinated LynA from 3-IB-PP1-treated BMDMs relative to resting BMDMs (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). LynA Y32 is therefore a site of inducible phosphorylation following activation of SFKs in primary macrophages. In resting BMDMs the vast majority of LynA is inactive (<xref ref-type="bibr" rid="bib23">Freedman et al., 2015</xref>) and therefore protected from bulk degradation by lack of Y32 phosphorylation. Phosphorylated Y32 peptide was, however, detectable at low levels in resting BMDMs. This suggests that the suppression of steady-state LynA expression by c-Cbl (<xref ref-type="fig" rid="fig1">Figure 1</xref>, <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>) is attributable to mass action, driven by degradation of small quantities of basally active LynA.</p><p>Although phosphorylation of LynA Y32 was detected in activated, nonubiquitinated LynA, it was 6.0- to 6.4-fold higher in polyubiquitinated LynA (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). It is therefore likely that phosphorylation of LynA Y32 is an early consequence of SFK activation and a prerequisite for rapid polyubiquitination by c-Cbl.</p></sec><sec id="s2-4"><title>Activated LynA induces its own degradation in trans</title><p>In macrophages and other hematopoietic cells SFKs are the first kinases to be activated upon ITAM-coupled receptor engagement, phosphorylating intracellular ITAMs, ITAM-associated Syk or Zap70 (<xref ref-type="bibr" rid="bib88">Yan et al., 2013</xref>; <xref ref-type="bibr" rid="bib84">Wang et al., 2010</xref>), and integrin-associated FAK or Pyk2 (<xref ref-type="bibr" rid="bib45">Lowell, 2011</xref>; <xref ref-type="bibr" rid="bib33">Han et al., 2013</xref>). We have reported that Syk and FAK are phosphorylated on activating tyrosine residues in Csk<sup>AS</sup> BMDMs treated with 3-IB-PP1 (<xref ref-type="bibr" rid="bib23">Freedman et al., 2015</xref>). To test whether these downstream kinases might participate in negative feedback leading to LynA degradation, we treated Csk<sup>AS</sup> macrophages with competitive inhibitors of Syk (<xref ref-type="bibr" rid="bib87">Yamamoto et al., 2003</xref>), FAK/Pyk2 (<xref ref-type="bibr" rid="bib9">Buckbinder et al., 2007</xref>), or the SFKs themselves (<xref ref-type="bibr" rid="bib34">Hanke et al., 1996</xref>) in combination with 3-IB-PP1. As expected, activation-loop phosphorylation of Erk1/2 and the SFKs was blocked in samples cotreated with the pan-SFK inhibitor PP2, activation-loop phosphorylation of Erk1/2 but <italic>not</italic> the SFKs was blocked in samples cotreated with the Syk inhibitor BAY-61–3606, and phosphorylation of Paxillin phosphorylation was blocked in samples cotreated with the FAK/Pyk2 inhibitor PF-431396 (<xref ref-type="fig" rid="fig5">Figure 5A</xref>).</p><fig id="fig5" position="float"><object-id pub-id-type="doi">10.7554/eLife.46043.028</object-id><label>Figure 5.</label><caption><title>Syk, FAK, and Pyk2 kinase activities are not necessary for the rapid degradation of LynA.</title><p>(<bold>A</bold>) Immunoblots showing expression of endogenous LynA protein in Csk<sup>AS</sup> BMDMs treated with 3-IB-PP1 only or cotreated with 3-IB-PP1 and the Syk inhibitor BAY 61–3606, the SFK inhibitor PP2, or the FAK/Pyk2 inhibitor PF-431396. Activated signaling proteins including SFKs (pSFK<sup>act</sup>, activation-loop-phosphorylation corresponding to Src<sup>pY416</sup>), pErk1/2, and Paxillin<sup>pY118</sup> (pPaxillin) are shown as controls for inhibitor function; β-Actin and total Erk1/2 are shown as loading controls. (<bold>B</bold>) Quantification of LynA protein during 3-IB-PP1 treatment only (black dotted) or with the inhibitors BAY 61–3606 (iSyk, light olive), PP2 (iSFK, red), or PF-431396 (iFAK/Pyk2, green), corrected for total protein content (TPS) and reported relative to the steady-state level of LynA. SEM, n = 3. Sig. from ANOVA<sub>2</sub>-Tukey: [3-IB-PP1 only vs. 3-IB-PP1+PP2, black asterisks], [3-IB-PP1+BAY 61–3606 vs. 3-IB-PP1+PP2, light olive asterisks], [3-IB-PP1+PF-431396 vs. 3-IB-PP1+PP2, green asterisks]; ****p&lt;0.0001. Other pairs ns. Refer to <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>.</p><p><supplementary-material id="fig5sdata1"><object-id pub-id-type="doi">10.7554/eLife.46043.029</object-id><label>Figure 5—source data 1.</label><caption><title>Quantification of LynA degradation in BMDMs treated with 3-IB-PP1 and inhibitors.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-46043-fig5-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-46043-fig5-v2.tif"/></fig><p>LynA degradation was unaffected by Syk or FAK/Pyk2 inhibition but abrogated by SFK inhibition (<xref ref-type="fig" rid="fig5">Figure 5A–B</xref>). Given these data, we conclude that neither Syk, FAK, or Pyk2 nor any of their downstream targets participate in a negative-feedback loop leading to LynA degradation. This suggests that the only kinases upstream of Syk, FAK, and Pyk2, the SFKs themselves, induce LynA degradation. This tight feedback circuit could explain the strikingly short half-life of activated LynA.</p><p>To investigate the role of LynA kinase activity in its degradation, we turned again to Jurkat-cell transfections, testing two functionally impaired variants of LynA: LynA<sup>T410K</sup>, which has disrupted substrate recognition (<xref ref-type="bibr" rid="bib90">Yokoyama and Miller, 1999</xref>), and LynA<sup>Y397F</sup>, which lacks the key autophosphorylation site that stabilizes the kinase active state and interacts with c-Cbl (<xref ref-type="bibr" rid="bib16">Chow and Veillette, 1995</xref>; <xref ref-type="bibr" rid="bib61">Sanjay et al., 2001</xref>; <xref ref-type="bibr" rid="bib8">Brown and Cooper, 1996</xref>). To minimize interference from T-cell endogenous SFKs, we used Lck-deficient JCaM1.6 cells; previous work has shown that endogenous Fyn does not independently activate ITAM signaling in this cell line (<xref ref-type="bibr" rid="bib72">Straus, 1992</xref>; <xref ref-type="bibr" rid="bib27">Goldsmith and Weiss, 1987</xref>). When transfected into JCaM1.6 cells along with memCsk<sup>AS</sup> and c-Cbl, only catalytically competent His<sub>6</sub>V5-tagged LynA was subject to rapid, 3-IB-PP1-induced degradation (<xref ref-type="fig" rid="fig6">Figure 6A</xref>); we did not detect degradation of the substrate-binding-impaired variant (T410K) or the activation-loop-mutated variant (Y397F). Zap70 phosphorylation was only visible in JCaM1.6 cells transfected with wild-type LynA, demonstrating the functional impairment of LynA<sup>T410K</sup> and LynA<sup>Y397F</sup>.</p><fig-group><fig id="fig6" position="float"><object-id pub-id-type="doi">10.7554/eLife.46043.030</object-id><label>Figure 6.</label><caption><title>SFK activity is required for rapid degradation of LynA.</title><p>(<bold>A</bold>) Immunoblots showing expression of transfected wild-type (wt), substrate-binding-impaired (T410K), or activation-loop-mutated (Y397F) His<sub>6</sub>V5-tagged LynA protein coexpressed in JCaM1.6 cells with memCsk<sup>AS</sup> and c-Cbl and treated with 3-IB-PP1. Interdomain-B-phosphorylated Zap70<sup>pY319</sup> (pZap70), an SFK target and prerequisite for Zap70 activation, reflects the catalytic activity of LynA; β-Actin is shown as a loading control. (<bold>B</bold>) Overexpression of LynA variants in Jurkat cells. pZap70 reflects 3-IB-PP1-induced Lck activation. (<bold>C</bold>) Quantification of V5-tagged LynA variants wt (black dotted), T410K (gray), and Y397F (orange) in Jurkat cells during 3-IB-PP1 treatment, corrected for total protein content (TPS) and reported relative to the steady-state level for each variant of LynA. SEM, n = 3. Sig. from ANOVA<sub>2</sub>-Tukey: [T410K vs. wt, gray asterisks], [Y397F vs. wt, orange asterisks]; **p=0.0015–0.0083. Other pairs ns. Refer to <xref ref-type="supplementary-material" rid="fig6sdata1">Figure 6—source data 1</xref>. Refer to <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref> for additional experiments with the catalytic-site mutant LynA<sup>K275R</sup>.</p><p><supplementary-material id="fig6sdata1"><object-id pub-id-type="doi">10.7554/eLife.46043.033</object-id><label>Figure 6—source data 1.</label><caption><title>Quantification of kinase-impaired LynA proteins expressed in Jurkat cells.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-46043-fig6-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-46043-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.46043.031</object-id><label>Figure 6—figure supplement 1.</label><caption><title>Catalytically dead LynA<sup>K275R</sup> is not targeted for rapid degradation.</title><p>(<bold>A</bold>) Immunoblots showing ectopic expression of wild-type (wt, black dotted) and active-site-mutated (K275R, cyan) His<sub>6</sub>V5-tagged LynA protein coexpressed in JCaM1.6 cells with memCsk<sup>AS</sup> and c-Cbl and treated with 3-IB-PP1. pZap70 shows the impaired function of LynA<sup>K275R</sup>; β-Actin is shown as a loading control. (<bold>B</bold>) Quantification of V5-tagged LynA protein corrected for total protein content (TPS), reported relative to the steady-state level for each LynA variant. SEM, n = 3. Sig. from ANOVA<sub>2</sub> with Sidak’s multiple comparison test: [K275R vs. wt] ***p=0.0008. Refer to <xref ref-type="supplementary-material" rid="fig6s1sdata1">Figure 6—figure supplement 1—source data 1</xref>.</p><p><supplementary-material id="fig6s1sdata1"><object-id pub-id-type="doi">10.7554/eLife.46043.032</object-id><label>Figure 6—figure supplement 1—source data 1.</label><caption><title>Quantification of LynA<sup>K275R </sup>protein in Jurkat cells during 3-IB-PP1 treatment.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-46043-fig6-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-46043-fig6-figsupp1-v2.tif"/></fig></fig-group><p>We then transfected the same variants of LynA into Lck-expressing Jurkat cells (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). The presence of phosphorylated Zap70 in all transfections demonstrates the expected activation of endogenous Lck in response to 3-IB-PP1 (<xref ref-type="bibr" rid="bib65">Schoenborn et al., 2011</xref>; <xref ref-type="bibr" rid="bib72">Straus, 1992</xref>; <xref ref-type="bibr" rid="bib11">Burgess et al., 1991</xref>; <xref ref-type="bibr" rid="bib60">Samelson et al., 1990</xref>). Activated Lck, however, was unable to induce degradation of LynA in trans, with no detectable loss of either catalytically-impaired variant (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). To ensure that the substrate-binding and conformational elements altered in the T410K and Y397F variants did not affect our results, we confirmed that the active-site mutant LynA<sup>K275R</sup> was similarly resistant to 3-IB-PP1-induced degradation (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>).</p><p>Observing that neither the Jurkat-cell SFKs (Lck/Fyn) nor the myeloid-cell SFK targets (Syk and FAK/Pyk2) participate in LynA degradation, we turned our focus to the major SFKs in macrophages. We showed above that wild-type LynA is degraded in 3-IB-PP1-treated Jurkat cells cotransfected with c-Cbl and memCsk<sup>AS</sup>, suggesting that LynA provides the sole initiating signal to trigger its own degradation, in (i) its ability to induce the phosphorylation of LynA Y32 and (ii) its ability to phosphorylate and activate c-Cbl. To determine whether this effect could be mediated in trans by LynA and the other macrophage-expressed SFKs, we performed experiments in which LynA<sup>T410K</sup> (not degraded on its own during 3-IB-PP1 treatment) was coexpressed with kinase-active SFKs in Lck-deficient JCaM1.6 cells. LynA<sup>T410K</sup> degradation would indicate that other SFKs could induce both LynA Y32 phosphorylation in trans and c-Cbl activation (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>). The composition of these transfected samples was assessed by immunoblotting for His<sub>6</sub>V5-tagged LynA<sup>T410K</sup> (for quantification in experimental samples) or wild-type His<sub>6</sub>V5-tagged LynA (as a positive control). Wild-type LynA and LynA<sup>Y32A</sup> were cotransfected as untagged constructs, so they could be resolved independently of His<sub>6</sub>V5-tagged LynA<sup>T410K</sup> on LynA immunoblots (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). Cotransfected SFKs were visualized using antibodies specific for inactive and active SFKs, the V5 epitope tag, and/or individual Src family members (<xref ref-type="fig" rid="fig7">Figure 7A</xref>, <xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2A</xref>). Cotransfected SFKs were classified by expression level, by ability to induce phosphorylation of the LynA<sup>T410K</sup> activation loop (pLynA<sup>act</sup>), phosphorylation of Zap70 (at an activating SFK substrate site in interdomain B, <xref ref-type="bibr" rid="bib88">Yan et al., 2013</xref>; <xref ref-type="bibr" rid="bib84">Wang et al., 2010</xref>), and phosphorylation of c-Cbl at Y731 (an SFK- but not Syk-dependent site of phosphorylation, <xref ref-type="bibr" rid="bib10">Buitrago et al., 2011</xref>) (<xref ref-type="fig" rid="fig7">Figure 7B</xref>).</p><fig-group><fig id="fig7" position="float"><object-id pub-id-type="doi">10.7554/eLife.46043.034</object-id><label>Figure 7.</label><caption><title>Cotransfected LynA, LynB, and Hck<sup>56</sup> can induce rapid degradation of LynA<sup>T410K</sup> in trans.</title><p>(<bold>A</bold>) Representative immunoblots showing levels of His<sub>6</sub>V5-tagged LynA<sup>T410K</sup> (#) cotransfected with empty vector or active SFK (co) in memCsk<sup>AS</sup>- and c-Cbl-expressing JCaM1.6 cells. Refer to <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref> for an illustration of the experimental layout. Cotransfected SFKs include untagged LynA, untagged LynA<sup>Y32A</sup>, His<sub>6</sub>V5-tagged LynB, the long and short isoforms of Hck (Hck<sup>59+56</sup>), the long isoform of Hck (Hck<sup>59</sup>), FynT (Fyn), FynB, and Fgr. FynT is also expressed endogenously. His<sub>6</sub>V5-tagged LynA<sup>T410K#</sup> (or wild-type LynA<sup>#</sup> in the positive control condition) was quantified from a total LynA blot (top panel). Colors correspond to later figure panels. Coexpressed SFKs are visualized via total SFK and pSFK<sup>inact</sup> (inhibitory-tail phosphorylated SFK, corresponding to Src<sup>pY530</sup>) blots as indicated. pSFK<sup>act</sup> (activation-loop phosphorylated, corresponding to Src<sup>pY416</sup>), pZap70, and p-c-Cbl blots are used to show 3-IB-PP1-induced activity of the cotransfected SFK; Erk1/2 is shown as a loading control. Refer to <xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2A</xref> for immunoblots of LynB, Fgr, and Fyn cotransfections. When cotransfected with LynA<sup>T410K</sup>, untagged wild-type LynA was expressed at very low levels, but its presence is inferred based on induction of Zap70 and c-Cbl phosphorylation with 3-IB-PP1 treatment. (<bold>B</bold>) Comparison of the expression (expr) levels of cotransfected SFKs (SFK<sup>co</sup>) and their ability to induce phosphorylation of the LynA<sup>T410K</sup> activation loop (pLynA<sup>act</sup>, the highest band in the pSFK<sup>act</sup> blots), Zap70<sup>pY319</sup> and c-Cbl<sup>pY731</sup> (p-c-Cbl) following 3-IB-PP1 treatment. If expression could not be directly compared with the wild-type LynA in the positive-control sample, pSFK<sup>inact</sup> and/or pSFK<sup>act</sup> blots werecompared, with the caveat that the antibodies may not bind different SFKs equally well (marked with asterisks). Despite transfection, Fyn was expressed at endogenous levels (endog). Refer to <xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2B</xref> for blots showing the effects of activating endogenous Lck. (<bold>C–D</bold>) Quantification of His<sub>6</sub>V5-tagged wild-type LynA alone (black dotted) or His<sub>6</sub>V5-tagged LynA<sup>T410K</sup> alone (gray dotted) or cotransfected with the kinase-active SFKs. All LynA quantifications (#) are corrected for total protein content (TPS) and reported relative to the steady-state level for each transfection condition. SEM, n = 5 for LynA<sup>T410K</sup> and LynA alone, SEM, n = 4 for all others. Sig. from ANOVA<sub>2</sub>-Tukey: [LynA<sup>T410K</sup> vs. LynA black asterisks], LynA<sup>T410K</sup> vs. LynA<sup>T410K</sup>+LynA, coral asterisks], [LynA<sup>T410K</sup> vs. LynA<sup>T410K</sup>+LynA<sup>Y32A</sup>, dark orange asterisks], [LynA<sup>T410K</sup> vs. LynA<sup>T410K</sup>+LynB, gold asterisks], [LynA<sup>T410K</sup> vs. LynA<sup>T410K</sup>+Hck<sup>59+56</sup>, teal asterisks], [Lyn vs. LynA<sup>T410K</sup>+Fyn, dark purple asterisk]; ***p=0.0007, **p=0.0017, *p=0.0180–0.0466. Other pairs ns. (<bold>C</bold>) Quantification of His<sub>6</sub>V5-tagged LynA<sup>T410K</sup> cotransfected with SFKs that induce degradation of LynA<sup>T410K</sup>. These include: untagged wild-type LynA (coral), untagged LynA<sup>Y32A</sup> (dark orange), His<sub>6</sub>V5-tagged LynB (gold dotted), and Hck<sup>59+56</sup> (teal). (<bold>D</bold>) Quantification of His<sub>6</sub>V5-tagged LynA<sup>T410K</sup> cotransfected with SFKs that do not induce degradation of LynA<sup>T410K</sup>: Hck<sup>59</sup> (tan), Fgr (blue dotted), Fyn (purple), and FynB (light purple). Refer to <xref ref-type="supplementary-material" rid="fig7sdata1">Figure 7—source data 1</xref>.</p><p><supplementary-material id="fig7sdata1"><object-id pub-id-type="doi">10.7554/eLife.46043.037</object-id><label>Figure 7—source data 1.</label><caption><title>Quantification of LynA<sup>T410K</sup> coexpressed in Jurkat cells with other SFKs.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-46043-fig7-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-46043-fig7-v2.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.46043.035</object-id><label>Figure 7—figure supplement 1.</label><caption><title>Assessing degradation of LynA mediated by SFKs in trans.</title><p>Experimental layout, showing interactions of a substrate-binding-impaired His<sub>6</sub>V5-tagged LynA<sup>T410K</sup>, which is not on its own degradable, with functionally-competent SFKs cotransfected into JCaM1.6 cells.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-46043-fig7-figsupp1-v2.tif"/></fig><fig id="fig7s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.46043.036</object-id><label>Figure 7—figure supplement 2.</label><caption><title>Additional immunoblots from cotransfection experiments.</title><p>(<bold>A</bold>) Immunoblots showing cotransfected LynB, Fgr, and Fyn and 3-IB-PP1-mediated phosphorylation events. (<bold>B</bold>) Immunoblots from Lck-expressing Jurkat cells showing phosphorylation of activation-loop Y397 of LynA<sup>T410K</sup>, interdomain B tyrosine 319 of Zap70, and tyrosine 731 of c-Cbl due to the activity of endogenous Lck in cells cotransfected with kinase-dead LynA constructs.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-46043-fig7-figsupp2-v2.tif"/></fig></fig-group><p>Cotransfected wild-type LynA, LynA<sup>Y32A</sup>, and LynB were all capable of inducing the degradation of LynA<sup>T410K </sup>in trans. Where depletion of LynA<sup>T410K</sup> transfected alone was undetectable after 5 min of 3-IB-PP1 treatment, cotransfected wild-type LynA, LynA<sup>Y32A</sup>, and LynB induced depletion of LynA<sup>T410K</sup> by 20%, 37%, and 40%, respectively; wild-type LynA alone was depleted by 40% at the same time point (<xref ref-type="fig" rid="fig7">Figure 7C</xref>). Although individual cells in a transiently transfected pool express varying levels of each construct, we were able to observe trends in the bulk expression levels of cotransfected SFKs. As reported by the LynA immunoblots for wild-type LynA and LynA<sup>Y32A</sup> (<xref ref-type="fig" rid="fig7">Figure 7A</xref>) and the V5 immunoblots for LynA and LynB (<xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2A</xref>), LynA<sup>Y32A</sup> and LynB are more highly expressed than wild-type LynA. This is consistent with our previous observations (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>). This difference in expression could explain the effectiveness of LynA<sup>Y32A</sup> and LynB in inducing degradation of LynA<sup>T410K</sup>; the unique-region substitution in LynA<sup>Y32A</sup> does not noticeably block this function or catalytic activity in general, at least compared to similarly expressed LynB. Potential differences in activity or signaling specificity, however, would be better investigated in a system that does not rely on overexpression.</p><p>Expression of Hck from a dual 59 kDa- and 56 kDa-expressing (Hck<sup>59+56</sup>) plasmid induced depletion of LynA<sup>T410K</sup> by 17% after a 5 min treatment with 3-IB-PP1 (<xref ref-type="fig" rid="fig7">Figure 7C</xref>). Based on estimates from pSFK blots, both isoforms of Hck were expressed at high levels and pLynA<sup>act</sup>, pZap70, and p-c-Cbl were strongly induced (<xref ref-type="fig" rid="fig7">Figure 7A–B</xref>). This activity, however, did not translate into a higher rate of LynA<sup>T410K</sup> degradation than the poorly expressed, cotransfected wild-type LynA (<xref ref-type="fig" rid="fig7">Figure 7A–B</xref>), suggesting that the ability to induce LynA degradation in trans depends on substrate specificity or other protein-protein interactions. Hck<sup>59</sup> alone was able to phosphorylate the activation loop of LynA<sup>T410K</sup> but unable to phosphorylate Zap70 or c-Cbl or induce degradation of LynA<sup>T410K</sup> (<xref ref-type="fig" rid="fig7">Figure 7A,B,D</xref>). This suggests that in the dual expression condition only the shorter isoform, Hck<sup>56</sup>, was responsible for mediating phosphorylation of Zap70 and c-Cbl and degradation of LynA.</p><p>Endogenous Fyn in Jurkat cells is not activated during 3-IB-PP1 treatment (<xref ref-type="fig" rid="fig7">Figure 7A</xref>), and we were unable to increase the expression or 3-IB-PP1-induced activation of Fyn by cotransfection. We did, however, detect overexpression and 3-IB-PP1-induced activation of a cotransfected brain isoform of Fyn (FynB). Like Hck<sup>59</sup>, FynB induced activation-loop phosphorylation of LynA<sup>T410K</sup> (<xref ref-type="fig" rid="fig7">Figure 7B</xref>) but did not phosphorylate Zap70 or c-Cbl or induce LynA<sup>T410K</sup> degradation (<xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2A</xref>).</p><p>Although neither was able to induce degradation of LynA<sup>T410K</sup>, Fgr and Lck were markedly different from Hck<sup>59</sup> and FynB in that, in addition to activation-loop-phosphorylating LynA<sup>T410K</sup>, they were also capable of inducing Zap70 and c-Cbl phosphorylation (<xref ref-type="fig" rid="fig7">Figure 7B,D</xref>, <xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2A–B</xref>). Again, this suggests that the failure of Lck and Fgr to mediate LynA degradation is due to substrate specificity rather than localization or lack of participation in ITAM signaling pathways.</p><p>Overall, these results show that LynA degradation can be induced by SFK activity in trans. Activated LynA, LynB, and Hck<sup>56</sup> can all mediate LynA degradation to some extent, but Lyn appears to do this most efficiently, due either to faster activation kinetics or more efficient phosphorylation of LynA and c-Cbl.</p></sec><sec id="s2-5"><title>Differential expression of c-Cbl tunes LynA protein levels and signaling in macrophages and mast cells</title><p>Analysis of data from the Immunological Genome Project shows that mRNA expression of Lyn and c-Cbl are differentially regulated across different cell types. Mast cells, for instance, express very low levels of <italic>Cbl</italic> mRNA (<xref ref-type="fig" rid="fig8">Figure 8</xref>) (<xref ref-type="bibr" rid="bib35">Heng and Painter, 2008</xref>; <xref ref-type="bibr" rid="bib20">Dwyer et al., 2016</xref>), which translates into a low level of c-Cbl protein expression (<xref ref-type="bibr" rid="bib30">Gustin et al., 2006</xref>). <italic>Cblb</italic> mRNA, in contrast, is abundant in mast cells.</p><fig id="fig8" position="float"><object-id pub-id-type="doi">10.7554/eLife.46043.038</object-id><label>Figure 8.</label><caption><title>Expression levels of <italic>Lyn</italic>, <italic>Cbl</italic>, and <italic>Cblb</italic> are regulated differentially in myeloid cells.</title><p>Mouse RNAseq data derived from the Immunological Genome Project (ImmGen, <ext-link ext-link-type="uri" xlink:href="http://rstats.immgen.org/Skyline/skyline.html">http://rstats.immgen.org/Skyline/skyline.html</ext-link>, <xref ref-type="bibr" rid="bib35">Heng and Painter, 2008</xref>; <xref ref-type="bibr" rid="bib20">Dwyer et al., 2016</xref>). <italic>Lyn</italic>, <italic>Cbl</italic>, and <italic>Cblb</italic> mRNA expression levels are shown for macrophages, mast cells, neutrophils, dendritic cells, and monocytes. Refer to <xref ref-type="supplementary-material" rid="fig8sdata1">Figure 8—source data 1</xref>.</p><p><supplementary-material id="fig8sdata1"><object-id pub-id-type="doi">10.7554/eLife.46043.039</object-id><label>Figure 8—source data 1.</label><caption><title>Expression data from Immgen.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-46043-fig8-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-46043-fig8-v2.tif"/></fig><p>As in macrophages, Lyn is a key regulator of mast-cell ITAM signaling (<xref ref-type="bibr" rid="bib68">Shelby et al., 2016</xref>), but the effect of disparate c-Cbl expression on LynA in the two cell types remains unknown. We generated bone-marrow-derived mast cells from Csk<sup>AS</sup> mice and performed surface marker analysis as we had for BMDMs (<xref ref-type="bibr" rid="bib23">Freedman et al., 2015</xref>). Csk<sup>AS</sup> mast cells were homogeneous in their expression of the mast-cell markers FcεR1α and c-Kit (CD117) (<xref ref-type="bibr" rid="bib40">Kalesnikoff and Galli, 2011</xref>) (<xref ref-type="fig" rid="fig9">Figure 9A</xref>).</p><p>We then used immunoblotting to compare the expression of c-Cbl, Cbl-b, and LynA in Csk<sup>AS</sup> mast cells and BMDMs and found that mast cells express very little c-Cbl (20% of the level in rested macrophages) and relatively high levels of Cbl-b (80% of the level in rested macrophages) (<xref ref-type="fig" rid="fig9">Figure 9B–C</xref>). Strikingly, low c-Cbl expression was accompanied by a complete resistance of LynA to degradation in the first 5 min of 3-IB-PP1 treatment (<xref ref-type="fig" rid="fig9">Figure 9D</xref>). Mast cells also had increased steady-state expression of LynA (30% higher than in rested BMDMs) (<xref ref-type="fig" rid="fig9">Figure 9E</xref>), despite low reported mRNA expression (<xref ref-type="fig" rid="fig8">Figure 8</xref>). These combined effects resulted in 3-4x more LynA protein in mast cells than in rested BMDMs and 2x more than in primed BMDMs between 3 and 5 min of 3-IB-PP1 treatment. Mast cells also had a stronger signaling response to 3-IB-PP1. Although the kinetics of Erk phosphorylation in mast cells varied, induction of pErk1/2 was consistently higher in mast cells than in macrophages, including in primed BMDMs (<xref ref-type="fig" rid="fig9">Figure 9F</xref>). We therefore hypothesized that cell-specific expression of c-Cbl tunes the abundance of LynA protein at steady state and the half-life of that protein during activation. Since mast cells are less dependent on c-Cbl for positive signaling (<italic>e.g.</italic> as a scaffold in PI3K activation), long-lived LynA potentiates a strong response to 3-IB-PP1. Thus mast cells bypass the LynA signaling checkpoint by maintaining low levels of c-Cbl and therefore high levels of activated LynA.</p><p>The relationship between c-Cbl expression, LynA degradation, and sensitivity to SFK-mediated signaling suggests that the responsiveness of myeloid cells can be tuned by changes in c-Cbl expression at the mRNA and/or protein level. As a direct test of this effect, we transfected mast cells derived from Csk<sup>AS</sup> bone marrow with a small activating (sa)RNA duplex (<xref ref-type="bibr" rid="bib56">Portnoy et al., 2011</xref>; <xref ref-type="bibr" rid="bib83">Voutila et al., 2017</xref>; <xref ref-type="bibr" rid="bib82">Voutila et al., 2012</xref>) designed to increase the expression of <italic>Cbl</italic> mRNA. Transfection of this saRNA into mast cells increased the expression of c-Cbl protein an average of 2-fold relative to mock-transfected cells (<xref ref-type="fig" rid="fig9">Figure 9G</xref>). Csk<sup>AS</sup> mast cells were then treated with 3-IB-PP1 for up to 15 min to activate SFKs and assess LynA degradation and signaling potential as reported by pErk1/2 (<xref ref-type="fig" rid="fig9">Figure 9H</xref>). Even this modest increase in mast-cell c-Cbl expression increased LynA degradation in response to 3-IB-PP1 and suppressed downstream phosphorylation of Erk1/2 (<xref ref-type="fig" rid="fig9">Figure 9I–J</xref>). 3-IB-PP1 treatment for 15 min led to a 30% reduction of LynA protein in c-Cbl-overexpressing mast cells; LynA degradation at this time point was undetectable in control mast cells (<xref ref-type="fig" rid="fig9">Figure 9I</xref>). Correspondingly, Erk1/2 phosphorylation was completely suppressed in mast cells treated with c-Cbl saRNA relative to control mast cells (<xref ref-type="fig" rid="fig9">Figure 9J</xref>). Together, these data are consistent with a model in which differential expression of c-Cbl in myeloid cells regulates the activation response of LynA, working together with transcriptional regulation to tune myeloid-cell responsiveness to SFK-mediated signaling.</p><fig id="fig9" position="float"><object-id pub-id-type="doi">10.7554/eLife.46043.040</object-id><label>Figure 9.</label><caption><title>Differential expression of c-Cbl tunes LynA protein levels and SFK-mediated downstream signaling in macrophages and mast cells.</title><p>(<bold>A</bold>) Flow cytometry showing surface expression of the mast-cell markers FcεR1α and c-Kit (CD117) in Csk<sup>AS</sup> bone-marrow-derived mast cells (red) compared to peritoneal B cells (gray). (<bold>B</bold>) Immunoblots of Csk<sup>AS</sup> mast cells and BMDMs (mϕ) after resting or IFN-γ priming, showing the levels of LynA, c-Cbl, Cbl-b, and pErk1/2 during 3-IB-PP1 treatment; total Erk1/2 is shown as a loading control. (<bold>C–F</bold>) Quantification of c-Cbl, Cbl-b, LynA, and pErk in mast cells (red), IFN-γ-primed mϕs (dark teal), and rested mϕs (light teal). (<bold>C</bold>) Quantification of steady-state c-Cbl and Cbl-b protein in mast cells and rested mϕs, corrected for total protein content (TPS) and reported relative to levels in primed mϕs. SEM, n = 3. Sig. from one-way ANOVA with Sidak’s multiple comparison test: [mast vs. rested mϕs] **p=0.0035. Others pairs ns. (<bold>D–E</bold>) Quantification of LynA in mast cells and mϕs during 3-IB-PP1 treatment, corrected for total protein content (TPS) and reported relative to the steady-state level of LynA in each cell type (<bold>D</bold>) or relative to the steady-state level of LynA in rested mϕs (<bold>E</bold>). SEM, n = 3 for mast cells and primed mϕs, n = 4 for rested mϕs. Sig. from ANOVA<sub>2</sub>-Tukey: [mast vs. rested mϕs, light teal asterisks], [mast vs. primed mϕs, dark teal asterisks]; ***p=0.0004–0.0008, **p=0.0025–0.0088, * P=0.0134–0.0466. Other pairs ns. (<bold>F</bold>) Quantification of pErk1/2 induction during 3-IB-PP1 treatment, corrected for total Erk1/2 expression and reported relative to the steady-state level of pErk1/2 in rested mϕs. SEM, n = 3 for mast cells, n = 4 for primed mϕs, n = 5 for rested mϕs. Sig. from ANOVA<sub>2</sub>-Sidak: [mast vs. rested mϕs, asterisk]; *p=0.0330. Other pairs ns. (<bold>G</bold>) Immunoblots showing steady-state expression of c-Cbl in Csk<sup>AS</sup> mast cells transfected in the presence or absence of <italic>Cbl</italic>-specific saRNA; Erk1/2 is shown as a loading control. (<bold>H</bold>) Immunoblots showing levels of LynA protein, pSyk, and pErk1/2 during 3-IB-PP1 treatment of <italic>Cbl</italic>-saRNA-transfected or mock-transfected mast cells. (<bold>I–J</bold>) Quantification of LynA and pErk in mast cells with (pink) and without (red) saRNA-induced upregulation of c-Cbl protein. SEM, n = 3. (<bold>I</bold>) Quantification of LynA protein during 3-IB-PP1 treatment, corrected for total protein content (TPS) and reported relative to the steady-state level for each transfection condition. Sig. from mixed-effects ANOVA analysis: *p=0.0229. (<bold>J</bold>) Quantification of pErk1/2 induction during 3-IB-PP1 treatment in saRNA-treated and mock-treated mast cells, corrected for total Erk1/2 expression and reported relative to the steady-state level for each condition. SEM, n = 3 for mast cells. Sig. from ANOVA<sub>2</sub>-Sidak: **p=0.0045. Refer to <xref ref-type="supplementary-material" rid="fig9sdata1">Figure 9—source data 1</xref>.</p><p><supplementary-material id="fig9sdata1"><object-id pub-id-type="doi">10.7554/eLife.46043.041</object-id><label>Figure 9—source data 1.</label><caption><title>Comparison of mast cells and macrophages.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-46043-fig9-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-46043-fig9-v2.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Polyubiquitination of signaling proteins by the Cbl family can lead to their degradation via the endolysosome or proteasome and to non-degradation-mediated inhibition (<xref ref-type="bibr" rid="bib19">Duan et al., 2004</xref>). These E3 ligases must in turn be tightly regulated to prevent hyperresponsive or aberrant immune signaling while maintaining proper pathogen clearance (<xref ref-type="bibr" rid="bib93">Zhu et al., 2016</xref>). Although highly homologous, c-Cbl and Cbl-b target different subsets of signaling proteins for inhibition and/or degradation (<xref ref-type="bibr" rid="bib78">Thien and Langdon, 2005</xref>; <xref ref-type="bibr" rid="bib49">Mohapatra et al., 2013</xref>), with c-Cbl polyubiquitinating the SFKs, including Lyn (<xref ref-type="bibr" rid="bib41">Kyo et al., 2003</xref>; <xref ref-type="bibr" rid="bib67">Shao et al., 2004</xref>), and Cbl-b acting on ITAM-coupled receptors, Syk, and other kinases (<xref ref-type="bibr" rid="bib57">Purev et al., 2009</xref>; <xref ref-type="bibr" rid="bib69">Sohn et al., 2003</xref>; <xref ref-type="bibr" rid="bib30">Gustin et al., 2006</xref>; <xref ref-type="bibr" rid="bib93">Zhu et al., 2016</xref>). c-Cbl binds via its phosphotyrosine-binding (PTB) domain to the SFK activation-loop phosphotyrosine (<xref ref-type="bibr" rid="bib61">Sanjay et al., 2001</xref>) and via its PXXP motifs to the SFK SH3 domain (<xref ref-type="bibr" rid="bib62">Sanjay et al., 2006</xref>). It is also an SFK substrate, requiring phosphorylation to become fully activated. These binding interfaces promote general c-Cbl interaction with all the SFKs. In this paper we report that c-Cbl targets LynA for rapid and specific degradation, a process that occurs with a half-life of a minute in BMDMs. In contrast, other E3 ligases contribute to the slower degradation mechanism shared among the other SFKs, including LynB, Fgr, Hck<sup>59</sup>, Hck<sup>56</sup>, Lck, FynB, and FynT, with the caveat that FynT does not seem to be activated in response to 3-IB-PP1.</p><p>c-Cbl is targeted to LynA via a noncanonical recognition site present in LynA but not the other SFKs. Although LynA and LynB have identical activation kinetics, lipidation sites, and activation-loop and SH3-domain sequences, LynA is degraded &gt;10 fold more quickly than LynB in macrophages treated with the Csk<sup>AS</sup> inhibitor/SFK activator 3-IB-PP1 (20). Exploiting the similarity between LynA and LynB to make a limited set of point mutations, we have discovered that, while activation-loop phosphorylation and SH3-domain interactions mediate slower-phase targeting by c-Cbl and other E3 ligases, rapid degradation of LynA is triggered by an interaction peculiar to its unique-domain insert region.</p><p>We have discovered that phosphorylation of Y32 in the unique-region insert of LynA is required for its rapid degradation. This phosphorylation occurs within seconds of LynA activation in macrophages, and flags LynA for rapid, c-Cbl-mediated polyubiquitination. Phosphorylation of LynA Y32 had been observed in neuroblastoma cell lines upon receptor-tyrosine-kinase activation (<xref ref-type="bibr" rid="bib54">Palacios-Moreno et al., 2015</xref>). In epidermoid carcinoma (A431) cells and breast tumor samples LynA Y32 is phosphorylated by the epidermal growth factor receptor (EGFR), allowing it to phosphorylate MCM-7 and stimulate cell proliferation (<xref ref-type="bibr" rid="bib36">Huang et al., 2013</xref>). We now present evidence that LynA Y32 is phosphorylated in primary macrophages, where this potentially positive-regulatory function paradoxically induces LynA to trigger its own c-Cbl-mediated polyubiquitination and degradation, a process underlying its function as a rheostat controlling the LynA checkpoint.</p><p>Kinase-impaired variants of LynA are not rapidly degraded, a result confirmed in macrophages treated with the SFK inhibitor PP2. Catalytically active LynA and LynB, however, can induce degradation of catalytically impaired LynA in trans. Interestingly, the shorter isoform of Hck can also induce degradation of LynA, although less efficiently than Lyn itself. Degradation of LynA depends on a minimum of two phosphorylation events: the phosphorylation of LynA Y32 and activating phosphorylation of c-Cbl (<xref ref-type="bibr" rid="bib22">Feshchenko et al., 1998</xref>; <xref ref-type="bibr" rid="bib18">Dou et al., 2012</xref>). The ability of individual Src family members to induce LynA degradation necessarily relies on the efficiency of these two processes. In cotransfection experiments, we found that some SFKs (FynB, Hck<sup>59</sup>, Fgr, and Lck) were unable to induce degradation of kinase dead LynA<sup>T410K</sup> despite an increase in their own activation-loop phosphorylation and their ability to phosphorylate the activation loop of LynA<sup>T410K</sup>. This suggests, perhaps surprisingly (<xref ref-type="bibr" rid="bib44">Lock et al., 1991</xref>; <xref ref-type="bibr" rid="bib12">Carréno et al., 2000</xref>), that these kinases are not localized away from LynA or otherwise lacking in activity. Instead, it is likely that the induction of LynA degradation occurs via specific protein-protein interactions and/or substrate recognition interfaces. Unlike FynB and Hck<sup>59</sup>, Fgr and Lck were able to phosphorylate c-Cbl, despite an earlier report that c-Cbl is a poor substrate for Lck and Zap70 (<xref ref-type="bibr" rid="bib22">Feshchenko et al., 1998</xref>). On the other hand, Syk and FynT have both been reported to phosphorylate and activate c-Cbl (<xref ref-type="bibr" rid="bib22">Feshchenko et al., 1998</xref>), but LynA degradation in 3-IB-PP1-treated BMDMs is unaffected by Syk inhibition and Fyn is not activated during 3-IB-PP1 treatment. Again, we conclude that the substrate preferences of the Src family members are tightly regulated, contradicting the assumption that downstream players in the ITAM signaling pathway are activated en bloc by semi-promiscuous kinases.</p><p>Rapid degradation of LynA is easily observed upon bulk SFK activation by 3-IB-PP1 but also affects the steady-state level of LynA protein, likely due to the selective degradation of small amounts (<xref ref-type="bibr" rid="bib23">Freedman et al., 2015</xref>) of basally active LynA over time. Although the unique region of LynA lacks a c-Cbl consensus recognition motif (<xref ref-type="bibr" rid="bib78">Thien and Langdon, 2005</xref>), pY32 could serve as a docking site for the PTB domain of c-Cbl. In this ultrafast feedback process, activation-loop- and Y32-autophosphorylated LynA could efficiently phosphorylate and activate c-Cbl and trigger its own degradation, potentially then releasing c-Cbl for other positive- and negative-regulatory signaling functions. Earlier work has shown that although the interactome of transfected LynA<sup>Y32F</sup> in mammary adenocarcinoma (MDA-MB-231) cells more closely resembles that of wild-type LynA than LynB, some LynA interactions are lost (<xref ref-type="bibr" rid="bib80">Tornillo et al., 2018</xref>). It is also possible that, by analogy to a similarly situated but non-homologous phosphorylation site in Hck (pY29) (<xref ref-type="bibr" rid="bib39">Johnson et al., 2000</xref>), phosphorylation of LynA Y32 could be directly activating. The unique regions of LynA and LynB make distinct SH3-domain contacts (<xref ref-type="bibr" rid="bib77">Teixeira et al., 2018</xref>), and phosphorylation could alter these interactions and increase kinase activity. Hyperactivated LynA could then efficiently phosphorylate and activate nearby or pre-complexed c-Cbl, triggering its own degradation more aggressively than do the other SFKs.</p><p>LynA and LynB have been reported to interact with different subsets of proteins in mast cells and in triple-negative breast cancer cells, with LynA signaling via ITAM (<xref ref-type="bibr" rid="bib2">Alvarez-Errico et al., 2010</xref>), cytoskeletal, and proliferative (<xref ref-type="bibr" rid="bib80">Tornillo et al., 2018</xref>) pathways and LynB initiating negative feedback via ITIMs and phosphatases (<xref ref-type="bibr" rid="bib2">Alvarez-Errico et al., 2010</xref>). In mammary epithelial cells the ratio of LynA and LynB is actively regulated by Epithelial Splicing Regulatory Protein 1 (ESRP1). LynA-upregulated tumors have the more invasive phenotype (<xref ref-type="bibr" rid="bib80">Tornillo et al., 2018</xref>). The positive-regulatory roles reported for LynA in mast and tumor cells complements our own observations that LynA degradation can block macrophage signaling through the Erk1/2, Akt, and NFAT pathways, which cannot be rescued by active LynB (<xref ref-type="bibr" rid="bib23">Freedman et al., 2015</xref>).</p><p>Aberrant activation driven by ITAM signaling pathways in macrophages is a known driver of autoimmune and inflammatory disease, with activated macrophages accumulating in chronically inflamed tissues in the absence of an active infection (<xref ref-type="bibr" rid="bib86">Wynn et al., 2013</xref>). Regulation of LynA protein expression and deactivation kinetics by c-Cbl could, via the LynA checkpoint, prevent the initiation of pathological signaling. The threshold for macrophage activation is modulated by changes to their local environment. For example, IFN-γ and LPS polarize macrophages for a pro-inflammatory response, whereas IL-4 and IL-13 polarize macrophages for tissue repair (i.e. collagen deposition) and inflammatory resolution (<xref ref-type="bibr" rid="bib25">Galli et al., 2011</xref>; <xref ref-type="bibr" rid="bib6">Bosurgi et al., 2017</xref>). We have reported that IFN-γ decreases the macrophage signaling threshold in part by increasing the expression of LynA (<xref ref-type="bibr" rid="bib23">Freedman et al., 2015</xref>). Dynamic changes in SFK and c-Cbl levels could modulate the macrophage activation threshold, ensuring that macrophages respond appropriately during times of infection (low threshold) and limiting aberrant activation in response to cellular debris and small-scale antibody complexes during inflammatory resolution (high threshold).</p><p>Like macrophages, mast cells reside in nearly every tissue and perform environment-specific functions in addition to sensing non-self (<xref ref-type="bibr" rid="bib25">Galli et al., 2011</xref>; <xref ref-type="bibr" rid="bib26">Gentek et al., 2018</xref>). While macrophages have distinct anti-inflammatory roles as professional phagocytes in the silent clearance of apoptotic cells and agents of wound healing, mast cells are constitutively primed for ITAM-induced triggering, releasing preformed granules that contain inflammatory cytokines, chemokines, prostaglandins, and proteases. Pursuant to these differing functions, macrophages continuously gauge ITAM ligand valency (<italic>i.e.</italic> particle size) and have a relatively high basal threshold for inflammatory activation (<xref ref-type="bibr" rid="bib28">Goodridge et al., 2011</xref>; <xref ref-type="bibr" rid="bib23">Freedman et al., 2015</xref>), while mast cells can be triggered by small-scale receptor clustering induced by low-valency or even monovalent FcεR-IgE-allergen complexes (<xref ref-type="bibr" rid="bib3">Andrews et al., 2009</xref>; <xref ref-type="bibr" rid="bib21">Felce et al., 2018</xref>). One striking difference between the macrophage and mast-cell ITAM regulatory machinery is that mast cells express almost no c-Cbl. In spite of low reported mRNA levels (ImmGen; <xref ref-type="bibr" rid="bib35">Heng and Painter, 2008</xref>; <xref ref-type="bibr" rid="bib20">Dwyer et al., 2016</xref>), mast cells constitutively express a high level of LynA protein, likely due to impaired steady-state degradation of basally active LynA. Furthermore, LynA is not degraded upon activation and 3-IB-PP1 triggers a stronger Erk phosphorylation response in the absence of ITAM-receptor ligation in mast cells than in rested macrophages.</p><p>In summary, we describe a model in which regulation of LynA and c-Cbl levels helps to determine an immune cell’s potential for inflammatory ITAM signaling. Regulated degradation tunes down the LynA rheostat, blocking cell signaling via the LynA checkpoint at low cellular doses of LynA and overriding the LynA checkpoint at higher doses. In macrophages this occurs on a continuum where LynA dose is highest in cells rendered more reactive by IFN-γ priming (polarization). Mast cells express almost no c-Cbl and maintain high levels of LynA at steady state and over time, consistent with permissive signaling in the absence of a large-scale ITAM receptor clustering event nucleated by multivalent receptor ligation. Appropriate regulation of immune receptor thresholds is critical for maintaining the function of innate immune cells; threshold dysregulation can lead to chronic feedback loops that drive inflammatory signaling in autoimmune disease and conversely tumor-supporting immunosuppressive signaling (<xref ref-type="bibr" rid="bib86">Wynn et al., 2013</xref>). Elucidating the mechanisms by which the LynA checkpoint is regulated may allow us to tune immune-cell sensitivity and reprogram pathological cells.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th>Reagent type <break/>(species) or resource</th><th>Designation</th><th>Source or reference</th><th>Identifiers</th><th>Additional <break/>information</th></tr></thead><tbody><tr><td>Genetic reagent (<italic>M. musculus</italic>)</td><td><italic>Csk<sup>AS</sup></italic></td><td>PMID: <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/21917715">21917715</ext-link></td><td><ext-link ext-link-type="uri" xlink:href="http://www.informatics.jax.org/allele/MGI:5563915">MGI: 5563915</ext-link></td><td>Dr. Arthur Weiss <break/>(University of California San Francisco)</td></tr><tr><td>Genetic reagent (<italic>M. musculus</italic>)</td><td><italic>Cbl<sup>-/-</sup></italic></td><td>PMID: <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/17868091">17868091</ext-link></td><td><ext-link ext-link-type="uri" xlink:href="http://www.informatics.jax.org/allele/MGI:2180576">MGI: 2180576</ext-link></td><td>Dr. Erik Peterson (University of Minnesota)</td></tr><tr><td>Genetic reagent (<italic>M. musculus</italic>)</td><td><italic>Cblb<sup>-/-</sup></italic></td><td>PMID: <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/10646609">10646609</ext-link></td><td><underline>MGI: 2180572</underline></td><td>Dr. Michael Farrar (University of Minnesota)</td></tr><tr><td>Cell line (<italic>H. sapiens)</italic></td><td>Jurkat</td><td>American Type <break/>Culture Collection</td><td>Cat#: TIB-152, RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/CVCL_0367">CVCL_0367</ext-link></td><td>Dr. Arthur Weiss (University of California San Francisco)</td></tr><tr><td>Cell line (<italic>H. sapiens</italic>)</td><td>JCaM1.6</td><td>American Type Culture Collection</td><td>Cat#: CRL-2063, RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/CVCL_0354">CVCL_0354</ext-link></td><td>Dr. Yoji Shimizu (University of Minnesota)</td></tr><tr><td>Recombinant DNA reagent (plasmid)</td><td>(mouse) LynA-V5-His6</td><td>This paper</td><td/><td>Progenitor from Dr. Juan Rivera (NIH) Vector: pEF6/V5-His</td></tr><tr><td>Recombinant DNA reagent (plasmid)</td><td>(mouse) LynB-V5-His6</td><td>This paper</td><td/><td>Progenitor from Dr. Juan Rivera (NIH) Vector: pEF6/V5-His</td></tr><tr><td>Recombinant DNA reagent (plasmid)</td><td>(mouse) LynA<sup>Y32A</sup>-V5-His6</td><td>This paper</td><td/><td>Progenitor from Dr. Juan Rivera (NIH) <break/>Vector: pEF6/V5-His</td></tr><tr><td>Recombinant DNA reagent (plasmid)</td><td>(mouse) LynA<sup>K40R</sup>-V5-His6</td><td>This paper</td><td/><td>Progenitor from Dr. Juan Rivera (NIH) Vector: pEF6/V5-His</td></tr><tr><td>Recombinant DNA reagent (plasmid)</td><td>(mouse) LynA<sup>T27A</sup>-V5-His6</td><td>This paper</td><td/><td>Progenitor from Dr. Juan Rivera (NIH) <break/>Vector: pEF6/V5-His</td></tr><tr><td>Recombinant DNA reagent (plasmid)</td><td>(mouse) LynA<sup>Y32F</sup>-V5-His6</td><td>This paper</td><td/><td>Progenitor from Dr. Juan Rivera (NIH) Vector: pEF6/V5-His</td></tr><tr><td>Recombinant DNA reagent (plasmid)</td><td>(mouse) LynA<sup>T410K</sup>-V5-His6</td><td>This paper</td><td/><td>Progenitor from Dr. Juan Rivera (NIH) Vector: pEF6/V5-His</td></tr><tr><td>Recombinant DNA reagent (plasmid)</td><td>(mouse) LynA<sup>Y397F</sup>-V5-His6</td><td>This paper</td><td/><td>Progenitor from Dr. Juan Rivera (NIH) Vector: pEF6/V5-His</td></tr><tr><td>Recombinant DNA reagent (plasmid)</td><td>(mouse) LynA<sup>K275R</sup>-V5-His6</td><td>This paper</td><td/><td>Progenitor from Dr. Juan Rivera (NIH) Vector: pEF6/V5-His</td></tr><tr><td>Recombinant DNA reagent (plasmid)</td><td>(mouse) LynA</td><td>This paper</td><td/><td>Progenitors from Dr. Juan Rivera (NIH) Vector: pEF6/V5-His</td></tr><tr><td>Recombinant DNA reagent (plasmid)</td><td>(mouse) LynA<sup>Y32A</sup></td><td>This paper</td><td/><td>Progenitors from Dr. Juan Rivera (NIH) Vector: pEF6/V5-His</td></tr><tr><td>Recombinant DNA reagent (plasmid)</td><td>His6-Xpress-c-Cbl (human)</td><td>PMID: <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/17110436">17110436</ext-link></td><td/><td>Dr. Arthur Weiss (University of California San Francisco) <break/>Vector: pEF</td></tr><tr><td>Recombinant DNA reagent (plasmid)</td><td>Xpress-Cbl-b (human)</td><td>PMID: <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/17110436">17110436</ext-link></td><td/><td>Dr. Arthur Weiss (University of California San Francisco) <break/>Vector: pEF</td></tr><tr><td>Recombinant DNA reagent (plasmid)</td><td>(mouse) Hck<sup>p59kDa</sup></td><td>This paper</td><td/><td>Dr. Clifford Lowell (University of California San Francisco) <break/>Vector: pMIG-W</td></tr><tr><td>Recombinant DNA reagent (plasmid)</td><td>(mouse) Hck<sup>p59+p56kDa</sup></td><td>This paper</td><td/><td>Dr. Clifford Lowell (University of California San Francisco) <break/>Vector: pMIG-W</td></tr><tr><td>Recombinant DNA reagent (plasmid)</td><td>(mouse) FynT</td><td>This paper</td><td/><td>Dr. Clifford Lowell (University of California San Francisco) <break/>Vector: pUC18</td></tr><tr><td>Recombinant DNA reagent (plasmid)</td><td>(human) FynB</td><td>This paper</td><td/><td>Dr. Clifford Lowell (University of California San Francisco) <break/>Vector: pLNCX</td></tr><tr><td>Recombinant DNA reagent (plasmid)</td><td>(mouse) Fgr</td><td>This paper</td><td/><td>Vector: pEF</td></tr><tr><td>Recombinant DNA reagent (plasmid)</td><td>UR(LynA)-eGFP</td><td>This paper</td><td/><td>vector: pcDNA3.1</td></tr><tr><td>Recombinant DNA reagent (plasmid)</td><td>UR(LynB)-eGFP</td><td>This paper</td><td/><td>vector: pcDNA3.1</td></tr><tr><td>Recombinant DNA reagent (plasmid)</td><td>UR(LynA<sup>Y32A</sup>)-eGFP</td><td>This paper</td><td/><td>vector: pcDNA3.1</td></tr><tr><td>Recombinant DNA reagent (plasmid)</td><td>eGFP</td><td>This paper</td><td/><td>Dr. Michael Farrar (University of Minnesota) vector: pMIGR</td></tr><tr><td>Sequence based reagent</td><td><italic>Cbl</italic> siRNA</td><td>This paper</td><td>5’-CCUACCAGGACAUUCAGAAAGCUUU-3’ <break/>5’-AAAGCUUUCUGAAUGUCCUGGUAGG-3’</td><td/></tr><tr><td>Sequence based reagent</td><td><italic>Cblb</italic> siRNA</td><td>This paper</td><td>5’-CUGACUUCUUGGUAUCUGAUAUATA-3’ <break/>5’-UAUAUAUCAGAUACCAAGAAGUCAGGU-3’</td><td/></tr><tr><td>Sequence based reagent</td><td><italic>Cbl</italic> saRNA</td><td>This paper</td><td>5’-UCAAUUCUAGAUAAAGGCG-3’ <break/>5’-CGCCUUUAUCUAGAAUUGA-3’</td><td/></tr><tr><td>Antibody</td><td>Mouse anti- β-Actin (8H10D10)</td><td>Cell Signaling</td><td>Cat. #: 3700 <break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2242334">AB_2242334</ext-link></td><td>WB (1:2000)</td></tr><tr><td>Antibody</td><td>Rabbit anti- c-Cbl (D4E10)</td><td>Cell Signaling</td><td>Cat. #: 8447 <break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10860763">AB_10860763</ext-link></td><td>WB (1:2000)</td></tr><tr><td>Antibody</td><td>Rabbit anti-Cbl-b (D3C12)</td><td>Cell Signaling</td><td>Cat. #: 9498 <break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2797707">AB_2797707</ext-link></td><td>WB (1:2000)</td></tr><tr><td>Antibody</td><td>Rabbit anti-p-c-Cbl (phosphoTyr<sup>731</sup>)</td><td>Cell Signaling</td><td>Cat. #: 3554 <break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2070452">AB_2070452</ext-link></td><td>WB (1:1000)</td></tr><tr><td>Antibody</td><td>Rabbit anti-pErk1/2 (phosphoThr<sup>202</sup>/phosphoTyr<sup>204</sup>, D13.14.4E)</td><td>Cell Signaling</td><td>Cat. #: 4370 <break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10694057">AB_10694057</ext-link></td><td>WB (1:2000)</td></tr><tr><td>Antibody</td><td>Mouse anti-Erk1/2 (3A7)</td><td>Cell Signaling</td><td>Cat. #: 9107 <break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10695739">AB_10695739</ext-link></td><td>WB (1:2000)</td></tr><tr><td>Antibody</td><td>Mouse anti-Fgr (6G2)</td><td>ProMab</td><td>Cat. #: 20318 <break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2802161">AB_2802161</ext-link></td><td>WB (1:2000)</td></tr><tr><td>Antibody</td><td>Rabbit anti-Fyn</td><td>Cell Signaling</td><td>Cat. #: 4023 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10698604">AB_10698604</ext-link></td><td>WB (1:2000)</td></tr><tr><td>Antibody</td><td>Goat anti-Hck (M-28)</td><td>Santa Cruz Biotechnology</td><td>Cat. #: sc-1428 <break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2114872">AB_2114872</ext-link></td><td>WB (1:1000)</td></tr><tr><td>Antibody</td><td>Rabbit anti-Lck (D88) XP(R)</td><td>Cell Signaling</td><td>Cat. #: 2984 <break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2136313">AB_2136313</ext-link></td><td>WB (1:2000)</td></tr><tr><td>Antibody</td><td>Rabbit anti-LynA (C13F9)</td><td>Cell Signaling</td><td>Cat. #: 2796 <break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2138391">AB_2138391</ext-link></td><td>WB (1:2000)</td></tr><tr><td>Antibody</td><td>Mouse anti-LynA + LynB (Lyn-01)</td><td>abcam</td><td>Cat. #: ab1890 <break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_1204641">AB_1204641</ext-link></td><td>WB (1:1000)</td></tr><tr><td>Antibody</td><td>Mouse anti-Myc (9B11)</td><td>Cell Signaling</td><td>Cat. #: 2276 <break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2148465">AB_2148465</ext-link></td><td>WB (1:2000)</td></tr><tr><td>Antibody</td><td>Rabbit anti-pPaxillin (phosphoTyr<sup>118</sup>)</td><td>Cell Signaling</td><td>Cat. #: 2541 <break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2174466">AB_2174466</ext-link></td><td>WB (1:2000)</td></tr><tr><td>Antibody</td><td>Rabbit anti-pSFK<sup>act</sup>(phosphoTyr<sup>416</sup>)</td><td>Cell Signaling</td><td>Cat. #: 2101 <break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_331697">AB_331697</ext-link></td><td>WB (1:2000)</td></tr><tr><td>Antibody</td><td>Rabbit anti-pSFK<sup>inact</sup>(phosphoTyr<sup>530</sup>)</td><td>Life Technologies/ThermoFisher</td><td>Cat. #: 44–912 <break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2533793">AB_2533793</ext-link></td><td>WB (1:1000)</td></tr><tr><td>Antibody</td><td>Rabbit anti-pZap70/pSyk (phosphoTyr<sup>319(Zap)/352(Syk)</sup>, 65E4)</td><td>Cell Signaling</td><td>Cat. #: 2717 <break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2218658">AB_2218658</ext-link></td><td>WB (1:2000)</td></tr><tr><td>Antibody</td><td>Rabbit V5-Tag (D3H8Q)</td><td>Cell Signaling</td><td>Cat. #: 13202 <break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2687461">AB_2687461</ext-link></td><td>WB (1:2000)</td></tr><tr><td>Antibody</td><td>Mouse anti-V5</td><td>Invitrogen</td><td>Cat. #: R960-25 <break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2556564">AB_2556564</ext-link></td><td>IP (1:200)</td></tr><tr><td>Antibody</td><td>Donkey anti-rabbit IgG 800CW</td><td>LI-COR</td><td>Cat. #: 925–32213 <break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2715510">AB_2715510</ext-link></td><td>WB (1:20000)</td></tr><tr><td>Antibody</td><td>Donkey anti-rabbit IgG 680LT</td><td>LI-COR</td><td>Cat. #: 925–68023 <break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10706167">AB_10706167</ext-link></td><td>WB (1:20000)</td></tr><tr><td>Antibody</td><td>Donkey anti-mouse IgG 800CW</td><td>LI-COR</td><td>Cat. #: 925–32212 <break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2716622">AB_2716622</ext-link></td><td>WB (1:20000)</td></tr><tr><td>Antibody</td><td>Donkey anti-mouse IgG 680LT</td><td>LI-COR</td><td>Cat. #: 925–68022 <break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10715072">AB_10715072</ext-link></td><td>WB (1:20000)</td></tr><tr><td>Antibody</td><td>Donkey anti-goat IgG 800CW</td><td>LI-COR</td><td>Cat. #: 926–32214 <break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_621846">AB_621846</ext-link></td><td>WB (1:20000)</td></tr><tr><td>Antibody</td><td>Anti FcεRIa (FITC)</td><td>BioLegend</td><td>Cat. #: 134305 <break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_1626102">AB_1626102</ext-link></td><td>Flow cytometry (1:100)</td></tr><tr><td>Antibody</td><td>Anti c-Kit (APC)</td><td>BioLegend</td><td>Cat. #: 105811 <break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_313220">AB_313220</ext-link></td><td>Flow cytometry (1:100)</td></tr><tr><td>Peptide, recombinant protein</td><td>recombinant mouse IFN-g</td><td>PeproTech</td><td>Cat. #:AF-315–05</td><td>25 U/mL</td></tr><tr><td>Peptide, recombinant protein</td><td>recombinant mouse IL-3</td><td>PeproTech</td><td>Cat. #: 213–13</td><td>10 ng/mL</td></tr><tr><td>Purified protein</td><td>Trypsin, sequencing grade</td><td>Promega</td><td>Cat. #: V5111</td><td/></tr><tr><td>Commercial assay</td><td>Pierce BCA Protein Assay</td><td>ThermoFisher</td><td>Cat. #: 23225</td><td/></tr><tr><td>Chemical compound, drug</td><td>3-IB-PP1</td><td>Kevan Shokat (University of California, San Francisco)</td><td/><td>10 µM</td></tr><tr><td>Chemical compound, drug</td><td>PP2</td><td>ThermoFisher</td><td>Cat. #: PHZ1223</td><td>20 µM</td></tr><tr><td>Chemical compound, drug</td><td>Bay 61–3606</td><td>EMD Millipore</td><td>Cat. #: 574714</td><td>1 µM</td></tr><tr><td>Chemical compound, drug</td><td>PF-431396</td><td>Tocris</td><td>Cat. #: 4278/10</td><td>10 µM</td></tr><tr><td>Software</td><td>Prism</td><td>GraphPad</td><td>RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_002798">SCR_002798</ext-link></td><td/></tr><tr><td>Software</td><td>Image Studio</td><td>LI-COR</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_013715">SCR_013715</ext-link></td><td/></tr><tr><td>Software</td><td>Illustrator</td><td>Adobe</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_010279">SCR_010279</ext-link></td><td/></tr><tr><td>Software</td><td>Photoshop</td><td>Adobe</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_014199">SCR_014199</ext-link></td><td/></tr><tr><td>Software</td><td>Fiji</td><td/><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_002285">SCR_002285</ext-link></td><td/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Mice</title><p>C57BL/6-derived <italic>Csk<sup>AS</sup></italic> mice are hemizygous for the <italic>Csk<sup>AS</sup></italic> BAC transgene on a <italic>Csk<sup>-/-</sup></italic> background, as described previously (<xref ref-type="bibr" rid="bib23">Freedman et al., 2015</xref>; <xref ref-type="bibr" rid="bib75">Tan et al., 2014</xref>). <italic>Csk<sup>AS</sup>Cblb<sup>-/-</sup>(Csk<sup>-/-</sup>)</italic> mice were generated by crossing <italic>Cblb<sup>-/-</sup></italic> female mice from M. Farrar (University of Minnesota) (<xref ref-type="bibr" rid="bib14">Chiang et al., 2000</xref>) with <italic>Csk<sup>+/-</sup> and Csk<sup>AS</sup></italic> male mice from our colony and then crossing <italic>Csk<sup>+/-</sup>Cblb<sup>-/-</sup> with Csk<sup>AS</sup>Csk<sup>+/-</sup>Cblb<sup>-/-</sup></italic> mice. Due to sterility of <italic>Cbl<sup>-/-</sup></italic> male mice, we were not able to produce a sustained lineage of <italic>Csk<sup>AS</sup>Cbl<sup>-/-</sup>(Csk<sup>-/-</sup>)</italic> mice, but we obtained three individuals by crossing <italic>Cbl<sup>-/-</sup></italic> female mice from E. Peterson (University of Minnesota) with <italic>Csk<sup>+/-</sup> and Csk<sup>AS</sup></italic> male mice from our colony and then crossing <italic>Csk<sup>+/-</sup>Cbl<sup>+/-</sup></italic>mice with <italic>Csk<sup>AS</sup>Cbl<sup>+/-</sup></italic> mice. All mice were housed in specific pathogen-free conditions and genotyped using real-time PCR (Transnetyx, Inc, Memphis, TN). All animal use complies with University of Minnesota (UMN) and National Institutes of Health (NIH) policy (Animal Welfare Assurance Number A3456-01). UMN is accredited by AAALAC, experiments involving mice were approved by the UMN Institutional Animal Care and Use Committee (IACUC, protocol # 1603-33559A). Animals are kept under supervision of a licensed doctor of veterinary medicine and supporting veterinary staff under strict NIH guidelines.</p></sec><sec id="s4-2"><title>Jurkat cell lines and transfection</title><p>The Jurkat T-cell strains Clone E6-1 (<xref ref-type="bibr" rid="bib85">Weiss and Stobo, 1984</xref>) and JCaM1.6 (Lck-deficient) (<xref ref-type="bibr" rid="bib72">Straus, 1992</xref>; <xref ref-type="bibr" rid="bib27">Goldsmith and Weiss, 1987</xref>) were gifts from the laboratories of A. Weiss (University of California, San Francisco) and Y. Shimizu (University of Minnesota), respectively. Both cell lines were authenticated by STR profiling and tested negative for mycoplasma (ATCC, Manassas, Virginia). Jurkat cell lines were cultured in RPMI-1640 medium supplemented with 5–10% fetal calf serum (Omega Scientific, Inc, Tarzana, CA) and 2 mM glutamine, penicillin and streptomycin (Sigma-Aldrich, St. Louis, MO) as described previously (<xref ref-type="bibr" rid="bib55">Phee et al., 2005</xref>). Jurkat and JCaM1.6 cells were transiently transfected via electroporation, as described previously (<xref ref-type="bibr" rid="bib55">Phee et al., 2005</xref>). Briefly, cells were grown overnight in antibiotic-free RPMI-1640 medium supplemented with 10% fetal bovine serum (Omega Scientific) and 2 mM glutamine (RPMI10). Batches of 15 M cells were resuspended in RPMI10 with 10–15 µg plasmid DNA per construct. Cells were rested, electroporated at 285 V for 10 ms in a BTX square-wave electroporator (Harvard Apparatus, Holliston, MA), resuspended in RPMI10, and allowed to recover overnight. One million live cells were then resuspended in phosphate-buffered saline (PBS), rested for 30 min at 37°C, and stimulated.</p></sec><sec id="s4-3"><title>Microscopy</title><p>Jurkat cells were transfected with memCsk<sup>AS</sup>, c-Cbl, and LynB (to ensure a response to 3-IB-PP1) along with constructs encoding the unique regions of LynA, LynB and LynA<sup>Y32A</sup> fused to eGFP. A construct containing eGFP alone was used as a control. 24 hr after transfection, cells were filtered to remove clumps of dead cells and resuspended in PBS containing Hoechst Stain (Thermo Fisher) and incubated for 30 min at 37°C in a 96-well plate. Cells were then stimulated with 3-IB-PP1 for 5 min before quenching with ice-cold PBS and collected by centrifuging for 5 min x 1500 rpm at 4°C. Cells were resuspended in ice-cold PBS and coverslipped on glass slides directly before imaging. Imaging was performed on a Leica DM600B epifluorescence microscope using DAPI and GFP channels. Exposure times for GFP were set to normalize the brightness of the GFP across the different transfection conditions, as cell-to-cell expression was variable. Images were pseudocolored and merged using ImageJ software (NIH) with the Fiji plugin (<xref ref-type="bibr" rid="bib64">Schindelin et al., 2012</xref>).</p></sec><sec id="s4-4"><title>DNA constructs and mutagenesis</title><p>Plasmids containing c-terminally His<sub>6</sub>V5-tagged mouse LynA and LynB were gifts from J. Rivera/R. Suzuki (National Institutes of Health) (<xref ref-type="bibr" rid="bib2">Alvarez-Errico et al., 2010</xref>). Myc-tagged mouse memCsk<sup>AS</sup> (also referred to as Lck11-CskAS, <xref ref-type="bibr" rid="bib65">Schoenborn et al., 2011</xref>) and Xpress-tagged human c-Cbl and Cbl-b (<xref ref-type="bibr" rid="bib50">Myers et al., 2006</xref>) were gifts from A. Weiss (University of California, San Francisco). Untagged mouse Hck<sup>56+59</sup>, Hck<sup>56</sup>, Fgr, and FynT (Fyn), and human FynB were gifts from C. Lowell (University of California, San Francisco.) Site-directed mutagenesis (QuikChange Lightning, Agilent Technologies, Santa Clara, CA) was used to prepare the point mutants referenced in the main text and to introduce stop codons removing epitope tags from Fgr, LynA, and LynA<sup>Y32A</sup>. Sequences of all constructs were verified by Sanger sequencing (GENEWIZ, South Plainfield, NJ).</p></sec><sec id="s4-5"><title>Preparation and flow cytometry of myeloid cells</title><p>BMDMs were prepared using standard methods (<xref ref-type="bibr" rid="bib91">Zhu et al., 2008</xref>). Briefly, bone marrow was extracted from femura and tibiae of mice aged 6–8 weeks. After hypotonic lysis of erythrocytes, BMDMs were derived on untreated plastic plates (BD Falcon, Sigma-Aldrich) by culturing in Dulbecco’s Modified Eagle Medium (DMEM, Corning Cellgro, Corning, NY) containing approximately 10% heat-inactivated fetal calf serum (Omega Scientific) (DMEM10) with 0.11 mg/ml sodium pyruvate (Corning), 2 mM penicillin/streptomycin/L-glutamine (Sigma-Aldrich), and 10% CMG-14–12-cell-conditioned medium as a source of M-CSF (<xref ref-type="bibr" rid="bib74">Takeshita et al., 2000</xref>). After 6 or 7 days cells were resuspended in enzyme-free ethylenediaminetetraacetic acid (EDTA) buffer and replated in untreated 6-well plates (BD Falcon, Sigma-Aldrich) at 1 M cells per well in unconditioned medium with or without priming in 25 U IFN-γ (PeproTech, Rocky Hill, NJ). Bone-marrow-derived mast cells were prepared as described previously (<xref ref-type="bibr" rid="bib40">Kalesnikoff and Galli, 2011</xref>), similiarly to BMDMs except for the substitution of 10 ng/ml IL-3 (PeproTech) for CMG-14–12-conditoned medium and a culture time of at least 5 weeks. Mast cells were subjected to flow-cytometry analysis (LSRFortessa, Becton Dickinson, Franklin Lakes, NJ) and found to be uniformly positive for FcεRIα (Mar-1, FITC-labeled, #134305) and c-Kit (2B8, APC-labeled, #105811), both from BioLegend (San Diego, CA). All myeloid cells were rested or primed overnight before stimulation.</p></sec><sec id="s4-6"><title>siRNA knockdown of <italic>Cbl</italic> and <italic>Cblb</italic></title><p>The siRNA sequence for knockdown of mouse <italic>Cbl</italic> was adapted from a human siRNA construct (A. Weiss, University of California, San Francisco). <italic>Cblb</italic> siRNA was designed using the Integrated DNA Technologies double-stranded siRNA design tools (IDT, Skokie, IL). Control double-stranded RNA from IDT was not predicted to be complementary to any sequence in the human or mouse transcriptome. The effective siRNA sequences from among those we tested are: <italic>Cbl</italic> guide sequence CCUACCAGGACAUUCAGAAAGCUUU (passenger sequence AAAGCUUUCUGAAUGUCCUGGUAGG), <italic>Cblb</italic> guide sequence (CUGACUUCUUGGUAUCUGAUAUATA (passenger sequence UAUAUAUCAGAUACCAAGAAGUCAGGU). Aliquots of 2 M BMDMs in 100 μl opti-MEM (ThermoFisher, Waltham, MA) were transfected with 1 μM siRNA via electroporation at 400 V for 10 ms using a BTX square-wave electroporator. Cells were then plated on 150 mm untreated cell culture dishes and rested in 10 ml DMEM10 for 30 min before adding 10 ml DMEM10 supplemented with sodium pyruvate and 10% CMG-14–12-cell-conditioned medium as described above. Transfections were pooled from several cuvettes to obtain enough cells for several stimulation conditions. After 24 h cells were resuspended in enzyme-free EDTA buffer and replated in untreated 6-well plates (BD Falcon, Sigma-Aldrich) at 1 M cells per well in unconditioned medium. Cells were used 48 hr after transfection.</p></sec><sec id="s4-7"><title>saRNA enrichment of c-Cbl</title><p>An saRNA sequence designed to upregulate transcription of <italic>Cbl</italic> was designed using an algorithm published previously (<xref ref-type="bibr" rid="bib82">Voutila et al., 2012</xref>). <italic>Cbl</italic>-targeting saRNA ‘CBL-Tr-NM_005188-Pr-30-Cp-0’ with guide sequence UCAAUUCUAGAUAAAGGCG (passenger sequence CGCCUUUAUCUAGAAUUGA) was ordered from IDT with 2’ O-methylated uracil tails (mUmU) to increase transfection efficiency. On the first day of transfection, aliquots of 10<sup>5</sup> mast cells were resuspended in 400 µl mast-cell medium in a 24-well plate and mixed with 100 µl saRNA + lipofectamine 2000 or 3000 for a final concentration of 5 nM saRNA. Cells were then rested overnight before a second transfection with 100 µl saRNA + lipofectamine. On day three the cells were transferred into fresh mast-cell medium and rested overnight. On the day of the experiment, mast-cell aliquots from the same saRNA condition were pooled, resuspended in 50 µl DMEM, and rested 2 hr before stimulation.</p></sec><sec id="s4-8"><title>Cell stimulation and immunoblotting</title><p>BMDM stimulations have been described previously (<xref ref-type="bibr" rid="bib23">Freedman et al., 2015</xref>). After resting, 1 M live Jurkat cells, mast cells, or adherent BMDMs were treated at 37°C in DMEM (myeloid cells) or PBS (Jurkat cells) with 10 µM 3-IB-PP1, a gift from K. Shokat (University of California, San Francisco). Signaling reactions were quenched by placing on ice and lysing cells in sodium dodecyl sulfate (SDS) buffer (128 mM Tris base, 10% glycerol, 4% SDS, 50 mM dithiothreitol (DTT), pH 6.8). Whole-cell lysates were prepared for immunoblotting by sonication with a Diagenode Bioruptor (Diagenode, Inc, Denville, NJ) for 3 min and boiling for 15 min. For immunoblotting 0.025 M cell equivalents were run in each lane of a 7% NuPage Tris-Acetate gel (Invitrogen, Carlsbad, CA) and then transferred to an Immobilon-FL PVDF membrane (EMD Millipore, Burlington, MA). REVERT Total Protein Stain (TPS, LI-COR Biosciences, Lincoln, NE) was used according to the standard protocol to quantify lane loading. After destaining, membranes were treated with Odyssey Blocking Buffer (TBS) for at least 1 hr. Blotting was performed using standard procedures, and blots were imaged on an Odyssey CLx near-infrared imager (LI-COR). Antibodies for immunoblotting were purchased from Cell Signaling Technology (Danvers, MA), ProMab Biotechnologies (Richmond, CA), Thermo Fisher Scientific (Waltham, MA), Abcam (Cambridge, UK), Santa Cruz (Dallas, TX), and LI-COR Biosciences as listed in the key resource table.</p></sec><sec id="s4-9"><title>Quantification, statistics, and image processing</title><p>Immunoblots were analyzed by densitometry using ImageStudio software (LI-COR). Images were background-subtracted, and bands of the appropriate molecular weight were demarcated and analyzed for each gel lane. Each value was corrected for the total lane protein content (REVERT TPS), with the exception of pErk1/2, which was corrected with reference to total Erk1/2. Data were further normalized to a control condition to show relative changes from a reference state: each-condition t = 0 or reference-condition t = 0 as indicated. For all figures, n values are biological replicates, reflecting independent experiments from different individual mice (except where indicated if sufficient numbers of animals were not available), different days and/or batches of cells, stimulus preparations, and experimental workflows. Statistical analysis was performed using Prism Software (Graphpad, La Jolla, CA). Significance was assessed using one- or two-way ANOVA analysis with Tukey’s or Sidak’s correction for multiple comparisons, with analysis of the mean at each time point or condition. Unless specified otherwise, error bars represent standard error of the mean from at least three independent experiments. Asterisks reflect specified P-values. Figures were prepared using Graphpad Prism and Adobe Creative Cloud software (San Jose, CA). Where appropriate, images were optimized by applying brightness/contrast changes to the whole image. No gamma or other nonlinear correction was applied. Images were rotated for figure preparation only after densitometry analysis.</p></sec><sec id="s4-10"><title>Preparation of macrophage LynA samples for targeted mass spectrometry analysis</title><p>BMDMs derived from <italic>Csk<sup>AS</sup>Cbl<sup>+/- </sup></italic>mice were rested or treated 15 s with 3-IB-PP1, washed with ice-cold PBS, and lysed in 1% Lauryl Maltoside Buffer containing 150 mM NaCl, 0.01% sodium azide, and protease and phosphatase inhibitors (MSSAFE, Sigma-Aldrich, St. Louis, MO). After scraping the plates, cells and detergent were sonicated on a Diagenode Biorupter for 5 min with a 50% duty cycle. The lysate was then cleared by centrifugation for 15 min at 14,000 rpm at 4°C in a tabletop centrifuge. Lysates were precleared for 30 min at 4°C with Protein G Sepharose beads (Sigma-Aldrich) and normal rabbit serum (Jackson ImmunoResearch, West Grove, PA). LynA-specific antibody (<xref ref-type="bibr" rid="bib23">Freedman et al., 2015</xref>) (C13F9, Cell Signaling) was pre-bound to Protein-G-Sepharose beads for at least 2 hr. A bicinchoninic acid (BCA) protein assay was performed on the whole-cell lysates (Thermo Fisher) to ensure that equal amounts of protein from untreated and 3-IB-PP1-treated cells would be subjected to immunoprecipitation. Lysates were then mixed continuously with antibody and beads for 2 hr at 4°C to immunoprecipitate LynA. Samples were applied to micro bio-spin chromatography columns (Bio-Rad, Hercules, CA), washed, and eluted with SDS Sample Buffer containing 125 mM Tris, 10% glycerol, 5% 2-mercaptoethanol, and 25% SDS. Samples were then concentrated to 40 µl using Ultracel-3K centrifugal spin columns (EMD Millipore). Each 40 µl immunoprecipitate sample was then resolved by gel electrophoresis. A bovine serum albumin (BSA) standard curve was used to quantifty the total protein in each IP sample and ensure that equal mass quantities were subjected to trypsin digest. For this calibration, we ran 0.05–20 µg BSA along with the immunoprecipitate samples on a 10% Mini-PROTEAN TGX gel (Bio-Rad) at 170 V. Total protein was visualized without fixation using SimplyBlue Safestain (Thermo Fisher) according to manufacturer's instructions. Following staining, the gel was washed 2 × 1 hr with water and imaged on a LI-COR Odyssey. Staining was quantified by densitometry, and BSA signals vs. mass quantities were fit to a linear function (GraphPad Prism). This function was then used to quantify the total protein in each immunoprecipitate. Gel pieces including lower-MW (nonubiquitinated) Lyn species and higher-MW (polyubiquitinated) species were excised, spiked with the isotope-labeled LynA Y32 phosphopeptide [H]TI[pY]VRDP[<sup>13</sup>C<sub>5</sub><sup>15</sup>N<sub>1</sub>]TSNK[OH] (pY32*, Sigma-Aldrich), and subjected to in-gel digestion with TPCK-treated sequencing-grade trypsin (Promega, Madison, WI) and STAGE Tip peptide cleanup as previously described (<xref ref-type="bibr" rid="bib79">Thu et al., 2016</xref>) except that iodoacetamide was used as the alkylating reagent. Digested samples were submitted for identification at the University of Minnesota Center for Mass Spectrometry and Proteomics.</p></sec><sec id="s4-11"><title>Mass spectrometry of LynA immunoprecipitates</title><p>Peptide separations were performed on an Easy-nLC 1000 HPLC (ThermoFisher) and loaded directly onto a 75 cm x 100 µm internal diameter fused silica PicoTip Emitter (New Objective, Woburn, MA), packed in-house with ReproSil-Pur C18-AQ (1.9 µm particle, 120 Å pore; Dr. Maish GmbH Ammerbuch, Germany) heated to 55°C. Peptide elution was performed using a tripartite gradient, decreasing the fraction of Buffer A (0.1% formic acid in water) and increasing the fraction of Buffer B (0.1% formic acid in acetonitrile) at a flow rate of 300 nl/min (Step 1: 5–10% Buffer B over 5 min, Step 2: 10–16% B over 40 min, and Step 3: 16–26% B over 5 min).</p><p>The column was mounted in a nanospray source in line with an Orbitrap Fusion mass spectrometer (Thermo Scientific). Spray voltage was 2.1 kV in positive mode, and the heated capillary was maintained at 275°C. The acquisition method combined two scan events corresponding to a full scan event and a parallel reaction monitoring (PRM) event targeting the singly-, doubly-, and triply-charged precursor ions of the three phosphorylated peptides without scheduling. The full scan event employed a <italic>m/z</italic> 380–1500 mass selection, an orbitrap resolution of 60,000 (at <italic>m/z</italic> 200), a target automatic gain control (AGC) value of 4e5, and maximum fill times of 50 ms. The PRM event employed an orbitrap resolution of 30,000 (at <italic>m/z</italic> 200), a target AGC value of 5e4 with a maximum ion injection time of 54 ms. The precursor ion of each targeted peptide was isolated using an isolation window of 1.6 <italic>m/z</italic>. Fragmentation was performed with a HCD collision energy of 30% and MS/MS scans were collected using a scan range from 100 to 1000 <italic>m/z</italic>. PRM data were collected in centroid mode. Data analysis was performed using manual integration using Thermo Xcalibur Qual Browser and Skyline (<xref ref-type="bibr" rid="bib47">MacLean et al., 2010</xref>). Peak searches were performed using PEAKS Studio X (Bioinformatics Solutions, Waterloo, Ontario). Experiments were run in triplicate, and the entire experiment was performed independently twice.</p></sec><sec id="s4-12"><title>Data and materials availability</title><p>Reagents and protocols will be provided upon request.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We are indebted to Kevan Shokat and Flora Rutaganira for their synthesis and donation of 3-IB-PP1 for this study. Many thanks also to Arthur Weiss, Clifford Lowell, Clare Abram, Yoji Shimizu, Brandon Burbach, Michael Farrar, Erik Peterson, Juan Rivera, Ryo Suzuki, Marianne Mollenauer, Terri Kadlecek, LeeAnn Higgins, and Whitney Swanson for reagents, methodological expertise, and discussion. Thanks also to Hai-Bin Ruan, John Connett, Marc Jenkins, Bryce Binstadt, Diane Lidke, Nicholas Levinson, Aditi Bapat, Frances Sjaastad, Anders Lindstedt, JT Greene, and Emily Ewan for valuable feedback and discussion of the project or manuscript.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing—original draft, Writing—review and editing</p></fn><fn fn-type="con" id="con2"><p>Formal analysis, Validation, Investigation, Visualization, Writing—original draft, Writing—review and editing</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Validation, Investigation, Visualization, Methodology, Writing—original draft, Writing—review and editing</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Validation, Investigation, Visualization, Writing—review and editing</p></fn><fn fn-type="con" id="con5"><p>Formal analysis, Validation, Investigation, Visualization, Writing—review and editing</p></fn><fn fn-type="con" id="con6"><p>Formal analysis, Methodology, Writing—review and editing</p></fn><fn fn-type="con" id="con7"><p>Formal analysis, Methodology, Writing—review and editing</p></fn><fn fn-type="con" id="con8"><p>Formal analysis, Methodology, Writing—review and editing</p></fn><fn fn-type="con" id="con9"><p>Formal analysis, Supervision, Methodology, Writing—review and editing</p></fn><fn fn-type="con" id="con10"><p>Formal analysis, Supervision, Funding acquisition, Project administration, Writing—review and editing</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Resources, Data curation, Software, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing—original draft, Project administration, Writing—review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All animal use complies with University of Minnesota (UMN) and National Institutes of Health (NIH) policy (Animal Welfare Assurance Number A3456-01). UMN is accredited by AAALAC, and all animal use was approved by the UMN Institutional Animal Care and Use Committee (IACUC, protocol # 1603-33559A). Animals are kept under supervision of a licensed doctor of veterinary medicine and supporting veterinary staff under strict NIH guidelines.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><object-id pub-id-type="doi">10.7554/eLife.46043.042</object-id><label>Transparent reporting form</label><media mime-subtype="pdf" mimetype="application" xlink:href="elife-46043-transrepform-v2.pdf"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for graphs in Figure 1, Figure 1-figure supplement 1, Figure 2, Figure 3, Figure 3-figure supplement 2, Figure 4, Figure 4-figure supplement 1, Figure 4-figure supplement 5, Figure 5, Figure 6, Figure 6-figure supplement 1, Figure 7, Figure 8, and Figure 9. Data sets and calibration curves resulting from our targeted mass spectrometry studies have been deposited in Panorama Public (<ext-link ext-link-type="uri" xlink:href="https://panoramaweb.org/project/Panorama%20Public/begin.view?">https://panoramaweb.org/project/Panorama%20Public/begin.view?</ext-link>).</p><p>The following dataset was generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Freedman</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2019">2019</year><data-title>Unique-region phosphorylation targets LynA for rapid degradation, tuning its expression and signaling in myeloid cells</data-title><source>Panorama</source><pub-id assigning-authority="other" pub-id-type="archive" xlink:href="http://panoramaweb.org/Freedman_LynA.url">Freedman_LynA</pub-id></element-citation></p><p>The following previously published datasets were used:</p><p><element-citation id="dataset3" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Heng</surname><given-names>TS</given-names></name><name><surname>Painter</surname><given-names>MW</given-names></name></person-group><year iso-8601-date="2016">2016</year><data-title>Immunological Genome Project C. Expression profiling of constitutive mast cells reveals a unique identity within the immune system</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE37448">GSE37448</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abram</surname> <given-names>CL</given-names></name><name><surname>Lowell</surname> <given-names>CA</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The diverse functions of src family kinases in macrophages</article-title><source>Frontiers in Bioscience</source><volume>13</volume><fpage>4426</fpage><lpage>4450</lpage><pub-id pub-id-type="doi">10.2741/3015</pub-id><pub-id pub-id-type="pmid">18508521</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alvarez-Errico</surname> <given-names>D</given-names></name><name><surname>Yamashita</surname> <given-names>Y</given-names></name><name><surname>Suzuki</surname> <given-names>R</given-names></name><name><surname>Odom</surname> <given-names>S</given-names></name><name><surname>Furumoto</surname> <given-names>Y</given-names></name><name><surname>Yamashita</surname> <given-names>T</given-names></name><name><surname>Rivera</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Functional analysis of lyn kinase A and B isoforms reveals redundant and distinct roles in fc epsilon RI-dependent mast cell activation</article-title><source>The Journal of Immunology</source><volume>184</volume><fpage>5000</fpage><lpage>5008</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0904064</pub-id><pub-id pub-id-type="pmid">20308635</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andrews</surname> <given-names>NL</given-names></name><name><surname>Pfeiffer</surname> <given-names>JR</given-names></name><name><surname>Martinez</surname> <given-names>AM</given-names></name><name><surname>Haaland</surname> <given-names>DM</given-names></name><name><surname>Davis</surname> <given-names>RW</given-names></name><name><surname>Kawakami</surname> <given-names>T</given-names></name><name><surname>Oliver</surname> <given-names>JM</given-names></name><name><surname>Wilson</surname> <given-names>BS</given-names></name><name><surname>Lidke</surname> <given-names>DS</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Small, mobile FcepsilonRI receptor aggregates are signaling competent</article-title><source>Immunity</source><volume>31</volume><fpage>469</fpage><lpage>479</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2009.06.026</pub-id><pub-id pub-id-type="pmid">19747859</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bakalar</surname> <given-names>MH</given-names></name><name><surname>Joffe</surname> <given-names>AM</given-names></name><name><surname>Schmid</surname> <given-names>EM</given-names></name><name><surname>Son</surname> <given-names>S</given-names></name><name><surname>Podolski</surname> <given-names>M</given-names></name><name><surname>Fletcher</surname> <given-names>DA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Size-Dependent segregation controls macrophage phagocytosis of Antibody-Opsonized targets</article-title><source>Cell</source><volume>174</volume><fpage>131</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.05.059</pub-id><pub-id pub-id-type="pmid">29958103</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blom</surname> <given-names>N</given-names></name><name><surname>Sicheritz-Pontén</surname> <given-names>T</given-names></name><name><surname>Gupta</surname> <given-names>R</given-names></name><name><surname>Gammeltoft</surname> <given-names>S</given-names></name><name><surname>Brunak</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Prediction of post-translational glycosylation and phosphorylation of proteins from the amino acid sequence</article-title><source>Proteomics</source><volume>4</volume><fpage>1633</fpage><lpage>1649</lpage><pub-id pub-id-type="doi">10.1002/pmic.200300771</pub-id><pub-id pub-id-type="pmid">15174133</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bosurgi</surname> <given-names>L</given-names></name><name><surname>Cao</surname> <given-names>YG</given-names></name><name><surname>Cabeza-Cabrerizo</surname> <given-names>M</given-names></name><name><surname>Tucci</surname> <given-names>A</given-names></name><name><surname>Hughes</surname> <given-names>LD</given-names></name><name><surname>Kong</surname> <given-names>Y</given-names></name><name><surname>Weinstein</surname> <given-names>JS</given-names></name><name><surname>Licona-Limon</surname> <given-names>P</given-names></name><name><surname>Schmid</surname> <given-names>ET</given-names></name><name><surname>Pelorosso</surname> <given-names>F</given-names></name><name><surname>Gagliani</surname> <given-names>N</given-names></name><name><surname>Craft</surname> <given-names>JE</given-names></name><name><surname>Flavell</surname> <given-names>RA</given-names></name><name><surname>Ghosh</surname> <given-names>S</given-names></name><name><surname>Rothlin</surname> <given-names>CV</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Macrophage function in tissue repair and remodeling requires IL-4 or IL-13 with apoptotic cells</article-title><source>Science</source><volume>356</volume><fpage>1072</fpage><lpage>1076</lpage><pub-id pub-id-type="doi">10.1126/science.aai8132</pub-id><pub-id pub-id-type="pmid">28495875</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname> <given-names>GD</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Dectin-1: a signalling non-TLR pattern-recognition receptor</article-title><source>Nature Reviews Immunology</source><volume>6</volume><fpage>33</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1038/nri1745</pub-id><pub-id pub-id-type="pmid">16341139</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname> <given-names>MT</given-names></name><name><surname>Cooper</surname> <given-names>JA</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Regulation, substrates and functions of src</article-title><source>Biochimica Et Biophysica Acta</source><volume>1287</volume><fpage>121</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1016/0304-419X(96)00003-0</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buckbinder</surname> <given-names>L</given-names></name><name><surname>Crawford</surname> <given-names>DT</given-names></name><name><surname>Qi</surname> <given-names>H</given-names></name><name><surname>Ke</surname> <given-names>HZ</given-names></name><name><surname>Olson</surname> <given-names>LM</given-names></name><name><surname>Long</surname> <given-names>KR</given-names></name><name><surname>Bonnette</surname> <given-names>PC</given-names></name><name><surname>Baumann</surname> <given-names>AP</given-names></name><name><surname>Hambor</surname> <given-names>JE</given-names></name><name><surname>Grasser</surname> <given-names>WA</given-names></name><name><surname>Pan</surname> <given-names>LC</given-names></name><name><surname>Owen</surname> <given-names>TA</given-names></name><name><surname>Luzzio</surname> <given-names>MJ</given-names></name><name><surname>Hulford</surname> <given-names>CA</given-names></name><name><surname>Gebhard</surname> <given-names>DF</given-names></name><name><surname>Paralkar</surname> <given-names>VM</given-names></name><name><surname>Simmons</surname> <given-names>HA</given-names></name><name><surname>Kath</surname> <given-names>JC</given-names></name><name><surname>Roberts</surname> <given-names>WG</given-names></name><name><surname>Smock</surname> <given-names>SL</given-names></name><name><surname>Guzman-Perez</surname> <given-names>A</given-names></name><name><surname>Brown</surname> <given-names>TA</given-names></name><name><surname>Li</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Proline-rich tyrosine kinase 2 regulates osteoprogenitor cells and bone formation, and offers an anabolic treatment approach for osteoporosis</article-title><source>PNAS</source><volume>104</volume><fpage>10619</fpage><lpage>10624</lpage><pub-id pub-id-type="doi">10.1073/pnas.0701421104</pub-id><pub-id pub-id-type="pmid">17537919</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buitrago</surname> <given-names>L</given-names></name><name><surname>Langdon</surname> <given-names>WY</given-names></name><name><surname>Sanjay</surname> <given-names>A</given-names></name><name><surname>Kunapuli</surname> <given-names>SP</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Tyrosine phosphorylated c-Cbl regulates platelet functional responses mediated by outside-in signaling</article-title><source>Blood</source><volume>118</volume><fpage>5631</fpage><lpage>5640</lpage><pub-id pub-id-type="doi">10.1182/blood-2011-01-328807</pub-id><pub-id pub-id-type="pmid">21967979</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burgess</surname> <given-names>KE</given-names></name><name><surname>Odysseos</surname> <given-names>AD</given-names></name><name><surname>Zalvan</surname> <given-names>C</given-names></name><name><surname>Druker</surname> <given-names>BJ</given-names></name><name><surname>Anderson</surname> <given-names>P</given-names></name><name><surname>Schlossman</surname> <given-names>SF</given-names></name><name><surname>Rudd</surname> <given-names>CE</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Biochemical identification of a direct physical interaction between the CD4:p56lck and ti(TcR)/CD3 complexes</article-title><source>European Journal of Immunology</source><volume>21</volume><fpage>1663</fpage><lpage>1668</lpage><pub-id pub-id-type="doi">10.1002/eji.1830210712</pub-id><pub-id pub-id-type="pmid">1829412</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carréno</surname> <given-names>S</given-names></name><name><surname>Gouze</surname> <given-names>ME</given-names></name><name><surname>Schaak</surname> <given-names>S</given-names></name><name><surname>Emorine</surname> <given-names>LJ</given-names></name><name><surname>Maridonneau-Parini</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Lack of palmitoylation redirects p59Hck from the plasma membrane to p61Hck-positive lysosomes</article-title><source>The Journal of Biological Chemistry</source><volume>275</volume><fpage>36223</fpage><lpage>36229</lpage><pub-id pub-id-type="doi">10.1074/jbc.M003901200</pub-id><pub-id pub-id-type="pmid">10967098</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carroll-Portillo</surname> <given-names>A</given-names></name><name><surname>Spendier</surname> <given-names>K</given-names></name><name><surname>Pfeiffer</surname> <given-names>J</given-names></name><name><surname>Griffiths</surname> <given-names>G</given-names></name><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Lidke</surname> <given-names>KA</given-names></name><name><surname>Oliver</surname> <given-names>JM</given-names></name><name><surname>Lidke</surname> <given-names>DS</given-names></name><name><surname>Thomas</surname> <given-names>JL</given-names></name><name><surname>Wilson</surname> <given-names>BS</given-names></name><name><surname>Timlin</surname> <given-names>JA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Formation of a mast cell synapse: fcεri membrane dynamics upon binding mobile or immobilized ligands on surfaces</article-title><source>The Journal of Immunology</source><volume>184</volume><fpage>1328</fpage><lpage>1338</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0903071</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiang</surname> <given-names>YJ</given-names></name><name><surname>Kole</surname> <given-names>HK</given-names></name><name><surname>Brown</surname> <given-names>K</given-names></name><name><surname>Naramura</surname> <given-names>M</given-names></name><name><surname>Fukuhara</surname> <given-names>S</given-names></name><name><surname>Hu</surname> <given-names>RJ</given-names></name><name><surname>Jang</surname> <given-names>IK</given-names></name><name><surname>Gutkind</surname> <given-names>JS</given-names></name><name><surname>Shevach</surname> <given-names>E</given-names></name><name><surname>Gu</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Cbl-b regulates the CD28 dependence of T-cell activation</article-title><source>Nature</source><volume>403</volume><fpage>216</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1038/35003235</pub-id><pub-id pub-id-type="pmid">10646609</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiffoleau</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>C-Type Lectin-Like receptors as emerging orchestrators of sterile inflammation represent potential therapeutic targets</article-title><source>Frontiers in Immunology</source><volume>9</volume><elocation-id>227</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2018.00227</pub-id><pub-id pub-id-type="pmid">29497419</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chow</surname> <given-names>LM</given-names></name><name><surname>Veillette</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>The src and csk families of tyrosine protein kinases in Hemopoietic cells</article-title><source>Seminars in Immunology</source><volume>7</volume><fpage>207</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1006/smim.1995.0026</pub-id><pub-id pub-id-type="pmid">8520026</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname> <given-names>Z</given-names></name><name><surname>Ma</surname> <given-names>S</given-names></name><name><surname>Zhou</surname> <given-names>H</given-names></name><name><surname>Zang</surname> <given-names>A</given-names></name><name><surname>Fang</surname> <given-names>Y</given-names></name><name><surname>Li</surname> <given-names>T</given-names></name><name><surname>Shi</surname> <given-names>H</given-names></name><name><surname>Liu</surname> <given-names>M</given-names></name><name><surname>Du</surname> <given-names>M</given-names></name><name><surname>Taylor</surname> <given-names>PR</given-names></name><name><surname>Zhu</surname> <given-names>HH</given-names></name><name><surname>Chen</surname> <given-names>J</given-names></name><name><surname>Meng</surname> <given-names>G</given-names></name><name><surname>Li</surname> <given-names>F</given-names></name><name><surname>Chen</surname> <given-names>C</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Jia</surname> <given-names>XM</given-names></name><name><surname>Lin</surname> <given-names>X</given-names></name><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Pearlman</surname> <given-names>E</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Feng</surname> <given-names>GS</given-names></name><name><surname>Xiao</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Tyrosine phosphatase SHP-2 mediates C-type lectin receptor-induced activation of the kinase syk and anti-fungal TH17 responses</article-title><source>Nature Immunology</source><volume>16</volume><fpage>642</fpage><lpage>652</lpage><pub-id pub-id-type="doi">10.1038/ni.3155</pub-id><pub-id pub-id-type="pmid">25915733</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dou</surname> <given-names>H</given-names></name><name><surname>Buetow</surname> <given-names>L</given-names></name><name><surname>Hock</surname> <given-names>A</given-names></name><name><surname>Sibbet</surname> <given-names>GJ</given-names></name><name><surname>Vousden</surname> <given-names>KH</given-names></name><name><surname>Huang</surname> <given-names>DT</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Structural basis for autoinhibition and phosphorylation-dependent activation of c-Cbl</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>19</volume><fpage>184</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1038/nsmb.2231</pub-id><pub-id pub-id-type="pmid">22266821</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname> <given-names>L</given-names></name><name><surname>Reddi</surname> <given-names>AL</given-names></name><name><surname>Ghosh</surname> <given-names>A</given-names></name><name><surname>Dimri</surname> <given-names>M</given-names></name><name><surname>Band</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>The cbl family and other ubiquitin ligases: destructive forces in control of antigen receptor signaling</article-title><source>Immunity</source><volume>21</volume><fpage>7</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2004.06.012</pub-id><pub-id pub-id-type="pmid">15345216</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dwyer</surname> <given-names>DF</given-names></name><name><surname>Barrett</surname> <given-names>NA</given-names></name><name><surname>Austen</surname> <given-names>KF</given-names></name><collab>Immunological Genome Project Consortium</collab></person-group><year iso-8601-date="2016">2016</year><article-title>Expression profiling of constitutive mast cells reveals a unique identity within the immune system</article-title><source>Nature Immunology</source><volume>17</volume><fpage>878</fpage><lpage>887</lpage><pub-id pub-id-type="doi">10.1038/ni.3445</pub-id><pub-id pub-id-type="pmid">27135604</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Felce</surname> <given-names>JH</given-names></name><name><surname>Sezgin</surname> <given-names>E</given-names></name><name><surname>Wane</surname> <given-names>M</given-names></name><name><surname>Brouwer</surname> <given-names>H</given-names></name><name><surname>Dustin</surname> <given-names>ML</given-names></name><name><surname>Eggeling</surname> <given-names>C</given-names></name><name><surname>Davis</surname> <given-names>SJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>CD45 exclusion- and cross-linking-based receptor signaling together broaden fcεri reactivity</article-title><source>Science Signaling</source><volume>11</volume><fpage>eaat0756</fpage><pub-id pub-id-type="doi">10.1126/scisignal.aat0756</pub-id><pub-id pub-id-type="pmid">30563863</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feshchenko</surname> <given-names>EA</given-names></name><name><surname>Langdon</surname> <given-names>WY</given-names></name><name><surname>Tsygankov</surname> <given-names>AY</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Fyn, yes, and syk phosphorylation sites in c-Cbl map to the same tyrosine residues that become phosphorylated in activated T cells</article-title><source>Journal of Biological Chemistry</source><volume>273</volume><fpage>8323</fpage><lpage>8331</lpage><pub-id pub-id-type="doi">10.1074/jbc.273.14.8323</pub-id><pub-id pub-id-type="pmid">9525940</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freedman</surname> <given-names>TS</given-names></name><name><surname>Tan</surname> <given-names>YX</given-names></name><name><surname>Skrzypczynska</surname> <given-names>KM</given-names></name><name><surname>Manz</surname> <given-names>BN</given-names></name><name><surname>Sjaastad</surname> <given-names>FV</given-names></name><name><surname>Goodridge</surname> <given-names>HS</given-names></name><name><surname>Lowell</surname> <given-names>CA</given-names></name><name><surname>Weiss</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>LynA regulates an inflammation-sensitive signaling checkpoint in macrophages</article-title><source>eLife</source><volume>4</volume><elocation-id>e09183</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.09183</pub-id><pub-id pub-id-type="pmid">26517880</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freeman</surname> <given-names>SA</given-names></name><name><surname>Goyette</surname> <given-names>J</given-names></name><name><surname>Furuya</surname> <given-names>W</given-names></name><name><surname>Woods</surname> <given-names>EC</given-names></name><name><surname>Bertozzi</surname> <given-names>CR</given-names></name><name><surname>Bergmeier</surname> <given-names>W</given-names></name><name><surname>Hinz</surname> <given-names>B</given-names></name><name><surname>van der Merwe</surname> <given-names>PA</given-names></name><name><surname>Das</surname> <given-names>R</given-names></name><name><surname>Grinstein</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Integrins form an expanding diffusional barrier that coordinates phagocytosis</article-title><source>Cell</source><volume>164</volume><fpage>128</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.11.048</pub-id><pub-id pub-id-type="pmid">26771488</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galli</surname> <given-names>SJ</given-names></name><name><surname>Borregaard</surname> <given-names>N</given-names></name><name><surname>Wynn</surname> <given-names>TA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Phenotypic and functional plasticity of cells of innate immunity: macrophages, mast cells and neutrophils</article-title><source>Nature Immunology</source><volume>12</volume><fpage>1035</fpage><lpage>1044</lpage><pub-id pub-id-type="doi">10.1038/ni.2109</pub-id><pub-id pub-id-type="pmid">22012443</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gentek</surname> <given-names>R</given-names></name><name><surname>Ghigo</surname> <given-names>C</given-names></name><name><surname>Hoeffel</surname> <given-names>G</given-names></name><name><surname>Bulle</surname> <given-names>MJ</given-names></name><name><surname>Msallam</surname> <given-names>R</given-names></name><name><surname>Gautier</surname> <given-names>G</given-names></name><name><surname>Launay</surname> <given-names>P</given-names></name><name><surname>Chen</surname> <given-names>J</given-names></name><name><surname>Ginhoux</surname> <given-names>F</given-names></name><name><surname>Bajénoff</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Hemogenic endothelial fate mapping reveals dual developmental origin of mast cells</article-title><source>Immunity</source><volume>48</volume><fpage>1160</fpage><lpage>1171</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2018.04.025</pub-id><pub-id pub-id-type="pmid">29858009</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldsmith</surname> <given-names>MA</given-names></name><name><surname>Weiss</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="1987">1987</year><article-title>Isolation and characterization of a T-lymphocyte somatic mutant with altered signal transduction by the antigen receptor</article-title><source>PNAS</source><volume>84</volume><fpage>6879</fpage><lpage>6883</lpage><pub-id pub-id-type="doi">10.1073/pnas.84.19.6879</pub-id><pub-id pub-id-type="pmid">3309950</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodridge</surname> <given-names>HS</given-names></name><name><surname>Reyes</surname> <given-names>CN</given-names></name><name><surname>Becker</surname> <given-names>CA</given-names></name><name><surname>Katsumoto</surname> <given-names>TR</given-names></name><name><surname>Ma</surname> <given-names>J</given-names></name><name><surname>Wolf</surname> <given-names>AJ</given-names></name><name><surname>Bose</surname> <given-names>N</given-names></name><name><surname>Chan</surname> <given-names>AS</given-names></name><name><surname>Magee</surname> <given-names>AS</given-names></name><name><surname>Danielson</surname> <given-names>ME</given-names></name><name><surname>Weiss</surname> <given-names>A</given-names></name><name><surname>Vasilakos</surname> <given-names>JP</given-names></name><name><surname>Underhill</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Activation of the innate immune receptor Dectin-1 upon formation of a 'phagocytic synapse'</article-title><source>Nature</source><volume>472</volume><fpage>471</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1038/nature10071</pub-id><pub-id pub-id-type="pmid">21525931</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guilliams</surname> <given-names>M</given-names></name><name><surname>Bruhns</surname> <given-names>P</given-names></name><name><surname>Saeys</surname> <given-names>Y</given-names></name><name><surname>Hammad</surname> <given-names>H</given-names></name><name><surname>Lambrecht</surname> <given-names>BN</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The function of fcγ receptors in dendritic cells and macrophages</article-title><source>Nature Reviews Immunology</source><volume>14</volume><fpage>94</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1038/nri3582</pub-id><pub-id pub-id-type="pmid">24445665</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gustin</surname> <given-names>SE</given-names></name><name><surname>Thien</surname> <given-names>CBF</given-names></name><name><surname>Langdon</surname> <given-names>WY</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Cbl-b is a negative regulator of inflammatory cytokines produced by IgE-Activated mast cells</article-title><source>The Journal of Immunology</source><volume>177</volume><fpage>5980</fpage><lpage>5989</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.177.9.5980</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamerman</surname> <given-names>JA</given-names></name><name><surname>Ni</surname> <given-names>M</given-names></name><name><surname>Killebrew</surname> <given-names>JR</given-names></name><name><surname>Chu</surname> <given-names>CL</given-names></name><name><surname>Lowell</surname> <given-names>CA</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The expanding roles of ITAM adapters FcRgamma and DAP12 in myeloid cells</article-title><source>Immunological Reviews</source><volume>232</volume><fpage>42</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.2009.00841.x</pub-id><pub-id pub-id-type="pmid">19909355</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamerman</surname> <given-names>JA</given-names></name><name><surname>Lanier</surname> <given-names>LL</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Inhibition of immune responses by ITAM-bearing receptors</article-title><source>Science's STKE : Signal Transduction Knowledge Environment</source><volume>2006</volume><elocation-id>re1</elocation-id><pub-id pub-id-type="doi">10.1126/stke.3202006re1</pub-id><pub-id pub-id-type="pmid">16449667</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>G</given-names></name><name><surname>Welch</surname> <given-names>EJ</given-names></name><name><surname>Liang</surname> <given-names>Y</given-names></name><name><surname>Fu</surname> <given-names>J</given-names></name><name><surname>Vogel</surname> <given-names>SM</given-names></name><name><surname>Lowell</surname> <given-names>CA</given-names></name><name><surname>Du</surname> <given-names>X</given-names></name><name><surname>Cheresh</surname> <given-names>DA</given-names></name><name><surname>Malik</surname> <given-names>AB</given-names></name><name><surname>Li</surname> <given-names>Z</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>A critical role for lyn kinase in strengthening endothelial integrity and barrier function</article-title><source>Blood</source><volume>122</volume><fpage>4140</fpage><lpage>4149</lpage><pub-id pub-id-type="doi">10.1182/blood-2013-03-491423</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanke</surname> <given-names>JH</given-names></name><name><surname>Gardner</surname> <given-names>JP</given-names></name><name><surname>Dow</surname> <given-names>RL</given-names></name><name><surname>Changelian</surname> <given-names>PS</given-names></name><name><surname>Brissette</surname> <given-names>WH</given-names></name><name><surname>Weringer</surname> <given-names>EJ</given-names></name><name><surname>Pollok</surname> <given-names>BA</given-names></name><name><surname>Connelly</surname> <given-names>PA</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Discovery of a novel, potent, and src family-selective tyrosine kinase inhibitor. Study of lck- and FynT-dependent T cell activation</article-title><source>The Journal of Biological Chemistry</source><volume>271</volume><fpage>695</fpage><lpage>701</lpage><pub-id pub-id-type="doi">10.1074/jbc.271.2.695</pub-id><pub-id pub-id-type="pmid">8557675</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heng</surname> <given-names>TS</given-names></name><name><surname>Painter</surname> <given-names>MW</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Immunological genome project C. the immunological genome project: networks of gene expression in immune cells</article-title><source>Nature Immunology</source><volume>9</volume><fpage>1091</fpage><lpage>1094</lpage></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname> <given-names>TH</given-names></name><name><surname>Huo</surname> <given-names>L</given-names></name><name><surname>Wang</surname> <given-names>YN</given-names></name><name><surname>Xia</surname> <given-names>W</given-names></name><name><surname>Wei</surname> <given-names>Y</given-names></name><name><surname>Chang</surname> <given-names>SS</given-names></name><name><surname>Chang</surname> <given-names>WC</given-names></name><name><surname>Fang</surname> <given-names>YF</given-names></name><name><surname>Chen</surname> <given-names>CT</given-names></name><name><surname>Lang</surname> <given-names>JY</given-names></name><name><surname>Tu</surname> <given-names>C</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Hsu</surname> <given-names>MC</given-names></name><name><surname>Kuo</surname> <given-names>HP</given-names></name><name><surname>Ko</surname> <given-names>HW</given-names></name><name><surname>Shen</surname> <given-names>J</given-names></name><name><surname>Lee</surname> <given-names>HH</given-names></name><name><surname>Lee</surname> <given-names>PC</given-names></name><name><surname>Wu</surname> <given-names>Y</given-names></name><name><surname>Chen</surname> <given-names>CH</given-names></name><name><surname>Hung</surname> <given-names>MC</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Epidermal growth factor receptor potentiates MCM7-mediated DNA replication through tyrosine phosphorylation of lyn kinase in human cancers</article-title><source>Cancer Cell</source><volume>23</volume><fpage>796</fpage><lpage>810</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2013.04.027</pub-id><pub-id pub-id-type="pmid">23764002</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunter</surname> <given-names>S</given-names></name><name><surname>Burton</surname> <given-names>EA</given-names></name><name><surname>Wu</surname> <given-names>SC</given-names></name><name><surname>Anderson</surname> <given-names>SM</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Fyn associates with cbl and phosphorylates tyrosine 731 in cbl, a binding site for phosphatidylinositol 3-kinase</article-title><source>Journal of Biological Chemistry</source><volume>274</volume><fpage>2097</fpage><lpage>2106</lpage><pub-id pub-id-type="doi">10.1074/jbc.274.4.2097</pub-id><pub-id pub-id-type="pmid">9890970</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaumouillé</surname> <given-names>V</given-names></name><name><surname>Farkash</surname> <given-names>Y</given-names></name><name><surname>Jaqaman</surname> <given-names>K</given-names></name><name><surname>Das</surname> <given-names>R</given-names></name><name><surname>Lowell</surname> <given-names>CA</given-names></name><name><surname>Grinstein</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Actin cytoskeleton reorganization by syk regulates fcγ receptor responsiveness by increasing its lateral mobility and clustering</article-title><source>Developmental Cell</source><volume>29</volume><fpage>534</fpage><lpage>546</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2014.04.031</pub-id><pub-id pub-id-type="pmid">24914558</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname> <given-names>TM</given-names></name><name><surname>Williamson</surname> <given-names>NA</given-names></name><name><surname>Scholz</surname> <given-names>G</given-names></name><name><surname>Jaworowski</surname> <given-names>A</given-names></name><name><surname>Wettenhall</surname> <given-names>RE</given-names></name><name><surname>Dunn</surname> <given-names>AR</given-names></name><name><surname>Cheng</surname> <given-names>HC</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Modulation of the catalytic activity of the src family tyrosine kinase hck by autophosphorylation at a novel site in the unique domain</article-title><source>Journal of Biological Chemistry</source><volume>275</volume><fpage>33353</fpage><lpage>33364</lpage><pub-id pub-id-type="doi">10.1074/jbc.M002022200</pub-id><pub-id pub-id-type="pmid">10934191</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalesnikoff</surname> <given-names>J</given-names></name><name><surname>Galli</surname> <given-names>SJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Antiinflammatory and immunosuppressive functions of mast cells</article-title><source>Methods in Molecular Biology</source><volume>677</volume><fpage>207</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1007/978-1-60761-869-0_15</pub-id><pub-id pub-id-type="pmid">20941613</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kyo</surname> <given-names>S</given-names></name><name><surname>Sada</surname> <given-names>K</given-names></name><name><surname>Qu</surname> <given-names>X</given-names></name><name><surname>Maeno</surname> <given-names>K</given-names></name><name><surname>Miah</surname> <given-names>SM</given-names></name><name><surname>Kawauchi-Kamata</surname> <given-names>K</given-names></name><name><surname>Yamamura</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Negative regulation of lyn protein-tyrosine kinase by c-Cbl ubiquitin-protein ligase in fc epsilon RI-mediated mast cell activation</article-title><source>Genes to Cells</source><volume>8</volume><fpage>825</fpage><lpage>836</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2443.2003.00679.x</pub-id><pub-id pub-id-type="pmid">14531861</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Law</surname> <given-names>CL</given-names></name><name><surname>Chandran</surname> <given-names>KA</given-names></name><name><surname>Sidorenko</surname> <given-names>SP</given-names></name><name><surname>Clark</surname> <given-names>EA</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Phospholipase C-gamma1 interacts with conserved phosphotyrosyl residues in the Linker region of syk and is a substrate for syk</article-title><source>Molecular and Cellular Biology</source><volume>16</volume><fpage>1305</fpage><lpage>1315</lpage><pub-id pub-id-type="doi">10.1128/MCB.16.4.1305</pub-id><pub-id pub-id-type="pmid">8657103</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liyasova</surname> <given-names>MS</given-names></name><name><surname>Ma</surname> <given-names>K</given-names></name><name><surname>Lipkowitz</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Molecular pathways: cbl proteins in tumorigenesis and antitumor immunity-opportunities for Cancer treatment</article-title><source>Clinical Cancer Research</source><volume>21</volume><fpage>1789</fpage><lpage>1794</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-13-2490</pub-id><pub-id pub-id-type="pmid">25477533</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lock</surname> <given-names>P</given-names></name><name><surname>Ralph</surname> <given-names>S</given-names></name><name><surname>Stanley</surname> <given-names>E</given-names></name><name><surname>Boulet</surname> <given-names>I</given-names></name><name><surname>Ramsay</surname> <given-names>R</given-names></name><name><surname>Dunn</surname> <given-names>AR</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Two isoforms of murine hck, generated by utilization of alternative translational initiation codons, exhibit different patterns of subcellular localization</article-title><source>Molecular and Cellular Biology</source><volume>11</volume><fpage>4363</fpage><lpage>4370</lpage><pub-id pub-id-type="doi">10.1128/MCB.11.9.4363</pub-id><pub-id pub-id-type="pmid">1875927</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lowell</surname> <given-names>CA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Src-family and syk kinases in activating and inhibitory pathways in innate immune cells: signaling cross talk</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>3</volume><elocation-id>a002352</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a002352</pub-id><pub-id pub-id-type="pmid">21068150</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lutz-Nicoladoni</surname> <given-names>C</given-names></name><name><surname>Wolf</surname> <given-names>D</given-names></name><name><surname>Sopper</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Modulation of immune cell functions by the E3 ligase Cbl-b</article-title><source>Frontiers in Oncology</source><volume>5</volume><elocation-id>58</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2015.00058</pub-id><pub-id pub-id-type="pmid">25815272</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacLean</surname> <given-names>B</given-names></name><name><surname>Tomazela</surname> <given-names>DM</given-names></name><name><surname>Shulman</surname> <given-names>N</given-names></name><name><surname>Chambers</surname> <given-names>M</given-names></name><name><surname>Finney</surname> <given-names>GL</given-names></name><name><surname>Frewen</surname> <given-names>B</given-names></name><name><surname>Kern</surname> <given-names>R</given-names></name><name><surname>Tabb</surname> <given-names>DL</given-names></name><name><surname>Liebler</surname> <given-names>DC</given-names></name><name><surname>MacCoss</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Skyline: an open source document editor for creating and analyzing targeted proteomics experiments</article-title><source>Bioinformatics</source><volume>26</volume><fpage>966</fpage><lpage>968</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btq054</pub-id><pub-id pub-id-type="pmid">20147306</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mkaddem</surname> <given-names>SB</given-names></name><name><surname>Murua</surname> <given-names>A</given-names></name><name><surname>Flament</surname> <given-names>H</given-names></name><name><surname>Titeca-Beauport</surname> <given-names>D</given-names></name><name><surname>Bounaix</surname> <given-names>C</given-names></name><name><surname>Danelli</surname> <given-names>L</given-names></name><name><surname>Launay</surname> <given-names>P</given-names></name><name><surname>Benhamou</surname> <given-names>M</given-names></name><name><surname>Blank</surname> <given-names>U</given-names></name><name><surname>Daugas</surname> <given-names>E</given-names></name><name><surname>Charles</surname> <given-names>N</given-names></name><name><surname>Monteiro</surname> <given-names>RC</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Lyn and fyn function as molecular switches that control immunoreceptors to direct homeostasis or inflammation</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>246</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-017-00294-0</pub-id><pub-id pub-id-type="pmid">28811476</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohapatra</surname> <given-names>B</given-names></name><name><surname>Ahmad</surname> <given-names>G</given-names></name><name><surname>Nadeau</surname> <given-names>S</given-names></name><name><surname>Zutshi</surname> <given-names>N</given-names></name><name><surname>An</surname> <given-names>W</given-names></name><name><surname>Scheffe</surname> <given-names>S</given-names></name><name><surname>Dong</surname> <given-names>L</given-names></name><name><surname>Feng</surname> <given-names>D</given-names></name><name><surname>Goetz</surname> <given-names>B</given-names></name><name><surname>Arya</surname> <given-names>P</given-names></name><name><surname>Bailey</surname> <given-names>TA</given-names></name><name><surname>Palermo</surname> <given-names>N</given-names></name><name><surname>Borgstahl</surname> <given-names>GE</given-names></name><name><surname>Natarajan</surname> <given-names>A</given-names></name><name><surname>Raja</surname> <given-names>SM</given-names></name><name><surname>Naramura</surname> <given-names>M</given-names></name><name><surname>Band</surname> <given-names>V</given-names></name><name><surname>Band</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Protein tyrosine kinase regulation by ubiquitination: critical roles of Cbl-family ubiquitin ligases</article-title><source>Biochimica Et Biophysica Acta (BBA) - Molecular Cell Research</source><volume>1833</volume><fpage>122</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2012.10.010</pub-id><pub-id pub-id-type="pmid">23085373</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Myers</surname> <given-names>MD</given-names></name><name><surname>Sosinowski</surname> <given-names>T</given-names></name><name><surname>Dragone</surname> <given-names>LL</given-names></name><name><surname>White</surname> <given-names>C</given-names></name><name><surname>Band</surname> <given-names>H</given-names></name><name><surname>Gu</surname> <given-names>H</given-names></name><name><surname>Weiss</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Src-like adaptor protein regulates TCR expression on thymocytes by linking the ubiquitin ligase c-Cbl to the TCR complex</article-title><source>Nature Immunology</source><volume>7</volume><fpage>57</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1038/ni1291</pub-id><pub-id pub-id-type="pmid">16327786</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naramura</surname> <given-names>M</given-names></name><name><surname>Jang</surname> <given-names>IK</given-names></name><name><surname>Kole</surname> <given-names>H</given-names></name><name><surname>Huang</surname> <given-names>F</given-names></name><name><surname>Haines</surname> <given-names>D</given-names></name><name><surname>Gu</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>c-Cbl and Cbl-b regulate T cell responsiveness by promoting ligand-induced TCR down-modulation</article-title><source>Nature Immunology</source><volume>3</volume><fpage>1192</fpage><lpage>1199</lpage><pub-id pub-id-type="doi">10.1038/ni855</pub-id><pub-id pub-id-type="pmid">12415267</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okuzumi</surname> <given-names>T</given-names></name><name><surname>Fiedler</surname> <given-names>D</given-names></name><name><surname>Zhang</surname> <given-names>C</given-names></name><name><surname>Gray</surname> <given-names>DC</given-names></name><name><surname>Aizenstein</surname> <given-names>B</given-names></name><name><surname>Hoffman</surname> <given-names>R</given-names></name><name><surname>Shokat</surname> <given-names>KM</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Inhibitor hijacking of akt activation</article-title><source>Nature Chemical Biology</source><volume>5</volume><fpage>484</fpage><lpage>493</lpage><pub-id pub-id-type="doi">10.1038/nchembio.183</pub-id><pub-id pub-id-type="pmid">19465931</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okuzumi</surname> <given-names>T</given-names></name><name><surname>Ducker</surname> <given-names>GS</given-names></name><name><surname>Zhang</surname> <given-names>C</given-names></name><name><surname>Aizenstein</surname> <given-names>B</given-names></name><name><surname>Hoffman</surname> <given-names>R</given-names></name><name><surname>Shokat</surname> <given-names>KM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Synthesis and evaluation of indazole based analog sensitive akt inhibitors</article-title><source>Molecular BioSystems</source><volume>6</volume><fpage>1389</fpage><lpage>1402</lpage><pub-id pub-id-type="doi">10.1039/c003917a</pub-id><pub-id pub-id-type="pmid">20582381</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palacios-Moreno</surname> <given-names>J</given-names></name><name><surname>Foltz</surname> <given-names>L</given-names></name><name><surname>Guo</surname> <given-names>A</given-names></name><name><surname>Stokes</surname> <given-names>MP</given-names></name><name><surname>Kuehn</surname> <given-names>ED</given-names></name><name><surname>George</surname> <given-names>L</given-names></name><name><surname>Comb</surname> <given-names>M</given-names></name><name><surname>Grimes</surname> <given-names>ML</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Neuroblastoma tyrosine kinase signaling networks involve FYN and LYN in endosomes and lipid rafts</article-title><source>PLOS Computational Biology</source><volume>11</volume><elocation-id>e1004130</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1004130</pub-id><pub-id pub-id-type="pmid">25884760</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phee</surname> <given-names>H</given-names></name><name><surname>Abraham</surname> <given-names>RT</given-names></name><name><surname>Weiss</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Dynamic recruitment of PAK1 to the immunological synapse is mediated by PIX independently of SLP-76 and Vav1</article-title><source>Nature Immunology</source><volume>6</volume><fpage>608</fpage><lpage>617</lpage><pub-id pub-id-type="doi">10.1038/ni1199</pub-id><pub-id pub-id-type="pmid">15864311</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Portnoy</surname> <given-names>V</given-names></name><name><surname>Huang</surname> <given-names>V</given-names></name><name><surname>Place</surname> <given-names>RF</given-names></name><name><surname>Li</surname> <given-names>LC</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Small RNA and transcriptional upregulation</article-title><source>Wiley Interdisciplinary Reviews: RNA</source><volume>2</volume><fpage>748</fpage><lpage>760</lpage><pub-id pub-id-type="doi">10.1002/wrna.90</pub-id><pub-id pub-id-type="pmid">21823233</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Purev</surname> <given-names>E</given-names></name><name><surname>Neff</surname> <given-names>L</given-names></name><name><surname>Horne</surname> <given-names>WC</given-names></name><name><surname>Baron</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>c-Cbl and Cbl-b act redundantly to protect osteoclasts from apoptosis and to displace HDAC6 from beta-tubulin, stabilizing microtubules and podosomes</article-title><source>Molecular Biology of the Cell</source><volume>20</volume><fpage>4021</fpage><lpage>4030</lpage><pub-id pub-id-type="doi">10.1091/mbc.e09-03-0248</pub-id><pub-id pub-id-type="pmid">19641021</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radivojac</surname> <given-names>P</given-names></name><name><surname>Vacic</surname> <given-names>V</given-names></name><name><surname>Haynes</surname> <given-names>C</given-names></name><name><surname>Cocklin</surname> <given-names>RR</given-names></name><name><surname>Mohan</surname> <given-names>A</given-names></name><name><surname>Heyen</surname> <given-names>JW</given-names></name><name><surname>Goebl</surname> <given-names>MG</given-names></name><name><surname>Iakoucheva</surname> <given-names>LM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Identification, analysis, and prediction of protein ubiquitination sites</article-title><source>Proteins: Structure, Function, and Bioinformatics</source><volume>78</volume><fpage>365</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1002/prot.22555</pub-id><pub-id pub-id-type="pmid">19722269</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rafiq</surname> <given-names>K</given-names></name><name><surname>Kolpakov</surname> <given-names>MA</given-names></name><name><surname>Seqqat</surname> <given-names>R</given-names></name><name><surname>Guo</surname> <given-names>J</given-names></name><name><surname>Guo</surname> <given-names>X</given-names></name><name><surname>Qi</surname> <given-names>Z</given-names></name><name><surname>Yu</surname> <given-names>D</given-names></name><name><surname>Mohapatra</surname> <given-names>B</given-names></name><name><surname>Zutshi</surname> <given-names>N</given-names></name><name><surname>An</surname> <given-names>W</given-names></name><name><surname>Band</surname> <given-names>H</given-names></name><name><surname>Sanjay</surname> <given-names>A</given-names></name><name><surname>Houser</surname> <given-names>SR</given-names></name><name><surname>Sabri</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>c-Cbl inhibition improves cardiac function and survival in response to myocardial ischemia</article-title><source>Circulation</source><volume>129</volume><fpage>2031</fpage><lpage>2043</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.113.007004</pub-id><pub-id pub-id-type="pmid">24583314</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samelson</surname> <given-names>LE</given-names></name><name><surname>Phillips</surname> <given-names>AF</given-names></name><name><surname>Luong</surname> <given-names>ET</given-names></name><name><surname>Klausner</surname> <given-names>RD</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Association of the fyn protein-tyrosine kinase with the T-cell antigen receptor</article-title><source>PNAS</source><volume>87</volume><fpage>4358</fpage><lpage>4362</lpage><pub-id pub-id-type="doi">10.1073/pnas.87.11.4358</pub-id><pub-id pub-id-type="pmid">2190221</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanjay</surname> <given-names>A</given-names></name><name><surname>Houghton</surname> <given-names>A</given-names></name><name><surname>Neff</surname> <given-names>L</given-names></name><name><surname>DiDomenico</surname> <given-names>E</given-names></name><name><surname>Bardelay</surname> <given-names>C</given-names></name><name><surname>Antoine</surname> <given-names>E</given-names></name><name><surname>Levy</surname> <given-names>J</given-names></name><name><surname>Gailit</surname> <given-names>J</given-names></name><name><surname>Bowtell</surname> <given-names>D</given-names></name><name><surname>Horne</surname> <given-names>WC</given-names></name><name><surname>Baron</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Cbl associates with Pyk2 and src to regulate src kinase activity, alpha(v)beta(3) integrin-mediated signaling, cell adhesion, and osteoclast motility</article-title><source>The Journal of Cell Biology</source><volume>152</volume><fpage>181</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1083/jcb.152.1.181</pub-id><pub-id pub-id-type="pmid">11149930</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanjay</surname> <given-names>A</given-names></name><name><surname>Miyazaki</surname> <given-names>T</given-names></name><name><surname>Itzstein</surname> <given-names>C</given-names></name><name><surname>Purev</surname> <given-names>E</given-names></name><name><surname>Horne</surname> <given-names>WC</given-names></name><name><surname>Baron</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Identification and functional characterization of an src homology domain 3 domain-binding site on cbl</article-title><source>FEBS Journal</source><volume>273</volume><fpage>5442</fpage><lpage>5456</lpage><pub-id pub-id-type="doi">10.1111/j.1742-4658.2006.05535.x</pub-id><pub-id pub-id-type="pmid">17094785</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scapini</surname> <given-names>P</given-names></name><name><surname>Pereira</surname> <given-names>S</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Lowell</surname> <given-names>CA</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Multiple roles of lyn kinase in myeloid cell signaling and function</article-title><source>Immunological Reviews</source><volume>228</volume><fpage>23</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.2008.00758.x</pub-id><pub-id pub-id-type="pmid">19290919</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schindelin</surname> <given-names>J</given-names></name><name><surname>Arganda-Carreras</surname> <given-names>I</given-names></name><name><surname>Frise</surname> <given-names>E</given-names></name><name><surname>Kaynig</surname> <given-names>V</given-names></name><name><surname>Longair</surname> <given-names>M</given-names></name><name><surname>Pietzsch</surname> <given-names>T</given-names></name><name><surname>Preibisch</surname> <given-names>S</given-names></name><name><surname>Rueden</surname> <given-names>C</given-names></name><name><surname>Saalfeld</surname> <given-names>S</given-names></name><name><surname>Schmid</surname> <given-names>B</given-names></name><name><surname>Tinevez</surname> <given-names>JY</given-names></name><name><surname>White</surname> <given-names>DJ</given-names></name><name><surname>Hartenstein</surname> <given-names>V</given-names></name><name><surname>Eliceiri</surname> <given-names>K</given-names></name><name><surname>Tomancak</surname> <given-names>P</given-names></name><name><surname>Cardona</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Fiji: an open-source platform for biological-image analysis</article-title><source>Nature Methods</source><volume>9</volume><fpage>676</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2019</pub-id><pub-id pub-id-type="pmid">22743772</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schoenborn</surname> <given-names>JR</given-names></name><name><surname>Tan</surname> <given-names>YX</given-names></name><name><surname>Zhang</surname> <given-names>C</given-names></name><name><surname>Shokat</surname> <given-names>KM</given-names></name><name><surname>Weiss</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Feedback circuits monitor and adjust basal Lck-dependent events in T cell receptor signaling</article-title><source>Science Signaling</source><volume>4</volume><elocation-id>ra59</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.2001893</pub-id><pub-id pub-id-type="pmid">21917715</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwartz</surname> <given-names>SL</given-names></name><name><surname>Cleyrat</surname> <given-names>C</given-names></name><name><surname>Olah</surname> <given-names>MJ</given-names></name><name><surname>Relich</surname> <given-names>PK</given-names></name><name><surname>Phillips</surname> <given-names>GK</given-names></name><name><surname>Hlavacek</surname> <given-names>WS</given-names></name><name><surname>Lidke</surname> <given-names>KA</given-names></name><name><surname>Wilson</surname> <given-names>BS</given-names></name><name><surname>Lidke</surname> <given-names>DS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Differential mast cell outcomes are sensitive to FcεRI-Syk binding kinetics</article-title><source>Molecular Biology of the Cell</source><volume>28</volume><fpage>3397</fpage><lpage>3414</lpage><pub-id pub-id-type="doi">10.1091/mbc.e17-06-0350</pub-id><pub-id pub-id-type="pmid">28855374</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shao</surname> <given-names>Y</given-names></name><name><surname>Yang</surname> <given-names>C</given-names></name><name><surname>Elly</surname> <given-names>C</given-names></name><name><surname>Liu</surname> <given-names>YC</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Differential regulation of the B cell receptor-mediated signaling by the E3 ubiquitin ligase cbl</article-title><source>Journal of Biological Chemistry</source><volume>279</volume><fpage>43646</fpage><lpage>43653</lpage><pub-id pub-id-type="doi">10.1074/jbc.M404082200</pub-id><pub-id pub-id-type="pmid">15304502</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shelby</surname> <given-names>SA</given-names></name><name><surname>Veatch</surname> <given-names>SL</given-names></name><name><surname>Holowka</surname> <given-names>DA</given-names></name><name><surname>Baird</surname> <given-names>BA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Functional nanoscale coupling of lyn kinase with IgE-FcεRI is restricted by the actin cytoskeleton in early antigen-stimulated signaling</article-title><source>Molecular Biology of the Cell</source><volume>27</volume><fpage>3645</fpage><lpage>3658</lpage><pub-id pub-id-type="doi">10.1091/mbc.e16-06-0425</pub-id><pub-id pub-id-type="pmid">27682583</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sohn</surname> <given-names>HW</given-names></name><name><surname>Gu</surname> <given-names>H</given-names></name><name><surname>Pierce</surname> <given-names>SK</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Cbl-b negatively regulates B cell antigen receptor signaling in mature B cells through ubiquitination of the tyrosine kinase syk</article-title><source>The Journal of Experimental Medicine</source><volume>197</volume><fpage>1511</fpage><lpage>1524</lpage><pub-id pub-id-type="doi">10.1084/jem.20021686</pub-id><pub-id pub-id-type="pmid">12771181</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sondermann</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The fcγr/IgG interaction as target for the treatment of autoimmune diseases</article-title><source>Journal of Clinical Immunology</source><volume>36</volume><fpage>95</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1007/s10875-016-0272-7</pub-id><pub-id pub-id-type="pmid">27039179</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stanley</surname> <given-names>E</given-names></name><name><surname>Ralph</surname> <given-names>S</given-names></name><name><surname>McEwen</surname> <given-names>S</given-names></name><name><surname>Boulet</surname> <given-names>I</given-names></name><name><surname>Holtzman</surname> <given-names>DA</given-names></name><name><surname>Lock</surname> <given-names>P</given-names></name><name><surname>Dunn</surname> <given-names>AR</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Alternatively spliced murine lyn mRNAs encode distinct proteins</article-title><source>Molecular and Cellular Biology</source><volume>11</volume><fpage>3399</fpage><lpage>3406</lpage><pub-id pub-id-type="doi">10.1128/MCB.11.7.3399</pub-id><pub-id pub-id-type="pmid">1710766</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Straus</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Genetic evidence for the involvement of the lck tyrosine kinase in signal transduction through the T cell antigen receptor</article-title><source>Cell</source><volume>70</volume><fpage>585</fpage><lpage>593</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(92)90428-F</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takai</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Roles of fc receptors in autoimmunity</article-title><source>Nature Reviews Immunology</source><volume>2</volume><fpage>580</fpage><lpage>592</lpage><pub-id pub-id-type="doi">10.1038/nri856</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeshita</surname> <given-names>S</given-names></name><name><surname>Kaji</surname> <given-names>K</given-names></name><name><surname>Kudo</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Identification and characterization of the new osteoclast progenitor with macrophage phenotypes being able to differentiate into mature osteoclasts</article-title><source>Journal of Bone and Mineral Research</source><volume>15</volume><fpage>1477</fpage><lpage>1488</lpage><pub-id pub-id-type="doi">10.1359/jbmr.2000.15.8.1477</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname> <given-names>YX</given-names></name><name><surname>Manz</surname> <given-names>BN</given-names></name><name><surname>Freedman</surname> <given-names>TS</given-names></name><name><surname>Zhang</surname> <given-names>C</given-names></name><name><surname>Shokat</surname> <given-names>KM</given-names></name><name><surname>Weiss</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Inhibition of the kinase csk in thymocytes reveals a requirement for actin remodeling in the initiation of full TCR signaling</article-title><source>Nature Immunology</source><volume>15</volume><fpage>186</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1038/ni.2772</pub-id><pub-id pub-id-type="pmid">24317039</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname> <given-names>R</given-names></name><name><surname>Langdon</surname> <given-names>WY</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Regulation of immune responses by E3 ubiquitin ligase Cbl-b</article-title><source>Cellular Immunology</source><volume>340</volume><elocation-id>103878</elocation-id><pub-id pub-id-type="doi">10.1016/j.cellimm.2018.11.002</pub-id><pub-id pub-id-type="pmid">30442330</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teixeira</surname> <given-names>J</given-names></name><name><surname>Fuentes</surname> <given-names>H</given-names></name><name><surname>Bielskutė</surname> <given-names>S</given-names></name><name><surname>Gairi</surname> <given-names>M</given-names></name><name><surname>Żerko</surname> <given-names>S</given-names></name><name><surname>Koźmiński</surname> <given-names>W</given-names></name><name><surname>Pons</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The two isoforms of lyn display different intramolecular fuzzy complexes with the SH3 domain</article-title><source>Molecules</source><volume>23</volume><fpage>2731</fpage><pub-id pub-id-type="doi">10.3390/molecules23112731</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thien</surname> <given-names>CB</given-names></name><name><surname>Langdon</surname> <given-names>WY</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>c-Cbl and Cbl-b ubiquitin ligases: substrate diversity and the negative regulation of signalling responses</article-title><source>Biochemical Journal</source><volume>391</volume><fpage>153</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1042/BJ20050892</pub-id><pub-id pub-id-type="pmid">16212556</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thu</surname> <given-names>YM</given-names></name><name><surname>Van Riper</surname> <given-names>SK</given-names></name><name><surname>Higgins</surname> <given-names>L</given-names></name><name><surname>Zhang</surname> <given-names>T</given-names></name><name><surname>Becker</surname> <given-names>JR</given-names></name><name><surname>Markowski</surname> <given-names>TW</given-names></name><name><surname>Nguyen</surname> <given-names>HD</given-names></name><name><surname>Griffin</surname> <given-names>TJ</given-names></name><name><surname>Bielinsky</surname> <given-names>AK</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Slx5/Slx8 promotes replication stress tolerance by facilitating mitotic progression</article-title><source>Cell Reports</source><volume>15</volume><fpage>1254</fpage><lpage>1265</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.04.017</pub-id><pub-id pub-id-type="pmid">27134171</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tornillo</surname> <given-names>G</given-names></name><name><surname>Knowlson</surname> <given-names>C</given-names></name><name><surname>Kendrick</surname> <given-names>H</given-names></name><name><surname>Cooke</surname> <given-names>J</given-names></name><name><surname>Mirza</surname> <given-names>H</given-names></name><name><surname>Aurrekoetxea-Rodríguez</surname> <given-names>I</given-names></name><name><surname>Vivanco</surname> <given-names>MDM</given-names></name><name><surname>Buckley</surname> <given-names>NE</given-names></name><name><surname>Grigoriadis</surname> <given-names>A</given-names></name><name><surname>Smalley</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Dual mechanisms of LYN kinase dysregulation drive aggressive behavior in breast Cancer cells</article-title><source>Cell Reports</source><volume>25</volume><fpage>3674</fpage><lpage>3692</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2018.11.103</pub-id><pub-id pub-id-type="pmid">30590041</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ueno</surname> <given-names>H</given-names></name><name><surname>Sasaki</surname> <given-names>K</given-names></name><name><surname>Honda</surname> <given-names>H</given-names></name><name><surname>Nakamoto</surname> <given-names>T</given-names></name><name><surname>Yamagata</surname> <given-names>T</given-names></name><name><surname>Miyagawa</surname> <given-names>K</given-names></name><name><surname>Mitani</surname> <given-names>K</given-names></name><name><surname>Yazaki</surname> <given-names>Y</given-names></name><name><surname>Hirai</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>c-Cbl is tyrosine-phosphorylated by interleukin-4 and enhances mitogenic and survival signals of interleukin-4 receptor by linking with the phosphatidylinositol 3'-kinase pathway</article-title><source>Blood</source><volume>91</volume><fpage>46</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">9414268</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voutila</surname> <given-names>J</given-names></name><name><surname>Sætrom</surname> <given-names>P</given-names></name><name><surname>Mintz</surname> <given-names>P</given-names></name><name><surname>Sun</surname> <given-names>G</given-names></name><name><surname>Alluin</surname> <given-names>J</given-names></name><name><surname>Rossi</surname> <given-names>JJ</given-names></name><name><surname>Habib</surname> <given-names>NA</given-names></name><name><surname>Kasahara</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Gene expression profile changes after Short-activating RNA-mediated induction of endogenous pluripotency factors in human mesenchymal stem cells</article-title><source>Molecular Therapy - Nucleic Acids</source><volume>1</volume><elocation-id>e35</elocation-id><pub-id pub-id-type="doi">10.1038/mtna.2012.20</pub-id><pub-id pub-id-type="pmid">23344177</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voutila</surname> <given-names>J</given-names></name><name><surname>Reebye</surname> <given-names>V</given-names></name><name><surname>Roberts</surname> <given-names>TC</given-names></name><name><surname>Protopapa</surname> <given-names>P</given-names></name><name><surname>Andrikakou</surname> <given-names>P</given-names></name><name><surname>Blakey</surname> <given-names>DC</given-names></name><name><surname>Habib</surname> <given-names>R</given-names></name><name><surname>Huber</surname> <given-names>H</given-names></name><name><surname>Saetrom</surname> <given-names>P</given-names></name><name><surname>Rossi</surname> <given-names>JJ</given-names></name><name><surname>Habib</surname> <given-names>NA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Development and mechanism of small activating RNA targeting CEBPA, a novel therapeutic in clinical trials for liver Cancer</article-title><source>Molecular Therapy</source><volume>25</volume><fpage>2705</fpage><lpage>2714</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2017.07.018</pub-id><pub-id pub-id-type="pmid">28882451</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>H</given-names></name><name><surname>Kadlecek</surname> <given-names>TA</given-names></name><name><surname>Au-Yeung</surname> <given-names>BB</given-names></name><name><surname>Goodfellow</surname> <given-names>HE</given-names></name><name><surname>Hsu</surname> <given-names>LY</given-names></name><name><surname>Freedman</surname> <given-names>TS</given-names></name><name><surname>Weiss</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>ZAP-70: an essential kinase in T-cell signaling</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>2</volume><elocation-id>a002279</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a002279</pub-id><pub-id pub-id-type="pmid">20452964</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiss</surname> <given-names>A</given-names></name><name><surname>Stobo</surname> <given-names>JD</given-names></name></person-group><year iso-8601-date="1984">1984</year><article-title>Requirement for the coexpression of T3 and the T cell antigen receptor on a malignant human T cell line</article-title><source>Journal of Experimental Medicine</source><volume>160</volume><fpage>1284</fpage><lpage>1299</lpage><pub-id pub-id-type="doi">10.1084/jem.160.5.1284</pub-id><pub-id pub-id-type="pmid">6208306</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wynn</surname> <given-names>TA</given-names></name><name><surname>Chawla</surname> <given-names>A</given-names></name><name><surname>Pollard</surname> <given-names>JW</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Macrophage biology in development, homeostasis and disease</article-title><source>Nature</source><volume>496</volume><fpage>445</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.1038/nature12034</pub-id><pub-id pub-id-type="pmid">23619691</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname> <given-names>N</given-names></name><name><surname>Takeshita</surname> <given-names>K</given-names></name><name><surname>Shichijo</surname> <given-names>M</given-names></name><name><surname>Kokubo</surname> <given-names>T</given-names></name><name><surname>Sato</surname> <given-names>M</given-names></name><name><surname>Nakashima</surname> <given-names>K</given-names></name><name><surname>Ishimori</surname> <given-names>M</given-names></name><name><surname>Nagai</surname> <given-names>H</given-names></name><name><surname>Li</surname> <given-names>YF</given-names></name><name><surname>Yura</surname> <given-names>T</given-names></name><name><surname>Bacon</surname> <given-names>KB</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>The orally available spleen tyrosine kinase inhibitor 2-[7-(3,4-dimethoxyphenyl)-imidazo[1,2-c]pyrimidin-5-ylamino]nicotinamide dihydrochloride (BAY 61-3606) blocks antigen-induced airway inflammation in rodents</article-title><source>Journal of Pharmacology and Experimental Therapeutics</source><volume>306</volume><fpage>1174</fpage><lpage>1181</lpage><pub-id pub-id-type="doi">10.1124/jpet.103.052316</pub-id><pub-id pub-id-type="pmid">12766258</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname> <given-names>Q</given-names></name><name><surname>Barros</surname> <given-names>T</given-names></name><name><surname>Visperas</surname> <given-names>PR</given-names></name><name><surname>Deindl</surname> <given-names>S</given-names></name><name><surname>Kadlecek</surname> <given-names>TA</given-names></name><name><surname>Weiss</surname> <given-names>A</given-names></name><name><surname>Kuriyan</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Structural basis for activation of ZAP-70 by phosphorylation of the SH2-kinase linker</article-title><source>Molecular and Cellular Biology</source><volume>33</volume><fpage>2188</fpage><lpage>2201</lpage><pub-id pub-id-type="doi">10.1128/MCB.01637-12</pub-id><pub-id pub-id-type="pmid">23530057</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yi</surname> <given-names>TL</given-names></name><name><surname>Bolen</surname> <given-names>JB</given-names></name><name><surname>Ihle</surname> <given-names>JN</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Hematopoietic cells express two forms of lyn kinase differing by 21 amino acids in the amino terminus</article-title><source>Molecular and Cellular Biology</source><volume>11</volume><fpage>2391</fpage><lpage>2398</lpage><pub-id pub-id-type="doi">10.1128/mcb.11.5.2391</pub-id><pub-id pub-id-type="pmid">2017160</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yokoyama</surname> <given-names>N</given-names></name><name><surname>Miller</surname> <given-names>WT</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Identification of residues involved in v-Src substrate recognition by site-directed mutagenesis</article-title><source>FEBS Letters</source><volume>456</volume><fpage>403</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1016/S0014-5793(99)00992-8</pub-id><pub-id pub-id-type="pmid">10462053</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname> <given-names>JW</given-names></name><name><surname>Brdicka</surname> <given-names>T</given-names></name><name><surname>Katsumoto</surname> <given-names>TR</given-names></name><name><surname>Lin</surname> <given-names>J</given-names></name><name><surname>Weiss</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Structurally distinct phosphatases CD45 and CD148 both regulate B cell and macrophage immunoreceptor signaling</article-title><source>Immunity</source><volume>28</volume><fpage>183</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2007.11.024</pub-id><pub-id pub-id-type="pmid">18249142</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname> <given-names>JW</given-names></name><name><surname>Doan</surname> <given-names>K</given-names></name><name><surname>Park</surname> <given-names>J</given-names></name><name><surname>Chau</surname> <given-names>AH</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Lowell</surname> <given-names>CA</given-names></name><name><surname>Weiss</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Receptor-like tyrosine phosphatases CD45 and CD148 have distinct functions in chemoattractant-mediated neutrophil migration and response to <italic>S. aureus</italic></article-title><source>Immunity</source><volume>35</volume><fpage>757</fpage><lpage>769</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2011.09.011</pub-id><pub-id pub-id-type="pmid">22078799</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname> <given-names>LL</given-names></name><name><surname>Luo</surname> <given-names>TM</given-names></name><name><surname>Xu</surname> <given-names>X</given-names></name><name><surname>Guo</surname> <given-names>YH</given-names></name><name><surname>Zhao</surname> <given-names>XQ</given-names></name><name><surname>Wang</surname> <given-names>TT</given-names></name><name><surname>Tang</surname> <given-names>B</given-names></name><name><surname>Jiang</surname> <given-names>YY</given-names></name><name><surname>Xu</surname> <given-names>JF</given-names></name><name><surname>Lin</surname> <given-names>X</given-names></name><name><surname>Jia</surname> <given-names>XM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>E3 ubiquitin ligase Cbl-b negatively regulates C-type lectin receptor-mediated antifungal innate immunity</article-title><source>The Journal of Experimental Medicine</source><volume>213</volume><fpage>1555</fpage><lpage>1570</lpage><pub-id pub-id-type="doi">10.1084/jem.20151932</pub-id><pub-id pub-id-type="pmid">27432944</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.46043.049</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Davis</surname><given-names>Roger J</given-names></name><role>Reviewing Editor</role><aff><institution>University of Massachusetts Medical School</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.</p></boxed-text><p>Thank you for submitting your article &quot;An orthogonal c-Cbl recognition mode targets LynA for rapid degradation and builds specificity into the LynA checkpoint&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Tadatsugu Taniguchi as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>Summary:</p><p>This is an interesting study that builds upon previous work by these authors that demonstrates a possible check-point role for LynA in macrophage activation caused by activation-induced degradation. This study demonstrates that this degradation is mediated by the E3 Ub ligase cCbl that targets the insert region on LynA and requires Tyr32. The data supporting the authors' conclusions are strong.</p><p>The major weakness of the study is that cCbl has already been reported to cause Lyn degradation. Nevertheless, the current study has merit because it demonstrates that this role is specific for LynA and because the study presents these observations within an important biological context. Freedman and co-workers demonstrate a rapid negative feedback loop in a specific spliced form of the Src family tyrosine kinase LynA that is not seen with the alternatively spliced form, LynB, or with other members of the SFK family. This is physiologically significant as MAST cells that use LynB, but not LynA, do not exhibit this phenotype and have a more sustained and higher levels of ERK activation.</p><p>Essential revisions:</p><p>1) What is the meaning of &quot;orthogonal&quot; in the title?</p><p>2) What is the function of Y32? Why does its phosphorylation enhance ubiquitination and degradation? It is suggested that this could be a binding site for cCBL as well as an activating phosphorylation? Was the binding of cCBL tested? This would be a logical mechanism of action. Does Y32 phosphorylation induce relocalization of Lyn into the cytoplasm from the membrane? That could also explain the mechanism.</p><p>3) Does the Y32 get autophosphorylated in an in vitro kinase reaction? If so, is this phosphorylation in cis or trans? For example, is autophosphorylation concentration-dependent in vitro. Can the Y32 phosphorylation be reconstituted using kinase-inactive and phosphorylation site mutated proteins?</p><p>4) What happens in mast cells if c-CBL is expressed? Would it result in loss of resting LynA? Would that attenuate ERK activation?</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.46043.050</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) What is the meaning of &quot;orthogonal&quot; in the title?</p></disp-quote><p>pY32-dependent recognition of LynA by c-Cbl is distinct from the known PXXP/SH3, PTB/pSFK activation loop, and kinase/substrate interactions mediating the slower degradation of all SFKs. We now convey this point in a less oblique manner in the revised title “Unique-region phosphorylation targets LynA for rapid degradation, tuning its expression and signaling in myeloid cells.” We have also revised the abstract and main text to emphasize the difference between canonical c-Cbl/SFK interactions and the preferential targeting of LynA for rapid polyubiquitination by c-Cbl.</p><disp-quote content-type="editor-comment"><p>2) What is the function of Y32? Why does its phosphorylation enhance ubiquitination and degradation?</p></disp-quote><p>In the original manuscript we reported that unique-region Y32 is the key residue marking LynA for rapid polyubiquitination and degradation. We speculated that this might be a site of phosphorylation, based on a prediction algorithm (NetPhos 2.0) and recent reports of this modification in tumor cells. However, we had no evidence that this site was actually phosphorylated in non-cancer cells or in hematopoietic cells, and thus the mechanism of Y32 in targeting LynA for rapid polyubiquitination was unclear. We have now performed quantitative, targeted LC-MS/MS analysis of LynA immunoprecipitates from resting and 3-IB-PP1-treated macrophages. The results of these experiments are reported in new Figure 4 and Figure 4—figure supplements 1-5. We can now unequivocally state that in primary macrophages LynA Y32 is a site of phosphorylation, induced upon SFK activation. Moreover, pY32 is massively enriched in polyubiquitinated LynA. We therefore conclude that activation of the SFKs leads to phosphorylation of LynA at position Y32, and that this is the mechanism by which LynA is targeted specifically for polyubiquitination and degradation.</p><disp-quote content-type="editor-comment"><p>It is suggested that this could be a binding site for cCBL as well as an activating phosphorylation? Was the binding of cCBL tested? This would be a logical mechanism of action.</p></disp-quote><p>These mass spectrometry experiments were quite labor intensive and occupied the entire revision time frame. We did perform co-immunoprecipitation experiments and found inducible association of c-Cbl with LynA, but we were unable to demonstrate that this association was due to Y32 phosphorylation. Like all SFKs, LynA interacts with c-Cbl via several binding interfaces, including the SH3 domain, the activation-loop peptide binding site, and the activation-loop phosphotyrosine. Additional cloning to isolate the contributions of each of these interfaces was not possible before resubmission.</p><disp-quote content-type="editor-comment"><p>Does Y32 phosphorylation induce relocalization of Lyn into the cytoplasm from the membrane? That could also explain the mechanism.</p></disp-quote><p>We probed for localization differences mediated by the unique regions of LynA, LynB, and LynA<sup>Y32A</sup> using epifluorescence microscopy. We were unable to get good staining of total LynA, but we were able to visualize eGFP-tagged unique-region constructs. As shown in new Figure 3—figure supplement 1. All three constructs were membrane localized in the presence and absence of 3-IB-PP1, even in the presence of a kinase-active LynB construct. While the LynA kinase domain may add some localization functionality, we can say that the Y32 mutation does not itself change the localization of the LynA unique region.</p><disp-quote content-type="editor-comment"><p>3) Does the Y32 get autophosphorylated in an in vitro kinase reaction? If so, is this phosphorylation in cis or trans? For example, is autophosphorylation concentration-dependent in vitro.</p></disp-quote><p>We used targeted mass spectrometry to detect phosphorylation of LynA Y32 with increasing doses of recombinant LynA (to probe cis vs. transautophosphorylation) or increasing doses of recombinant Hck (to probe transphosphorylation). Unfortunately, the data were uninterpretable because recombinant LynA purified from insect cells is already phosphorylated at position Y32. We are continuing to troubleshoot these experiments, but they are likely to take several more months and so unfortunately were not possible for this revision.</p><disp-quote content-type="editor-comment"><p>Can the Y32 phosphorylation be reconstituted using kinase-inactive and phosphorylation site mutated proteins?</p></disp-quote><p>We measured the ability of different Src family members to induce degradation of kinase-dead LynA<sup>T410K</sup>, which is not on its own degraded during 3-IB-PP1 treatment. LynA degradation can be specifically induced in trans by LynA, LynB, LynA<sup>Y32A</sup>, and Hck<sup>56</sup> (the shorter isoform of Hck). In contrast, Fyn, Fgr, Hck<sup>59</sup>, and Lck were unable to induce degradation of LynA. These data, presented in new Figure 7 and Figure 7—figure supplement 1-2, reveal SFK-specific regulation of LynA degradation, with LynA itself likely inducing its own degradation via Y32 autophosphorylation.</p><disp-quote content-type="editor-comment"><p>4) What happens in mast cells if c-CBL is expressed? Would it result in loss of resting LynA? Would that attenuate ERK activation?</p></disp-quote><p>We treated mast cells with small activating (sa)RNAs designed to increase transcription of c-Cbl mRNA. One of these constructs was found to increase c-Cbl expression an average of 2-fold, and we were able to detect an increase in LynA degradation and corresponding decrease in Syk and Erk phosphorylation in response to 3-IB-PP1 in c-Cbl overexpressing mast cells relative to mock-transfected cells (new panels, Figure 9G-J). With this modest increase in c-Cbl expression, steady-state expression of LynA was not significantly affected.</p></body></sub-article></article>